<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25563670</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>225</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Feb</Month><Day>28</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Bcl-2 associated with severity of manic symptoms in bipolar patients in a manic phase.</ArticleTitle><Pagination><MedlinePgn>305-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2014.12.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(14)01013-0</ELocationID><Abstract><AbstractText>B cell lymphoma protein-2 (Bcl-2) may contribute to the pathophysiology of bipolar disorder, and may be involved in the therapeutic action of anti-manic drugs. The aim of this study was to investigate serum levels of Bcl-2 in bipolar patients in a manic phase, and evaluate the Bcl-2 changes after treatment. We consecutively enrolled 23 bipolar inpatients in a manic phase and 40 healthy subjects; 20 bipolar patients were followed up with treatment. Serum Bcl-2 levels were measured with assay kits. All 20 patients were evaluated by examining the correlation between Bcl-2 levels and Young Mania Rating Scale (YMRS) scores, using Spearman׳s correlation coefficients. The serum Bcl-2 levels in bipolar patients in a manic phase were higher than in healthy subjects, but without a significant difference. The YMRS scores were significantly negatively associated with serum Bcl-2 levels (p=0.042). Bcl-2 levels of the 20 bipolar patients were measured at the end of treatment. Using the Wilcoxon Signed Rank test, we found no significant difference in the Bcl-2 levels of bipolar patients after treatment. Our results suggest that Bcl-2 levels might be an indicator of severity of manic symptoms in bipolar patients in a manic phase. </AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wei-Ting</ForeName><Initials>WT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Department of Psychiatry, Zuoying Armed Forces, General Hospital, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Tiao-Lai</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Meng-Chang</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan. Electronic address: water444@ms21.hinet.net.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bcl-2</Keyword><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Mania</Keyword><Keyword MajorTopicYN="N">YMRS</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25563670</ArticleId><ArticleId IdType="pii">S0165-1781(14)01013-0</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2014.12.020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27759214</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>6</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome.</ArticleTitle><Pagination><MedlinePgn>511-519</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12437</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Bipolar I disorder (BD-I) is associated with gray matter volume (GMV) alterations in neural regions important for emotional regulation. Reductions found in patients with multiple episodes are not seen at illness onset, suggesting that changes occur with illness progression, although no prospective studies to date have examined this. In the present study, we assessed GMV at baseline and one year following a first manic episode, examining the impact of episode recurrence on the trajectory of change.</AbstractText><AbstractText Label="METHODS">A total of 41 recently remitted first manic episode patients with BD-I and 25 healthy subjects (HS) underwent 3T magnetic resonance imaging at baseline and one year later. Using voxel-based morphometry, we compared GMV change between HS, patients who experienced a recurrence of a mood episode (BD<sub>recurr</sub> ), and patients in sustained remission (BD<sub>well</sub> ).</AbstractText><AbstractText Label="RESULTS">The GMV change from baseline to one year did not differ significantly between HS and the full BD-I group or BD<sub>well</sub> and HS. However, the BD<sub>recurr</sub> group had greater GMV loss than HS in left frontal and bilateral temporal regions, and BD<sub>well</sub> patients involving bilateral frontal, temporal and left parietal regions.</AbstractText><AbstractText Label="CONCLUSIONS">GMV change early in the course of BD-I is associated with clinical outcome, such that neuroprogression found in patients who experience a recurrence of a mood episode is not seen in those with sustained remission. These findings have important implications for the treatment of BD-I as they suggest that prevention of recurrence might minimize neuroprogression of the disease, possibly requiring a multipronged early intervention approach to achieve this goal.</AbstractText><CopyrightInformation>© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kozicky</LastName><ForeName>Jan-Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGirr</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Marjorie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Vancouver Coastal Health Authority, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silveira</LastName><ForeName>Leonardo E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Molecular Psychiatry, Centro de Pesquisas Experimentais, Hospital de Clínicas de Porto Alegre and INCT for Translational Medicine, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keramatian</LastName><ForeName>Kamyar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>Ivan J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>BC Psychosis Program, British Columbia Mental Health and Addictions Services, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Raymond W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>Lakshmi N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada. yatham@mail.ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017050" MajorTopicYN="N">Episode of Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="Y">Gray Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">
MRI
</Keyword><Keyword MajorTopicYN="Y">
VBM
</Keyword><Keyword MajorTopicYN="Y">Neuroprogression</Keyword><Keyword MajorTopicYN="Y">Recovery</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">first-episode mania</Keyword><Keyword MajorTopicYN="Y">longitudinal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27759214</ArticleId><ArticleId IdType="doi">10.1111/bdi.12437</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18162331</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0376-8716</ISSN><JournalIssue CitedMedium="Print"><Volume>94</Volume><Issue>1-3</Issue><PubDate><Year>2008</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Drug and alcohol dependence</Title><ISOAbbreviation>Drug Alcohol Depend</ISOAbbreviation></Journal><ArticleTitle>Predictors of dropout from group therapy among patients with bipolar and substance use disorders.</ArticleTitle><Pagination><MedlinePgn>272-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Bipolar and substance use disorders frequently co-occur. Integrated treatment for these disorders has been shown to be effective at reducing substance use, but no study has examined attrition from dual diagnosis group therapy. The current study identified baseline demographic and clinical characteristics that predict treatment dropout among patients with co-occurring bipolar and substance use disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Using binary and multivariate analyses, baseline data were analyzed as part of a randomized controlled trial of integrated group therapy for bipolar and substance use disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Cigarette smoking, recent mood episode, and lack of a college education were strong predictors of dropout after controlling for demographic and substance use variables.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Given the strength of smoking as a predictor of dropout as well as the high rate of smoking among this population, a greater focus on the relationship between smoking and bipolar disorder is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Graff</LastName><ForeName>Fiona S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Harvard Medical School and McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Margaret L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Roger D</ForeName><Initials>RD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 DA022288-01A1</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 DA022288</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA 15968</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA015968-05</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DA015968</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Drug Alcohol Depend</MedlineTA><NlmUniqueID>7513587</NlmUniqueID><ISSNLinking>0376-8716</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>11</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18162331</ArticleId><ArticleId IdType="pii">S0376-8716(07)00433-4</ArticleId><ArticleId IdType="doi">10.1016/j.drugalcdep.2007.11.002</ArticleId><ArticleId IdType="pmc">PMC2268018</ArticleId><ArticleId IdType="mid">NIHMS41864</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Subst Abuse Treat. 2003 Jan;24(1):59-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12646331</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Aug;161(8):1433-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15285970</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):807-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15289279</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 1998 Sep 1;52(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">9788001</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Nov;61(11):1107-15</Citation><ArticleIdList><ArticleId IdType="pubmed">15520358</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Drug Alcohol Abuse. 2002;28(1):55-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11853135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gen Hosp Psychiatry. 2005 Sep-Oct;27(5):321-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16168792</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Dec;67(12):1907-11</Citation><ArticleIdList><ArticleId IdType="pubmed">17194268</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Jan;164(1):100-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17202550</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 May;61(5):361-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10847311</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):269-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11249805</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2004 Nov;55(11):1258-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15534014</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16169190</PMID><DateCompleted><Year>2006</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>05</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>80</Volume><Issue>2-3</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Schizotypal dimensions: continuity between schizophrenia and bipolar disorders.</ArticleTitle><Pagination><MedlinePgn>235-42</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Family studies have suggested that schizophrenia and bipolar disorders share some susceptibility factors. Schizotypal personality disorder (SPD) may be an intermediate phenotype common both to schizophrenia and bipolar disorders. We explored the familiality of schizotypal dimensions by comparing the magnitude of schizotypal dimensions between schizophrenic and bipolar relatives. We also looked for intra-familial resemblance for these dimensions, and for an increased familial risk of schizophrenia and/or bipolar disorders associated with a particular schizotypal dimension.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used the Schizotypal Personality Questionnaire (SPQ) to study the three schizotypal dimensions (disorganization, negative and positive) in a sample of unaffected first-degree relatives of schizophrenic (N=85), psychotic bipolar (N=63) and bipolar (N=32) probands. Differences between groups were tested using a two-tailed t-test or ANOVA for continuous variables and a chi-squared test for discrete variables. We used the intraclass correlation method to study the intra-familial correlation. Linear mixed models were used to measure the familial risk.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The disorganization dimension appears to be common to relatives of both schizophrenia and psychotic bipolar disorders, but not in the relatives of non-psychotic bipolar probands. This dimension also increases the familial risk of these two disorders. The negative dimension shows intra-familial resemblance (R=0.29), we failed to observe the expected familiality for the disorganized dimension.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The shared nature of the disorganization dimension shown by a similar familial risk for schizophrenia and psychotic bipolar disorders suggests that same genetic background may underlie psychotic disorders. Although, negative dimension is familial, it is not associated for an increased familial risk for both disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schürhoff</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Département hospitalo-universitaire de Psychiatrie, Hôpital Albert Chenevier et Henri Mondor (AP-HP), 40 rue Mesly, 94000 Créteil, France. schurhof@ext.jussieu.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laguerre</LastName><ForeName>Audrey</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Szöke</LastName><ForeName>Andreï</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Méary</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>Marion</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006778" MajorTopicYN="N">Hospitals, Psychiatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>03</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>5</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16169190</ArticleId><ArticleId IdType="pii">S0920-9964(05)00322-1</ArticleId><ArticleId IdType="doi">10.1016/j.schres.2005.07.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21953909</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0879</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><MedlineDate>2011 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Clinical psychology &amp; psychotherapy</Title><ISOAbbreviation>Clin Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>Behavioural risk of bipolar disorder in an analogue population: the role of cognitive, developmental and interpersonal factors.</ArticleTitle><Pagination><MedlinePgn>411-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpp.781</ELocationID><Abstract><AbstractText>Research to date has identified the contribution of a number of cognitive, developmental and interpersonal risk factors in the development of bipolar affective disorder. However, further work is needed to understand the mechanisms and interactions between these risk factors in relation to bipolar mood instability. The aim of this study is to explore the possibility of identifying high risk of bipolar disorder through cognitive and interpersonal factors and to further expand our knowledge regarding the relationship between such factors. The findings from this work demonstrate that when both cognitive and interpersonal variables are entered into one model to predict bipolar high risk, direct effects are observed for the interpersonal factors, which then have a fully mediational effect on the cognitive factors. This work proposes that interpersonal factors develop and maintain cognitive risk factors and that future formulations and treatment of bipolar disorder need to focus on addressing such interpersonal issues.</AbstractText><CopyrightInformation>Copyright © 2011 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwannauer</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Health in Social Science, The University of Edinburgh, Edinburgh, UK. m.schwannauer@ed.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noble</LastName><ForeName>Abbi</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fraser</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>08</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Psychol Psychother</MedlineTA><NlmUniqueID>9416196</NlmUniqueID><ISSNLinking>1063-3995</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="N">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="Y">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016013" MajorTopicYN="N">Likelihood Functions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="Y">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012606" MajorTopicYN="N" Type="Geographic">Scotland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21953909</ArticleId><ArticleId IdType="doi">10.1002/cpp.781</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">33587793</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>06</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Hypomania associated with high dose ketamine treatment.</ArticleTitle><Pagination><MedlinePgn>426-428</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.13059</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yuliang</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5073-1165</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozerdem</LastName><ForeName>Aysegul</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vande Voort</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Balwinder</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-7062-8192</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>William M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva-Posse</LastName><ForeName>Patricio</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry &amp; Psychology, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>690G0D6V8H</RegistryNumber><NameOfSubstance UI="D007649">Ketamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007649" MajorTopicYN="Y">Ketamine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087122" MajorTopicYN="N">Mania</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>01</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>15</Day><Hour>17</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33587793</ArticleId><ArticleId IdType="doi">10.1111/bdi.13059</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiat. 2014;76(12):970-976.</Citation></Reference><Reference><Citation>Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215-218.</Citation></Reference><Reference><Citation>Allen ND, Rodysill BR, Bostwick JM. A report of affective switching associated with ketamine: The case of ketamine-induced mania is not closed. Bipolar Disord. 2019;21(2):176.</Citation></Reference><Reference><Citation>McCloud TL, Caddy C, Jochim J, et al. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults. Cochrane Database Syst Rev. 2015;(9):CD011611.</Citation></Reference><Reference><Citation>Dossett EC, Land AJ, Gitlin MJ, Frye MA. Lack of mania prophylaxis associated with lamotrigine monotherapy in manic-predominant bipolar I disorder. J Clin Psych. 2007;68(6):973-974.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6231330</PMID><DateCompleted><Year>1984</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>1984</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Classification of depressive illness. Clinico-psychological correlates.</ArticleTitle><Pagination><MedlinePgn>53-66</MedlinePgn></Pagination><Abstract><AbstractText>347 patients with primary depressive illness were studied. Patients were classified on the Newcastle Diagnostic Scale and their depression was rated on the Hamilton Rating Scale for Depression (HRS) and self-rated on the Beck Depression Inventory (BDI). Clinical and personality factors were studied in relation to classification. Personality was measured by the Eysenck Personality Questionnaire, Fould's Personality Deviance Scale, the Marke-Nyman Temperament Scale and the Crown-Crisp Experimental Index. The frequency distribution of the Newcastle scores of all 347 patients was unequivocally unimodal. Significant positive correlations were obtained between patients' Newcastle scores, age, and HRS scores but not with BDI scores. Patients with non-endogenous depression showed clinical and personality differences compared with those with endogenous depression, and with a group of bipolar depressives.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abou-Saleh</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Coppen</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005120" MajorTopicYN="N">Extraversion, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6231330</ArticleId><ArticleId IdType="pii">0165-0327(84)90008-9</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(84)90008-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">24070907</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>152-154</Volume><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A multinational study to pilot the modified Hypomania Checklist (mHCL) in the assessment of mixed depression.</ArticleTitle><Pagination><MedlinePgn>478-82</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.07.032</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00603-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mixed depression is a common, dimensional phenomenon that is increasingly recognized in unipolar and bipolar disorders. We piloted a modified version of the Hypomania Checklist (mHCL-32) to assess the prevalence and clinical correlates of concurrent manic (hypo) symptoms in depressed patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The mHCL-32, Young Mania Rating Scale (YMRS) and Hamilton Rating Scale for Depression (HAMD-24) were utilized in the assessment of unipolar (UP=61) and bipolar (BP=44) patients with an index major depressive episode confirmed by the Structured Clinical Interview for DSM-IV (SCID). Differential mHLC-32 item endorsement was compared between UP and BP. Correlation analyses assessed the association of symptom dimensions measured by mHCL-32, YMRS and HAMD-24.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference between mood groups in the mean mHCL-32 and YMRS scores. Individual mHLC-32 items of increased libido, quarrels, and caffeine intake were endorsed more in BP vs. UP patients. The mHCL-32 active-elevated subscale score was positively correlated with the YMRS in BP patients and negatively correlated with HAMD-24 in UP patients. Conversely, the mHCL-32 irritable-risk taking subscale score was positively correlated with HAMD-24 in BP and with YMRS in UP patients.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Small sample size and cross-sectional design.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Modifying the HCL to screen for (hypo) manic symptoms in major depression may have utility in identifying mixed symptoms in both bipolar vs. unipolar depression. Further research is encouraged to quantify mixed symptoms with standardized assessments.</AbstractText><CopyrightInformation>© 2013 Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altinbas</LastName><ForeName>Kursat</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Canakkale Onsekiz Mart University, Canakkale, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ozerdem</LastName><ForeName>Aysegul</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Miguel L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Manuel E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Yalin</LastName><ForeName>Nefize</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Ersoy</LastName><ForeName>Zeliha</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Aydemir</LastName><ForeName>Omer</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Quiroz</LastName><ForeName>Danilo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Oztekin</LastName><ForeName>Signem</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Geske</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Feeder</LastName><ForeName>Scott E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057189" MajorTopicYN="N">Checklist</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Depression</Keyword><Keyword MajorTopicYN="N">Modified hypomania checklist</Keyword><Keyword MajorTopicYN="N">Unipolar</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24070907</ArticleId><ArticleId IdType="pii">S0165-0327(13)00603-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.07.032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7994522</PMID><DateCompleted><Year>1995</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>165</Volume><Issue>3</Issue><PubDate><Year>1994</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium prophylaxis in recurrent affective illness.</ArticleTitle><Pagination><MedlinePgn>409</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brogan</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Br J Psychiatry. 1994 Jun;164(6):741-6</RefSource><PMID Version="1">7952980</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="N">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7994522</ArticleId><ArticleId IdType="pii">S0007125000072858</ArticleId><ArticleId IdType="doi">10.1192/bjp.165.3.409b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32942345</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2155-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>The primary care companion for CNS disorders</Title><ISOAbbreviation>Prim Care Companion CNS Disord</ISOAbbreviation></Journal><ArticleTitle>Little Agreement on Treating Residual Bipolar Disorder Symptoms in a Child.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4088/PCC.19m02574</ELocationID><ELocationID EIdType="pii" ValidYN="Y">19m02574</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">There is a paucity of studies on treatment of childhood-onset bipolar disorder and its associated comorbidities, which leads to a wide diversity of opinion on choice and sequencing of treatment options.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">From December 2018 to January 2019, a graphic depiction of medications and weekly ratings of symptoms of mania, depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), and oppositional behavior that parents had rated on their 9-year-old child over a period of several years was sent to experts in child and adult bipolar disorder. These responding medical doctors (MDs, 8 child and 18 adult psychiatrists) rated a comprehensive list of medications that they would choose (and with what priority) to treat the child's now improved mood (mania and depression) but continued mild to moderate symptoms of anxiety, ADHD, and oppositional behavior.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">In the whole group, the drugs most highly endorsed were lamotrigine: 69%, lithium: 62%, lurasidone: 62%, quetiapine: 54%, aripiprazole: 46%, and valproate: 42%. Among the antidepressants, 38% endorsed a selective serotonin reuptake inhibitor, 12% a serotonin-norepinephrine reuptake inhibitor, and 27% bupropion. Of the child MDs, 75% suggested increasing the 1-mg dose of risperidone, while few adult MDs suggested this. Conversely, 56% of the adult MDs suggested using valproate, while only 1 child MD did so. There was little consensus on how to manage ADHD symptoms unresponsive to methylphenidate 36 mg/d. How these treatment options were sequenced also varied widely.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">There was wide variation in suggestions on to how to treat persistent symptoms of anxiety, ADHD, and oppositional behavior in a child whose mania and depression had been brought under good control. We surmise that this great diversity in recommendations among experts in child and adult bipolar disorder stems at least partially from inadequate literature on treatment and that a new emphasis on funding and conducting studies on efficacy and effectiveness is needed.</AbstractText><CopyrightInformation>© Copyright 2020 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, George Washington University School of Medicine, Bipolar Collaborative Network, 5415 W Cedar Lane, Ste 201-B, Bethesda, MD 20814. robert.post@speakeasy.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, George Washington University School of Medicine, Bipolar Collaborative Network, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, George Washington University School of Medicine, Bipolar Collaborative Network, Bethesda, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Virginia Commonwealth University, Richmond, Virginia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016429">Clinical Conference</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care Companion CNS Disord</MedlineTA><NlmUniqueID>101547532</NlmUniqueID><ISSNLinking>2155-7780</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011322" MajorTopicYN="N">Primary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>20</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32942345</ArticleId><ArticleId IdType="doi">10.4088/PCC.19m02574</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11157432</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>178</Volume><PubDate><Year>2001</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebral white matter lesions in bipolar affective disorder: relationship to outcome.</ArticleTitle><Pagination><MedlinePgn>172-6</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Twenty per cent of patients with bipolar affective disorder suffer an illness that responds inadequately to treatment and has a poor outcome. Many patients, but not all, with bipolar disorder show white matter abnormalities on T(2)-weighted magnetic resonance imaging (MRI).</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To explore the hypothesis that white matter abnormalities on MRI are seen more frequently in subjects whose illness has a poor outcome compared with those with a good outcome or controls.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Two groups of age- and gender-matched patients with bipolar disorder (14 with a good outcome and 15 with a poor outcome) and 15 controls, aged 20-65 years, were studied. Axial T(2)-weighted MRI scans were examined for the presence and severity of white matter abnormalities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Significantly more poor outcome group members had deep subcortical punctate, but not periventricular, white matter hyperintensities than the good outcome group (P:=0.035) or controls (P:=0.003) and these abnormalities were of greater severity (P:=0.030 and P:&lt;0.014, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Subcortical white matter lesions are associated with poor outcome bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Tranwell Unit, Queen Elizabeth Hospital, Windy Nook Road, Gateshead NE9 6SX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shepherd</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Eccleston</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Macmillan</LastName><ForeName>I C</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Goswami</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>McAllister</LastName><ForeName>V L</ForeName><Initials>VL</Initials></Author><Author ValidYN="Y"><LastName>Ferrier</LastName><ForeName>I N</ForeName><Initials>IN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="N">Brain Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002552" MajorTopicYN="N">Cerebral Ventricles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>2</Month><Day>7</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>18</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>2</Month><Day>7</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11157432</ArticleId><ArticleId IdType="pii">S0007125000265161</ArticleId><ArticleId IdType="doi">10.1192/bjp.178.2.172</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15541070</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Changes in neuronal activation in patients with bipolar disorder during performance of a working memory task.</ArticleTitle><Pagination><MedlinePgn>540-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Several lines of evidence suggest that deficits in cognition persist in bipolar patients during periods of euthymia. Working memory impairment has been observed in euthymic bipolar patients and noted to be a significant source of functional deficits in psychiatric disorders. Functional changes associated with these cognitive deficits however, remain poorly understood. We hypothesized that patients with bipolar disorder would demonstrate changes in neuronal activation in specific regions forming part of the working memory network.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Fifteen euthymic bipolar patients and fifteen age- and gender-matched healthy controls were recruited. Subjects participated in fMRI scans during which a two-back working memory task alternated with a zero-back control/attention task using a block-design paradigm. Groups were analyzed separately, and intergroup comparisons were made using an exploratory, voxel-by-voxel analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar patients performed more poorly on the cognitive tasks than did healthy controls (F = 3.77, p = 0.04). After covarying for task performance and reaction time, bipolar patients demonstrated significantly greater activation than healthy subjects in several regions including the fronto-polar prefrontal cortex, temporal cortex, basal ganglia, thalamus, and posterior parietal cortex. No areas showed a significant decrease in activation, compared with healthy controls.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that decreased working memory performance in bipolar patients reflects specific neurofunctional deficits. These deficits may represent primary areas of neuropathology or be secondary to neuropathology elsewhere in the working memory network. Continued research utilizing other imaging modalities may further clarify the underlying neuropathology involved in these cognitive deficits.</AbstractText><CopyrightInformation>Blackwell Munksgaard, 2004</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Caleb M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0559, USA. cal.adler@psychiatry.uc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Scott K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Schmithorst</LastName><ForeName>Vince</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Tuchfarber</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH58170</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15541070</ArticleId><ArticleId IdType="pii">BDI117</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00117.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28483070</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Prevalence of metabolic syndrome and its clinical correlates among patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>109-114</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(16)30437-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2017.01.020</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the prevalence of metabolic syndrome (MetS) in patients with bipolar disorder (BD) and examine the clinical correlates of MetS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Sixty-seven patients with BD were evaluated for presence for MetS. The consensus definition was used to define MetS. The clinical variables were recorded on the basis of information provided by the patients, accompanying caregivers and review of treatment records. The symptoms severity of present depressive and manic episode was assessed by using Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS) respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prevalence of MetS was 53.7%. Patients with MetS were older than the patients with BD alone (P=0.001). Increased waist circumference was the most common abnormal parameter (74.6%) followed by low high density lipoprotein (HDL) (71.6%) and raised triglycerides (64.2%). High blood pressures were recorded in 35.8% with high fasting blood glucose levels were seen in 33.3%. MetS was associated with greater number of life time episodes (p=0.010), longer duration of illness (p=0.010), greater numbers of lifetime depressive episodes (p&lt;0.001). Substance use (alcohol and nicotine) associated with significantly higher prevalence of high blood pressure among MetS patients (p&lt;0.001) while abnormal triglyceride level shown associated with substance use (p=0.010). Age of the patients, number of lifetime depressive episodes and use of Olanzapine were found to predictive of the development of MetS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients with BD have high prevalence of MetS and its presence correlates with clinical variables.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, PGIMER, Chandigarh, India. Electronic address: ak_pal2000@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Narayanaswamy</LastName><ForeName>Janardhanan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NIMHANS, Bangalore, India. Electronic address: jairamnimhans@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venkatasubramanian</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, NIMHANS, Bangalore, India. Electronic address: venkat.nimhans@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raguram</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India. Electronic address: profraguram@gmal.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grover</LastName><ForeName>Sandeep</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, PGIMER, Chandigarh, India. Electronic address: drsandeepg2002@yahoo.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aswath</LastName><ForeName>Manju</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India. Electronic address: manjuaswath@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008075">Lipoproteins, HDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014280">Triglycerides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008075" MajorTopicYN="N">Lipoproteins, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="N">Metabolic Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014280" MajorTopicYN="N">Triglycerides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055105" MajorTopicYN="N">Waist Circumference</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Correlates</Keyword><Keyword MajorTopicYN="N">Metabolic syndrome</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>01</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28483070</ArticleId><ArticleId IdType="pii">S1876-2018(16)30437-3</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2017.01.020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23856945</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1439-3522</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Bipolar disorder and compliance].</ArticleTitle><Pagination><MedlinePgn>398-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1055/s-0033-1335380</ELocationID><Abstract><AbstractText>According to literature data the lack of compliance is a massive problem in up to 50 % of the patients with bipolar affective disorders and can lead to severe long-term complications in the further course of the diseases. In this case report we present various strategies that are intended to improve compliance. </AbstractText><CopyrightInformation>© Georg Thieme Verlag KG Stuttgart · New York.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bengesser</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Universitätsklinik für Psychiatrie, Medizinische Universität Graz, Österreich. Susanne.Bengesser@gmx.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reininghaus</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Birner</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lackner</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Kapfhammer</LastName><ForeName>H-P</ForeName><Initials>HP</Initials></Author><Author ValidYN="Y"><LastName>Reininghaus</LastName><ForeName>E Z</ForeName><Initials>EZ</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Bipolar affektive Störung und Compliance.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="Y">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23856945</ArticleId><ArticleId IdType="doi">10.1055/s-0033-1335380</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6943593</PMID><DateCompleted><Year>1981</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>3</Issue><PubDate><Year>1981</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Lateralized auditory processing in depression: dichotic click detection.</ArticleTitle><Pagination><MedlinePgn>253-66</MedlinePgn></Pagination><Abstract><AbstractText>The intensity needed to detect dichotic click stimuli was measured in 14 bipolar depressed patients, 19 unipolar depressed patients, and 15 normal controls. The results replicated, in unmedicated bipolar depressed patients, an earlier finding of reversed lateral asymmetry in medicated affective psychotic patients. Two new findings concern the relation of lateral asymmetry patterns to diagnostic subtypes of the Research Diagnostic Criteria and symptom ratings on the Schedule for Affective Disorders and Schizophrenia. First, patients with bipolar disorders (history of mania or hypomania) were more likely than patients with unipolar disorders to display reversed lateral asymmetry. Second, greater severity of depressive or endogenous symptoms was associated with less lateral asymmetry.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bruder</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sutton</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Berger-Gross</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Quitkin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-30906</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001307" MajorTopicYN="Y">Auditory Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001309" MajorTopicYN="N">Auditory Threshold</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="Y">Discrimination Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="Y">Dominance, Cerebral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6943593</ArticleId><ArticleId IdType="pii">0165-1781(81)90027-5</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(81)90027-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24864536</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2014</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1062-3388</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Managed care (Langhorne, Pa.)</Title><ISOAbbreviation>Manag Care</ISOAbbreviation></Journal><ArticleTitle>Old drug in new package promises to calm the agitated.</ArticleTitle><Pagination><MedlinePgn>50-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morrow</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Manag Care</MedlineTA><NlmUniqueID>9303583</NlmUniqueID><ISSNLinking>1062-3388</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>LER583670J</RegistryNumber><NameOfSubstance UI="D008152">Loxapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>H</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008152" MajorTopicYN="N">Loxapine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24864536</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18950389</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2008</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Difficulty identifying spinocerebellar ataxia 17 from preceding psychiatric symptoms.</ArticleTitle><Pagination><MedlinePgn>625</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1440-1819.2008.01860.x</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohi</LastName><ForeName>Kazutaka</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hashimoto</LastName><ForeName>Ryota</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sugai</LastName><ForeName>Fuminobu</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Yuka</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Tagami</LastName><ForeName>Shinji</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Takamura</LastName><ForeName>Hironori</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Morihara</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Okochi</LastName><ForeName>Masayasu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Toshihisa</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kudo</LastName><ForeName>Takashi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sakoda</LastName><ForeName>Saburo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002869" MajorTopicYN="Y">Chromosome Aberrations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020754" MajorTopicYN="N">Spinocerebellar Ataxias</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18950389</ArticleId><ArticleId IdType="pii">PCN1860</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.2008.01860.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24636453</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2014</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Differences in incidence of suicide attempts between bipolar I and II disorders and major depressive disorder.</ArticleTitle><Pagination><MedlinePgn>652-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12195</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Whether risk of suicide attempts (SAs) differs between patients with bipolar disorder (BD) and patients with major depressive disorder (MDD) is unclear. We investigated whether cumulative risk differences are due to dissimilarities in time spent in high-risk states, incidence per unit time in high-risk states, or both.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Incidence rates for SAs during various illness phases, based on prospective life charts, were compared between patients from the Jorvi Bipolar Study (n = 176; 18 months) and the Vantaa Depression Study (n = 249; five years). Risk factors and their interactions with diagnosis were investigated with Cox proportional hazards models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">By 18 months, 19.9% of patients with BD versus 9.5% of patients with MDD had attempted suicide. However, patients with BD spent 4.6% of the time in mixed episodes, and more time in major depressive episodes (MDEs) (35% versus 21%, respectively) and in subthreshold depression (39% versus 31%, respectively) than those with MDD. Compared with full remission, the combined incidence rates of SAs were 5-, 25-, and 65-fold in subthreshold depression, MDEs, and BD mixed states, respectively. Between cohorts, incidence of attempts was not different during comparable symptom states. In Cox models, hazard was elevated during MDEs and subthreshold depression, and among patients with preceding SAs, female patients, those with poor social support, and those aged &lt; 40 years, but was unrelated to BD diagnosis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The observed higher cumulative incidence of SAs among patients with BD than among those with MDD is mostly due to patients with BD spending more time in high-risk illness phases, not to differences in incidence during these phases, or to bipolarity itself. BD mixed phases contribute to differences involving very high incidence, but short duration. Diminishing the time spent in high-risk phases is crucial for prevention.</AbstractText><CopyrightInformation>© 2014 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holma</LastName><ForeName>K Mikael</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Mood, Depression, and Suicidal Behaviour Unit, National Institute for Health and Welfare, Helsinki, Finland; Psychiatry, City of Helsinki Health Centre, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haukka</LastName><ForeName>Jari</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Suominen</LastName><ForeName>Kirsi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Valtonen</LastName><ForeName>Hanna M</ForeName><Initials>HM</Initials></Author><Author ValidYN="Y"><LastName>Mantere</LastName><ForeName>Outi</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Melartin</LastName><ForeName>Tarja K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Sokero</LastName><ForeName>T Petteri</ForeName><Initials>TP</Initials></Author><Author ValidYN="Y"><LastName>Oquendo</LastName><ForeName>Maria A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Isometsä</LastName><ForeName>Erkki T</ForeName><Initials>ET</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005387" MajorTopicYN="N" Type="Geographic">Finland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">major depressive disorder</Keyword><Keyword MajorTopicYN="N">suicide</Keyword><Keyword MajorTopicYN="N">suicide attempts</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24636453</ArticleId><ArticleId IdType="doi">10.1111/bdi.12195</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6957903</PMID><DateCompleted><Year>1982</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>1982</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>The dexamethasone suppression test as a predictor of sleep deprivation antidepressant effect.</ArticleTitle><Pagination><MedlinePgn>93-9</MedlinePgn></Pagination><Abstract><AbstractText>An abnormal dexamethasone suppression test (DST) result, a sensitive and specific marker for endogenous depression, was found to be associated with an antidepressant response to sleep deprivation in patients who met DSM-III criteria for Major Depressive Episode regardless of whether they met criteria for melancholia or psychotic subtypes of this disorder. These findings support previous reports of an association between an abnormal DST result and antidepressant effects of sleep deprivation in depressed patients. Our results extend the positive association between an abnormal DST result and the antidepressant response to sleep deprivation to include depressed patients who are clinically nonmelancholic during their current episode but who have an abnormal DST result.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>King</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Dowdy</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2T01 MH-05135-34</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="Y">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011863" MajorTopicYN="N">Radioimmunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="Y">Sleep Deprivation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6957903</ArticleId><ArticleId IdType="pii">0165-1781(82)90057-9</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(82)90057-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22840553</PMID><DateCompleted><Year>2012</Year><Month>12</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-5418</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>8</Issue><PubDate><Year>2012</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Abnormal amygdala and prefrontal cortex activation to facial expressions in pediatric bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>821-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaac.2012.06.005</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Previous functional magnetic resonance imaging (fMRI) studies in pediatric bipolar disorder (BD) have reported greater amygdala and less dorsolateral prefrontal cortex (DLPFC) activation to facial expressions compared to healthy controls. The current study investigates whether these differences are associated with the early or late phase of activation, suggesting different temporal characteristics of brain responses.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 20 euthymic adolescents with familial BD (14 male) and 21 healthy control subjects (13 male) underwent fMRI scanning during presentation of happy, sad, and neutral facial expressions. Whole-brain voxelwise analyses were conducted in SPM5, using a three-way analysis of variance (ANOVA) with factors group (BD and healthy control [HC]), facial expression (happy, sad, and neutral versus scrambled), and phase (early and late, corresponding to the first and second half of each block of faces).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant group differences in task performance, age, gender, or IQ. Significant activation from the main effect of group included greater DLPFC activation in the HC group, and greater amygdala/hippocampal activation in the BD group. The interaction of Group × Phase identified clusters in the superior temporal sulcus/insula and visual cortex, where activation increased from the early to late phase of the block for the BD but not the HC group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings are consistent with previous studies that suggest deficient prefrontal cortex regulation of heightened amygdala response to emotional stimuli in pediatric BD. Increasing activation over time in superior temporal and visual cortices suggests difficulty processing or disengaging attention from emotional faces in BD.</AbstractText><CopyrightInformation>Copyright © 2012 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garrett</LastName><ForeName>Amy S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Center for Interdisciplinary Brain Sciences Research and the Pediatric Bipolar Disorders Program at Stanford University School of Medicine, Stanford, CA 94305-5719, USA. agarrett@stanford.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Allan L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Ryan G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Manpreet K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Adleman</LastName><ForeName>Nancy E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Karchemskiy</LastName><ForeName>Asya</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kiki D</ForeName><Initials>KD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH01142</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH64460-01</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD031715</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH19908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH050047</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD31715</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH050047</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 MH001142</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH019908</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH064460</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>06</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000294" MajorTopicYN="N">Adolescent Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000679" MajorTopicYN="N">Amygdala</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001526" MajorTopicYN="N">Behavioral Symptoms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005149" MajorTopicYN="Y">Facial Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013647" MajorTopicYN="N">Task Performance and Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>05</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22840553</ArticleId><ArticleId IdType="pii">S0890-8567(12)00417-0</ArticleId><ArticleId IdType="doi">10.1016/j.jaac.2012.06.005</ArticleId><ArticleId IdType="pmc">PMC3408885</ArticleId><ArticleId IdType="mid">NIHMS391377</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):158-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17097071</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):530-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19624392</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Aug;132(3):344-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21470688</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Jun;26(2):389-413</Citation><ArticleIdList><ArticleId IdType="pubmed">15907298</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2010 Oct;49(10):1064-80</Citation><ArticleIdList><ArticleId IdType="pubmed">20855051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):577-88</Citation><ArticleIdList><ArticleId IdType="pubmed">16403183</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Nov 30;164(2):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18930635</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Mar 15;55(6):578-87</Citation><ArticleIdList><ArticleId IdType="pubmed">15013826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2009 Nov;34(6):418-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19949718</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2004;144:171-82</Citation><ArticleIdList><ArticleId IdType="pubmed">14650848</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8900-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16735472</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2011 Aug;216(4):485-99</Citation><ArticleIdList><ArticleId IdType="pubmed">21390505</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2005 Aug;20(6):415-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16106488</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):679-92</Citation><ArticleIdList><ArticleId IdType="pubmed">17988357</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Dec 30;184(3):135-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21050725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Nov 15;58(10):763-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16310510</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2012 Mar;51(3):294-303</Citation><ArticleIdList><ArticleId IdType="pubmed">22365465</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Nov;118(1-3):19-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19243839</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2005 Dec;183(3):308-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16249909</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Apr 1;71(7):603-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22206876</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2001 Feb 12;12(2):379-83</Citation><ArticleIdList><ArticleId IdType="pubmed">11209954</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Brain Mapp. 2012 Dec;33(12):2920-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21954087</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2008 Oct 8;19(15):1523-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18797310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Jun;11(4):391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">19500092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Jul;71(7):864-72</Citation><ArticleIdList><ArticleId IdType="pubmed">20667291</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 1;67(5):422-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20159144</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2012 Feb;22(2):100-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21820878</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2008 Jan;49(1):88-96</Citation><ArticleIdList><ArticleId IdType="pubmed">18181882</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2012 Jan 2;59(1):738-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21854858</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2010;6:285-312</Citation><ArticleIdList><ArticleId IdType="pubmed">20192795</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):781-92</Citation><ArticleIdList><ArticleId IdType="pubmed">15289277</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Oct;34(10):1229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">911222</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Ther Exp Psychiatry. 2007 Jun;38(2):168-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17107657</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Feb 15;69(4):381-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21051038</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2009 Apr;18(2):273-89, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">19264264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1995 Sep;7(3):127-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8646272</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Oct 7;13(14):1737-41</Citation><ArticleIdList><ArticleId IdType="pubmed">12395114</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Jun;162(6):1211-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15930074</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 1979 Oct;64(4):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">492809</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Mar;165(3):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18245175</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1999 Nov;10(5):607-19</Citation><ArticleIdList><ArticleId IdType="pubmed">10547338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):344-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20565443</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Aug 30;193(2):71-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21676596</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1996 Nov;17(5):875-87</Citation><ArticleIdList><ArticleId IdType="pubmed">8938120</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Mar;48(3):308-319</Citation><ArticleIdList><ArticleId IdType="pubmed">19242292</ArticleId></ArticleIdList></Reference><Reference><Citation>Postgrad Med. 2010 Jul;122(4):94-104</Citation><ArticleIdList><ArticleId IdType="pubmed">20675973</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Jan;167(1):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19917597</ArticleId></ArticleIdList></Reference><Reference><Citation>Magn Reson Med. 1998 Mar;39(3):361-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9498591</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurobiol Exp (Wars). 2008;68(2):229-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18511959</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Mar 1;55(1):411-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21095230</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Dec;50(12):1275-89.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">22115148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Dec;10(8):916-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19594507</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Mar 15;61(6):819-21</Citation><ArticleIdList><ArticleId IdType="pubmed">17338904</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 1997 Feb;5(2):83-96</Citation><ArticleIdList><ArticleId IdType="pubmed">9345540</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Jan 15;162(1):27-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18063349</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Jun;9(4):345-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17547581</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Apr;40(4):450-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11314571</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8039462</PMID><DateCompleted><Year>1994</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>20 Spec No 1</Volume><PubDate><Year>1994</Year><Month>Apr</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Patient education of the depressed patient and his family].</ArticleTitle><Pagination><MedlinePgn>237-43</MedlinePgn></Pagination><Abstract><AbstractText>The information available to the patient and to his family today pose new conditions for the care of the depressed; it facilitates the acceptance of the illness and of its effects, it is indispensable for the therapeutic relationship as well as for the effective observance by the patient of his treatment, and thus contributes to the improvement of the quality of life of the depressed. Certain rules must be observed in the transmission of this information: it must be accessible and understandable to everyone, it must be concise, it must be repeated and revised according to circumstances, it must discourage self-diagnosis and self-prescription by the patient. This information is to be transmitted chiefly by the doctor and the pharmacist. The depressed may also appeal to complementary sources of informations: books, journals and more rarely scientific publications. Patients' associations provide another potential source for the dissemination of information. Their chief objective is to provide this information not only to the patients and their immediate entourage, but also to the population at large.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gay</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>SHU, Hôpital Sainte-Anne, Paris.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lévy-Attar</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>L'information du déprimé et de son entourage.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="Y">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>14</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8039462</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1791267</PMID><DateCompleted><Year>1992</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>PDQ-R personality disorders in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>217-21</MedlinePgn></Pagination><Abstract><AbstractText>The prevalence of personality traits and disorders in bipolar patients as reported in the literature varies widely. The Personality Diagnostic Questionnaire-Revised (PDQ-R) is a self-report instrument for DSM-IIIR personality disorders found to have validity, but with high sensitivity and moderate specificity. This study was designed to assess personality disorders in bipolar patients using the PDQ-R. Fifty bipolar patients in a long-term lithium treatment program completed the PDQ-R. Over one half the patients (58%) scored for one or more personality disorders. A total of 71 diagnoses was made among the 50 patients, or a mean of 1.42 per patient. The majority of the axis II diagnoses were from cluster B, with borderline the most prevalent, followed by histrionic. The PDQ-R has high sensitivity but moderate specificity and may overdiagnose personality disorders in bipolar patients. The PDQ-R may register subclinical aspects of affective disorder as personality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>St. Vincent's Hospital and Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayo</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Sciutto</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1791267</ArticleId><ArticleId IdType="pii">0165-0327(91)90103-Y</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(91)90103-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24261315</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Exploring the recovery concept in bipolar disorder: a decision tree analysis of psychosocial correlates of recovery stages.</ArticleTitle><Pagination><MedlinePgn>366-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12153</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The recovery movement has generated interest in the concept of personal recovery, but little attention has been paid to it in relation to bipolar disorder (BD). The aim of this study was to examine personal recovery in BD using a staged model, exploring whether different stages are associated with different psychosocial and clinical profiles.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adults with BD in remission (n = 75) were recruited from an outpatient psychiatric clinic in Hong Kong. Their average age was 45 years, with 11% and 45% working part time and full time, respectively. The data included stages of recovery, sociodemographic characteristics, clinical information, and perceptions of the importance of recovery factors and the resilience-engendering features of health services. Decision tree analysis was used to identify the predictors of stages of recovery, and receiver operating characteristic curves were employed to detect the rates of correct classification within the staged model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">'Respect, hope, and self-directed empowerment', older age, binge drinking history, early first diagnosis, and 'meaningful role' were all associated with being in a later stage of personal recovery. The first two variables demonstrated better classification accuracy than the last three. Using these variables, the classification accuracy of Stages 2-4 was adequate.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There are associations between the stage of recovery and psychosocial variables among individuals with BD in remission. Interventions that promote 'respect, hope, and self-directed empowerment' have the potential to facilitate personal recovery from BD.</AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Samson</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Social Work and Social Administration, University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Ka-Fai</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Davidson</LastName><ForeName>Larry</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ng</LastName><ForeName>King-Lam</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Chong Ho</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003663" MajorTopicYN="Y">Decision Trees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Chinese</Keyword><Keyword MajorTopicYN="N">clinical remission</Keyword><Keyword MajorTopicYN="N">mood disorder</Keyword><Keyword MajorTopicYN="N">personal recovery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24261315</ArticleId><ArticleId IdType="doi">10.1111/bdi.12153</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11093073</PMID><DateCompleted><Year>2001</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>42 Suppl 1</Volume><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids.</ArticleTitle><Pagination><MedlinePgn>50-1</MedlinePgn></Pagination><Abstract><AbstractText>Topiramate is a newly developed anticonvulsant agent with possible mood-stabilizing properties. Little is known about the short- and long-term effects of topiramate monotherapy in bipolar disorder. We here present the case of a 60-year-old female bipolar patient who received topiramate alone as maintenance treatment after recovering from euphoric mania. During 7 months, she was free from new manic symptomatology and she was able to reduce her overweight by 16.5 kg. The patient who is known to have a strongly hyperthymic temperament described symptoms of fatigue and sedation and eventually discontinued topiramate monotherapy. When she presented again in our bipolar clinic, severe euphoric mania had developed. After hospitalization, she slowly responded to oral sodium valproate loading plus zotepine. Her weight increased again and so did her triglyceride serum levels. Topiramate treatment and discontinuation did not seem to affect cholesterol serum levels.</AbstractText><CopyrightInformation>Copyright 2000 S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Erfurth</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Münster, Germany. erfurth@uni-muenster.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0H73WJJ391</RegistryNumber><NameOfSubstance UI="D000077236">Topiramate</NameOfSubstance></Chemical><Chemical><RegistryNumber>30237-26-4</RegistryNumber><NameOfSubstance UI="D005632">Fructose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001835" MajorTopicYN="N">Body Weight</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005632" MajorTopicYN="N">Fructose</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077236" MajorTopicYN="N">Topiramate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>3</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>28</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11093073</ArticleId><ArticleId IdType="pii">54854</ArticleId><ArticleId IdType="doi">10.1159/000054854</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11007724</PMID><DateCompleted><Year>2000</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Associations between bipolar disorder and other psychiatric disorders during adolescence and early adulthood: a community-based longitudinal investigation.</ArticleTitle><Pagination><MedlinePgn>1679-81</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study investigated cross-sectional and longitudinal associations between bipolar disorder and other psychiatric disorders during adolescence and early adulthood.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Psychiatric interviews were administered to a representative community sample of 717 youths and their mothers in 1983 (mean age of youths=14 years) and again in 1985-1986, and 1991-1993.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A wide range of psychiatric disorders co-occurred with bipolar disorder during adolescence and early adulthood. Adolescent anxiety disorders were uniquely associated with increased risk for early adulthood bipolar disorder after adolescent bipolar disorder was accounted for. Manic symptoms during adolescence were associated with increased risk for anxiety and depressive disorders during early adulthood after adolescent anxiety and depressive disorders were accounted for.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Adolescents with anxiety disorders may be at increased risk for bipolar disorder or clinically significant manic symptoms during early adulthood. Adolescents with manic symptoms may be at increased risk for anxiety and depressive disorders during early adulthood.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>J G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA. jjohnso@pi.cpmc.columbia.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Brook</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DA-03188</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-36971</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016001" MajorTopicYN="N">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>29</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11007724</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.157.10.1679</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12727708</PMID><DateCompleted><Year>2003</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>May</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Age at onset in bipolar I affective disorder: further evidence for three subgroups.</ArticleTitle><Pagination><MedlinePgn>999-1001</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Preliminary data suggested that there are three subgroups of bipolar affective disorder based on age at onset. The authors sought to replicate those findings and determine the cut-off age of each subgroup.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Admixture analysis was used to determine the best-fitting model for the observed ages at onset of 368 consecutively admitted patients. The results obtained were compared with those of the previously described model. The authors also investigated whether affected siblings are more likely to belong to the same theoretical age-at-onset subgroup as identified by admixture analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The existence of three subgroups defined by age at onset was confirmed. The mean ages estimated in this model were 17.4 years (SD=2.3), 25.1 years (SD=6.2), and 40.4 years (SD=11.3). Affected siblings were more likely to belong to the same theoretical subgroup.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There are three age-at-onset subgroups of bipolar patients, and specific familial vulnerability factors might underlie each subgroup.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hôpital Henri Mondor et Albert Chenevier, Assistance Publique-Hôpitaux de Paris, 51 Avenue du Mal de Lattre de Tassigny, 94010 Créteil Cedex, France. bellivier@im3.inserm.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golmard</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Rietschel</LastName><ForeName>Marcella</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Schulze</LastName><ForeName>Thomas G</ForeName><Initials>TG</Initials></Author><Author ValidYN="Y"><LastName>Malafosse</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Preisig</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>McKeon</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Mynett-Johnson</LastName><ForeName>Lesley</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Chantal</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>Marion</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017677" MajorTopicYN="N">Age Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035781" MajorTopicYN="N">Siblings</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>5</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>6</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>5</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12727708</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.160.5.999</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24590850</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>02</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Season>Spring</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[Creativity and bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>50-9</MedlinePgn></Pagination><Abstract><AbstractText>The relationship between creativity and bipolar disorder has been an intriguing topic since ancient times. Early studies focused on describing characteristics of creative people. From the last quarter of the twentieth century, researchers began to focus on the relationship between mood disorders and creativity. Initially, the studies were based on biographical texts and the obtained results indicated a relationship between these two concepts. The limitations of the retrospective studies led the researchers to develop systematic investigations into this area. The systematic studies that have focused on artistic creativity have examined both the prevalence of mood disorders and the creative process. In addition, a group of researchers addressed the relationship in terms of affective temperaments. Through the end of the 90's, the scope of creativity was widened and the notion of everyday creativity was proposed. The emergence of this notion led researchers to investigate the associations of the creative process in ordinary (non-artist) individuals. In this review, the descriptions of creativity and creative process are mentioned. Also, the creative process is addressed with regards to bipolar disorder. Then, the relationship between creativity and bipolar disorder are evaluated in terms of aforementioned studies (biographical, systematic, psychobiographical, affective temperaments). In addition, a new model, the "Shared Vulnerability Model" which was developed to explain the relationship between creativity and psychopathology is introduced. Finally, the methodological limitations and the suggestions for resolving these limitations are included.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maçkalı</LastName><ForeName>Zeynep</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Gülöksüz</LastName><ForeName>Sinan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Oral</LastName><ForeName>Timuçin</ForeName><Initials>T</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Yaratıcılık ve iki uçlu bozukluk.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="Y">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24590850</ArticleId><ArticleId IdType="pii">926</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17985761</PMID><DateCompleted><Year>2008</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0026-4075</ISSN><JournalIssue CitedMedium="Print"><Volume>172</Volume><Issue>10</Issue><PubDate><Year>2007</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Military medicine</Title><ISOAbbreviation>Mil Med</ISOAbbreviation></Journal><ArticleTitle>Evaluation of data obtained from military disability medical administrative databases for service members with schizophrenia or bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1032-8</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We are studying associations between selected biomarkers and schizophrenia or bipolar disorder among military personnel. To assess potential diagnostic misclassification and to estimate the date of illness onset, we reviewed medical records for a subset of cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two psychiatrists independently reviewed 182 service medical records retrieved from the Department of Veterans Affairs. Data were evaluated for diagnostic concordance between database diagnoses and reviewers. Interreviewer variability was measured by using proportion of agreement and the kappa statistic. Data were abstracted to estimate date of onset.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">High levels of agreement existed between database diagnoses and reviewers (proportion, 94.7%; kappa = 0.88) and between reviewers (proportion, 92.3%; kappa = 0.87). The median time between illness onset and initiation of medical discharge was 1.6 and 1.1 years for schizophrenia and bipolar disorder, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">High levels of agreement between investigators and database diagnoses indicate that diagnostic misclassification is unlikely. Discharge procedure initiation date provides a suitable surrogate for disease onset.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Millikan</LastName><ForeName>Amy M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Division of Preventive Medicine, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Natalya S</ForeName><Initials>NS</Initials></Author><Author ValidYN="Y"><LastName>Niebuhr</LastName><ForeName>David W</ForeName><Initials>DW</Initials></Author><Author ValidYN="Y"><LastName>Torrey</LastName><ForeName>E Fuller</ForeName><Initials>EF</Initials></Author><Author ValidYN="Y"><LastName>Cowan</LastName><ForeName>David N</ForeName><Initials>DN</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuanzhang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Kaminski</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mil Med</MedlineTA><NlmUniqueID>2984771R</NlmUniqueID><ISSNLinking>0026-4075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006233" MajorTopicYN="N">Disabled Persons</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008887" MajorTopicYN="Y">Military Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008889" MajorTopicYN="Y">Military Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014493" MajorTopicYN="N">United States Department of Veterans Affairs</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>1</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17985761</ArticleId><ArticleId IdType="doi">10.7205/milmed.172.10.1032</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14971866</PMID><DateCompleted><Year>2004</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1040-1237</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>3-4</Issue><PubDate><MedlineDate>2003 Sep-Dec</MedlineDate></PubDate></JournalIssue><Title>Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists</Title><ISOAbbreviation>Ann Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Matching the bipolar patient and the mood stabilizer.</ArticleTitle><Pagination><MedlinePgn>203-16</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder poses many treatment challenges, including "matching" a particular patient with the optimal treatment regimen. Although there are a number of extant guidelines to assist the clinician in selecting treatment, these recommendations are largely based on general variables and fail to take into account the subtleties and complications that confront a clinician in practice. An analysis of predictors of medication response in bipolar disorder provides a basis for matching patients with optimal medication regimens. Response to treatment may depend on the polarity of an episode or on clinical features such as mixed or psychotic symptomatology and rate of cycling. Comorbid psychiatric disorders such as substance abuse, anxiety disorders, or attention-deficit/hyperactivity disorder should also be considered in designing a treatment regimen. Similarly, medical conditions, especially metabolic abnormalities or kidney insufficiency, must be taken into account. Selection of medication may also involve an analysis of demographic factors, including family and personal history of response to a particular agent. When selecting the most appropriate mood stabilizer for a patient--particularly when polypharmacy is required--the clinician should keep potential side effects and drug interactions in mind. Randomized, controlled studies in bipolar populations are needed to further characterize optimal matching of patient and medication.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gelenberg</LastName><ForeName>Alan J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Arizona Health Sciences Center, Tucson, Arizona 85724-5002, USA. alang@email.arizona.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pies</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Psychiatry</MedlineTA><NlmUniqueID>8911021</NlmUniqueID><ISSNLinking>1040-1237</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>110</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>2</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>8</Month><Day>11</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>2</Month><Day>20</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14971866</ArticleId><ArticleId IdType="doi">10.1023/b:acli.0000008174.46414.a4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24962329</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1360-0443</ISSN><JournalIssue CitedMedium="Internet"><Volume>109</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Addiction (Abingdon, England)</Title><ISOAbbreviation>Addiction</ISOAbbreviation></Journal><ArticleTitle>Neurofunctional changes in adolescent cannabis users with and without bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1901-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/add.12668</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To compare regional brain activation among adolescents with bipolar disorder and co-occurring cannabis use disorder.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Cross-sectional study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Cincinnati, OH, USA.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Adolescents with bipolar disorder (BP, n = 14), adolescents with cannabis use disorder (MJ, n = 13), adolescents with co-occurring cannabis use and bipolar disorders (BPMJ, n = 25) and healthy adolescents (HC, n = 15).</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Cannabis craving, substance use, Blood Oxygenation Level Dependent (BOLD) signal assessed by the Marijuana Craving Questionnaire (MCQ), Teen-Addiction Severity Index (T-ASI) and a cannabis cue-reactivity task during a functional magnetic resonance imaging (fMRI) session, respectively.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">The BP group exhibited significantly greater brain activation than the BPMJ group in the right amygdala (F = 4.14, P = 0.046), left nucleus accumbens (F = 3.8, P = 0.02), left thalamus (F = 3.8, P &lt; 0.05) and the right thalamus (F = 6.2, P = 0.02). The BP group exhibited significantly greater activation than the HC group in the left nucleus accumbens (F = 11.5, P = 0.0001), right thalamus (F = 4.9, P = 0.03) and the left striatum (F = 3.6, P = 0.04). Left amygdala activation of the BPMJ group trended towards being significantly negatively correlated with the number of joints smoked (R = -0.4, P = 0.06).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar adolescents with comorbid cannabis use do not exhibit the same over-activation of the regions involved in emotional processing as seen in adolescents with bipolar disorder alone. The absence of these findings in patients with comorbid bipolar and cannabis use disorders suggests that these individuals may have a unique endophenotype of bipolar disorder or that cannabis use may alter brain activation uniquely in bipolar disorder patients who use cannabis.</AbstractText><CopyrightInformation>© 2014 Society for the Study of Addiction.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bitter</LastName><ForeName>Samantha M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Neuroscience, Division of Bipolar Disorder Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA; University Research Council's (URC) Undergraduate Student Research Fellowship, University of Cincinnati, Cincinnati, OH, USA; School of Energy, Environmental, Biological and Medical Engineering, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Caleb M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Eliassen</LastName><ForeName>James C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Wade A</ForeName><Initials>WA</Initials></Author><Author ValidYN="Y"><LastName>Welge</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Burciaga</LastName><ForeName>Joaquin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shear</LastName><ForeName>Paula K</ForeName><Initials>PK</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>DelBello</LastName><ForeName>Melissa P</ForeName><Initials>MP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Addiction</MedlineTA><NlmUniqueID>9304118</NlmUniqueID><ISSNLinking>0965-2140</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002189" MajorTopicYN="N">Marijuana Abuse</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescent</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cannabis</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">functional magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">marijuana</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24962329</ArticleId><ArticleId IdType="doi">10.1111/add.12668</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30996193</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1349-7235</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>15</Issue><PubDate><Year>2019</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Internal medicine (Tokyo, Japan)</Title><ISOAbbreviation>Intern Med</ISOAbbreviation></Journal><ArticleTitle>The Delayed Diagnosis of Thyroid Storm in Patients with Psychosis.</ArticleTitle><Pagination><MedlinePgn>2195-2199</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2169/internalmedicine.2681-19</ELocationID><Abstract><AbstractText>We herein report two cases of patients with thyroid storm with a delayed diagnosis due to psychosis. The patients were a 63-year-old woman with bipolar II disorder and a 37-year-old man with major depressive disorder. The psychoses in both patients were well controlled with medication. Although they both showed symptoms of thyrotoxicosis, the symptoms were ignored, presumably because the psychological manifestations of worsening of psychosis and thyroid storm are similar. When the mental or physical state of patients with psychosis changes, thyroid hormone levels should be measured for early treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishihara</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugawa</LastName><ForeName>Taku</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiroshima-Hamanaka</LastName><ForeName>Kaho</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amano</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umakoshi</LastName><ForeName>Hironobu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuiki</LastName><ForeName>Mika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusakabe</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satoh-Asahara</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimatsu</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagami</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Intern Med</MedlineTA><NlmUniqueID>9204241</NlmUniqueID><ISSNLinking>0918-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013963">Thyroid Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="Y">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013958" MajorTopicYN="N">Thyroid Crisis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013963" MajorTopicYN="N">Thyroid Hormones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013971" MajorTopicYN="N">Thyrotoxicosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Graves' disease</Keyword><Keyword MajorTopicYN="N">central nervous system</Keyword><Keyword MajorTopicYN="N">psychosis</Keyword><Keyword MajorTopicYN="N">thyroid storm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30996193</ArticleId><ArticleId IdType="doi">10.2169/internalmedicine.2681-19</ArticleId><ArticleId IdType="pmc">PMC6709321</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Psychiatry. 2002;7(2):140-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11840307</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2006;20(11):897-909</Citation><ArticleIdList><ArticleId IdType="pubmed">17044727</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2011 Dec;16(12):1234-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20938433</ArticleId></ArticleIdList></Reference><Reference><Citation>Thyroid. 2012 Jul;22(7):661-79</Citation><ArticleIdList><ArticleId IdType="pubmed">22690898</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Jul 29;8(7):e69637</Citation><ArticleIdList><ArticleId IdType="pubmed">23922765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Endocrinol Metab. 2015 Feb;100(2):451-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25343237</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocr Pract. 2015 Feb;21(2):182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25370315</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocr J. 2016 Dec 30;63(12):1025-1064</Citation><ArticleIdList><ArticleId IdType="pubmed">27746415</ArticleId></ArticleIdList></Reference><Reference><Citation>Epilepsia. 1980 Feb;21(1):91-6</Citation><ArticleIdList><ArticleId IdType="pubmed">6766396</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19631671</PMID><DateCompleted><Year>2009</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7064</ISSN><JournalIssue CitedMedium="Internet"><Volume>57</Volume><Issue>5-6</Issue><PubDate><MedlineDate>2009 Oct-Nov</MedlineDate></PubDate></JournalIssue><Title>Neuropharmacology</Title><ISOAbbreviation>Neuropharmacology</ISOAbbreviation></Journal><ArticleTitle>GABA(A) receptors and their associated proteins: implications in the etiology and treatment of schizophrenia and related disorders.</ArticleTitle><Pagination><MedlinePgn>481-95</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuropharm.2009.07.027</ELocationID><Abstract><AbstractText>Gamma-aminobutyric acid type A (GABA(A)) receptors play an important role in mediating fast synaptic inhibition in the brain. They are ubiquitously expressed in the CNS and also represent a major site of action for clinically relevant drugs. Recent technological advances have greatly clarified the molecular and cellular roles played by distinct GABA(A) receptor subunit classes and isoforms in normal brain function. At the same time, postmortem and genetic studies have linked neuropsychiatric disorders including schizophrenia and bipolar disorder with GABAergic neurotransmission and various specific GABA(A) receptor subunits, while evidence implicating GABA(A)R-associated proteins is beginning to emerge. In this review we discuss the mounting genetic, molecular, and cellular evidence pointing toward a role for GABA(A) receptor heterogeneity in both schizophrenia etiology and therapeutic development. Finally, we speculate on the relationship between schizophrenia-related disorders and selected GABA(A) receptor associated proteins, key regulators of GABA(A) receptor trafficking, targeting, clustering, and anchoring that often carry out these functions in a subtype-specific manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charych</LastName><ForeName>Erik I</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>Wyeth Research, Neuroscience Discovery, Princeton NJ 08852, USA. charyce@wyeth.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Brandon</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS051195-05</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS081986</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047478-06</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS080064</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051195</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056359-04</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS054900</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 NS054900-030003</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS056359</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS047478</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropharmacology</MedlineTA><NlmUniqueID>0236217</NlmUniqueID><ISSNLinking>0028-3908</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>351</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>07</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19631671</ArticleId><ArticleId IdType="pii">S0028-3908(09)00240-8</ArticleId><ArticleId IdType="doi">10.1016/j.neuropharm.2009.07.027</ArticleId><ArticleId IdType="pmc">PMC2836902</ArticleId><ArticleId IdType="mid">NIHMS136975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci. 2009 Feb 25;29(8):2344-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19244511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 1998 Jun;50(2):291-313</Citation><ArticleIdList><ArticleId IdType="pubmed">9647870</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 1999 Oct;65(4):1114-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10486331</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 1987 Oct 27;142(3):483-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2828079</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2003 Mar 13;339(1):5-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12618287</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1998 Feb 7;81(1):73-80</Citation><ArticleIdList><ArticleId IdType="pubmed">9514592</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Sep;104(1-3):96-107</Citation><ArticleIdList><ArticleId IdType="pubmed">18715757</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2005 Jun 2;46(5):703-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15924857</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2002 Sep;43(4):492-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12367596</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17154-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16284244</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1999 Jan 7;397(6714):69-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9892355</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Interv. 2003 Jun;3(4):220-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14993449</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1999 Jun;23(2):365-76</Citation><ArticleIdList><ArticleId IdType="pubmed">10399941</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Feb 6;28(6):1356-65</Citation><ArticleIdList><ArticleId IdType="pubmed">18256255</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Mar;33(4):837-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17507911</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2009 Jan;56(1):141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18760291</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2001;43(3):141-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11287792</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Mar;162(3):475-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15741464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(4):405-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11986984</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Sep;14(9):865-73</Citation><ArticleIdList><ArticleId IdType="pubmed">18317464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Dec;10(12):1074-88, 1057</Citation><ArticleIdList><ArticleId IdType="pubmed">16172613</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Apr;165(4):479-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18281411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 1996;35(9-10):1383-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9014155</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurophysiol. 1999 Apr;81(4):1903-16</Citation><ArticleIdList><ArticleId IdType="pubmed">10200225</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Dec;165(12):1594-603</Citation><ArticleIdList><ArticleId IdType="pubmed">18923069</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Neurobiol. 1995;38:95-138</Citation><ArticleIdList><ArticleId IdType="pubmed">8537206</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):34-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12802786</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1996 Aug;126(4):323-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8878348</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2006 Mar 8;25(5):987-99</Citation><ArticleIdList><ArticleId IdType="pubmed">16467845</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Mar 1;53(5):376-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12614990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2006 Jan;316(1):410-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16183706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Jan 12;25(2):372-83</Citation><ArticleIdList><ArticleId IdType="pubmed">15647480</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Jan;12(1):74-86</Citation><ArticleIdList><ArticleId IdType="pubmed">17043677</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1998 Jun 1;395(2):231-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9603375</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19942-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18077426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Nov 1;19(21):9228-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10531426</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Sep 1;50(5):364-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11543740</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14865-70</Citation><ArticleIdList><ArticleId IdType="pubmed">9405705</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Pharmacol Toxicol. 1998;38:321-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9597158</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jun 23;24(25):5816-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15215304</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1986 May 23;232(4753):1004-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2422758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1996 Sep 1;16(17):5415-24</Citation><ArticleIdList><ArticleId IdType="pubmed">8757254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mutat. 2009 Jan;30(1):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18615734</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res Program Bull. 1972 Nov;10(4):468-82</Citation><ArticleIdList><ArticleId IdType="pubmed">4663826</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 2006 Jul;36(4):577-90</Citation><ArticleIdList><ArticleId IdType="pubmed">16557364</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 1991;14:335-60</Citation><ArticleIdList><ArticleId IdType="pubmed">2031574</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5341-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9560277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 Feb 10;281(6):3552-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16339760</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9891-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10449790</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Dec;76(24):13069-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12438634</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Jun;31(6):1249-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16319920</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1993 Apr 2;607(1-2):324-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8386975</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Feb 11;24(6):1478-85</Citation><ArticleIdList><ArticleId IdType="pubmed">14960621</ArticleId></ArticleIdList></Reference><Reference><Citation>Recept Channels. 1998;5(2):113-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9606716</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1998 Mar 1;18(5):1693-703</Citation><ArticleIdList><ArticleId IdType="pubmed">9464994</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2008 May;31(5):234-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18395805</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2004 Apr;74(4):705-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15024690</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 1989;75(3):457-69</Citation><ArticleIdList><ArticleId IdType="pubmed">2744104</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12736-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15310851</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 1996 Apr;19(4):139-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8658597</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2003 Jun;98(3):299-323</Citation><ArticleIdList><ArticleId IdType="pubmed">12782242</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Feb;13(2):147-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17471287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2000 Apr;3(4):366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10725926</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2005 Apr;29(4):493-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15834213</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Feb;134(2):138-43</Citation><ArticleIdList><ArticleId IdType="pubmed">835733</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2002 Feb;5(2):175-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11802172</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2001 Apr;2(4):240-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11283747</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Sep;29(9):1610-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15114343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1989 Jan;177(1):52-3</Citation><ArticleIdList><ArticleId IdType="pubmed">2642535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol. 1995 Dec 1;489 ( Pt 2):529-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8847645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2009 Mar;40(3):301-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19103291</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Biol. 2005 Dec 20;15(24):R980-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16360673</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">8876241</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1991 Oct 18;254(5030):432-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1718042</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2003 Sep 25;349(1):9-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12946574</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2006 Mar;316(3):1335-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16326923</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2004 Apr 22;47(9):2176-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15084116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Jul;93(1-3):374-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17412563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Dec;9(12):1091-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15241432</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Cell Biol. 2008 Feb;20(1):12-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18242072</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Sep;12(9):854-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17767149</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 1987 Feb 10;26(3):805-11</Citation><ArticleIdList><ArticleId IdType="pubmed">3032237</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 1990 Mar;4(5):1469-80</Citation><ArticleIdList><ArticleId IdType="pubmed">2155149</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Biochem. 2006 Mar;39(3):210-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16472798</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Aug 1;22(15):6353-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12151513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1993 May;43(5):813-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7684817</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2008 Feb;42(3):184-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17207817</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2007 Sep 5;26(17):3888-99</Citation><ArticleIdList><ArticleId IdType="pubmed">17690689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Mar;11(3):273-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16302009</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14033-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11717462</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Apr;159(4):539-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11925290</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Mar 1;48(1):69-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11278155</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 Oct 1;40(7):568-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8886289</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Aug 11;24(32):7074-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15306641</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Jan;100(2):279-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17083446</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 May;186:364-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15863738</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2008 Jun;38(2):277-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18424167</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19878-83</Citation><ArticleIdList><ArticleId IdType="pubmed">17170134</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2007 May 23;2(5):e462</Citation><ArticleIdList><ArticleId IdType="pubmed">17520021</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Apr 15;280(15):14723-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15644324</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1998 Jul;21(1):87-97</Citation><ArticleIdList><ArticleId IdType="pubmed">9697854</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1988 Dec 2;242(4883):1306-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2848320</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1993 Dec 9;366(6455):565-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7504783</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Nov 9;25(45):10469-78</Citation><ArticleIdList><ArticleId IdType="pubmed">16280585</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2004 Dec 29;119(7):1013-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15620359</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2002 Aug 16;277(33):30079-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12034717</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Neurobiol. 2000;14(1):1-21</Citation><ArticleIdList><ArticleId IdType="pubmed">11253953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1993 Nov;61(5):1620-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8228981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2005 Oct;30(2):197-206</Citation><ArticleIdList><ArticleId IdType="pubmed">16095914</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17705-10</Citation><ArticleIdList><ArticleId IdType="pubmed">15591354</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Dec 8;275(49):38856-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10978327</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Jan 5;25(1):96-107</Citation><ArticleIdList><ArticleId IdType="pubmed">15634771</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Cell Biol. 2004 Sep;83(9):449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15540461</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2004 Jun;174(1):143-50</Citation><ArticleIdList><ArticleId IdType="pubmed">15205885</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jun 30;24(26):5881-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15229235</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2006 Oct 1;312(16):3084-95</Citation><ArticleIdList><ArticleId IdType="pubmed">16857187</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Jul 1;22(13):5572-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12097508</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1990 Feb;37(2):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1689453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2004 Oct 29;1025(1-2):237-40</Citation><ArticleIdList><ArticleId IdType="pubmed">15464766</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Apr;52(4):258-66</Citation><ArticleIdList><ArticleId IdType="pubmed">7702443</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2000 Oct;28(1):53-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11086983</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2002 Jan;125(Pt 1):4-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11834588</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1995 Aug;13(1):9-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8526975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2001 Jul;18(1):13-25</Citation><ArticleIdList><ArticleId IdType="pubmed">11461150</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1995 May;16(5):162-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7624971</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1996 Jul-Aug;30(4):239-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8905533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 2006 Feb;39 Suppl 1:S10-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16508890</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 1998 Dec;87(3):551-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9758222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1995 Aug 14;359(1):154-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8557845</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):854-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16894595</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Mar 1;63(5):530-3</Citation><ArticleIdList><ArticleId IdType="pubmed">17870056</ArticleId></ArticleIdList></Reference><Reference><Citation>Results Probl Cell Differ. 2006;43:25-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17068966</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurosci Ther. 2008 Spring;14(1):25-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18482097</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1977 Nov 11;136(2):345-50</Citation><ArticleIdList><ArticleId IdType="pubmed">922488</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 1999 Dec;11(12):4457-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10594673</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1990;16(1):31-56</Citation><ArticleIdList><ArticleId IdType="pubmed">2333480</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1567-71</Citation><ArticleIdList><ArticleId IdType="pubmed">1531874</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Dec;165(12):1585-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18923067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Jun;9(6):603-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14699426</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Genet. 2006 Feb;16(1):9-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16395124</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Mol Brain Res. 1995 Jan;28(1):175-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7707873</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2002 Mar 1;22(5):1541-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11880484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1991 Feb;39(2):157-63</Citation><ArticleIdList><ArticleId IdType="pubmed">1705000</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2007 May;30(5):220-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17400299</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Nov 5-11;330(6143):25-6</Citation><ArticleIdList><ArticleId IdType="pubmed">2823147</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Dec;11(12):1092-105</Citation><ArticleIdList><ArticleId IdType="pubmed">16983389</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2001 Oct;25(4):489-97</Citation><ArticleIdList><ArticleId IdType="pubmed">11557162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Feb;99(1-3):333-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18042347</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2009 Jul;34(8):1885-903</Citation><ArticleIdList><ArticleId IdType="pubmed">19339966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1991 Sep;40(3):333-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1654510</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jan 1;55(1):40-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14706423</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacologia. 1974;39(2):105-19</Citation><ArticleIdList><ArticleId IdType="pubmed">4155802</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1993 Feb;43(2):240-4</Citation><ArticleIdList><ArticleId IdType="pubmed">8381510</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genet. 2005 Aug;117(4):349-56</Citation><ArticleIdList><ArticleId IdType="pubmed">15915326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1999 Nov 1;19(21):9289-97</Citation><ArticleIdList><ArticleId IdType="pubmed">10531433</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17553960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2001 Jun;17(6):973-82</Citation><ArticleIdList><ArticleId IdType="pubmed">11414787</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1994 May;12(5):1081-95</Citation><ArticleIdList><ArticleId IdType="pubmed">8185945</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Jun 1;47(11):1000-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10838068</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1986 Dec 18-31;324(6098):670-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2432430</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Nov;57(11):1061-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11074872</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2000 Mar 10;858(2):371-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10708689</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1989 Apr 13;338(6216):582-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2538761</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Mar 1;61(5):653-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16950232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1994 Mar;45(3):475-80</Citation><ArticleIdList><ArticleId IdType="pubmed">8145733</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1990 Mar 22;293(4):599-615</Citation><ArticleIdList><ArticleId IdType="pubmed">2329196</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2005 Feb;6(2):95-108</Citation><ArticleIdList><ArticleId IdType="pubmed">15716906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2000 Mar 24;275(12):8921-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10722739</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2000 Jan;3(1):22-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10607391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Feb 14;278(7):5399-409</Citation><ArticleIdList><ArticleId IdType="pubmed">12435728</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2007 Aug 29;2(8):e809</Citation><ArticleIdList><ArticleId IdType="pubmed">17726539</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 2006 Sep;36(5):640-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16622805</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 1996 Feb;66(2):685-91</Citation><ArticleIdList><ArticleId IdType="pubmed">8592140</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2008 Oct;39(2):161-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18625319</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1987 Jul 16-22;328(6127):221-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3037384</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2004 Nov 18;47(24):5829-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15537339</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2008 May;9(5):331-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18382465</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jun 7;447(7145):661-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17554300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2004 Apr;89(1):7-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15030384</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1991 Jan;4(1):9-15</Citation><ArticleIdList><ArticleId IdType="pubmed">1706183</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Feb;13(2):187-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17579608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2001 May 14;433(4):526-49</Citation><ArticleIdList><ArticleId IdType="pubmed">11304716</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Feb 1;47(3):210-20</Citation><ArticleIdList><ArticleId IdType="pubmed">10682218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Feb;9(2):213-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14699422</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Sep;86(1-3):1-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16842972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 2000 May 15;420(4):481-98</Citation><ArticleIdList><ArticleId IdType="pubmed">10805922</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2003 Oct;24(2):442-50</Citation><ArticleIdList><ArticleId IdType="pubmed">14572465</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Brain Res Rev. 2001 Nov;37(1-3):301-12</Citation><ArticleIdList><ArticleId IdType="pubmed">11744095</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Dec 3;13(17):2355-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12488826</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):299-303</Citation><ArticleIdList><ArticleId IdType="pubmed">9989567</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">14601037</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Mar;91(1-3):51-61</Citation><ArticleIdList><ArticleId IdType="pubmed">17270400</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2005 Sep 2;334(3):817-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16023997</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Apr;12(4):385-97</Citation><ArticleIdList><ArticleId IdType="pubmed">17264840</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2002 Oct 4;951(2):237-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12270502</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2002 Oct;12(10):1063-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12217970</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2002 Aug 16;296(2):492-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12163046</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2008 Jul;40(7):827-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18583979</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:405A-406A</Citation><ArticleIdList><ArticleId IdType="pubmed">1323398</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jul 15;13(14):1471-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15150161</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2004 Aug 15;129B(1):104-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15274050</ArticleId></ArticleIdList></Reference><Reference><Citation>Life Sci. 2002 Dec 20;72(4-5):443-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12467885</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Jan;64(1):19-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17199051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2009 Jun 19;284(25):17253-17265</Citation><ArticleIdList><ArticleId IdType="pubmed">19380581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Interv. 2008 Apr;8(2):99-107</Citation><ArticleIdList><ArticleId IdType="pubmed">18403654</ArticleId></ArticleIdList></Reference><Reference><Citation>J Histochem Cytochem. 2005 Dec;53(12):1517-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16087704</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Feb;64(2):156-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17283283</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2004 Sep;29(9):1597-609</Citation><ArticleIdList><ArticleId IdType="pubmed">15100702</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2005 Dec;77(6):918-36</Citation><ArticleIdList><ArticleId IdType="pubmed">16380905</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2001 Jan;2(1):11-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11253355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Rev. 1995 Jun;47(2):181-234</Citation><ArticleIdList><ArticleId IdType="pubmed">7568326</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15066-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9844016</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10806-10</Citation><ArticleIdList><ArticleId IdType="pubmed">7479888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharmacol. 1993 Jun;43(6):970-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8391122</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2004 Jul;90(1):173-89</Citation><ArticleIdList><ArticleId IdType="pubmed">15198677</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Aug;71(2):337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12098102</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2008 Feb;45(2):100-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17893116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1995 Sep;15(3):563-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7546736</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurosci. 2001 Feb;13(3):428-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11168550</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):40-68; image 5</Citation><ArticleIdList><ArticleId IdType="pubmed">15263907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Feb;15(2):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19078961</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Mar;51(3):199-214</Citation><ArticleIdList><ArticleId IdType="pubmed">8122957</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1996 May 15;16(10):3166-77</Citation><ArticleIdList><ArticleId IdType="pubmed">8627355</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 1998 Apr;32(4):375-85</Citation><ArticleIdList><ArticleId IdType="pubmed">9596562</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14439-44</Citation><ArticleIdList><ArticleId IdType="pubmed">14623958</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1994 Mar 1;341(1):95-116</Citation><ArticleIdList><ArticleId IdType="pubmed">8006226</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2002;136:157-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12143379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2005 Apr;6(4):312-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15803162</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 1998 Nov;1(7):563-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10196563</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Jul;158(7):1105-13</Citation><ArticleIdList><ArticleId IdType="pubmed">11431233</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jan 7;24(1):207-17</Citation><ArticleIdList><ArticleId IdType="pubmed">14715953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2003 Jun;23(2):264-78</Citation><ArticleIdList><ArticleId IdType="pubmed">12812758</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 1994 Nov;271(2):677-82</Citation><ArticleIdList><ArticleId IdType="pubmed">7965782</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1982 Apr 20;206(4):397-416</Citation><ArticleIdList><ArticleId IdType="pubmed">7096634</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 1988 Aug;2(11):2707-11</Citation><ArticleIdList><ArticleId IdType="pubmed">3135223</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2003 Dec;13(12):1369-74</Citation><ArticleIdList><ArticleId IdType="pubmed">14615302</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2003 Jan;28(1):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12496935</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2005 Feb;76(2):237-48</Citation><ArticleIdList><ArticleId IdType="pubmed">15614721</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1996 May;14(5):301-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8703299</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8594-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10900017</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1979 Feb 3;1(8110):237-9</Citation><ArticleIdList><ArticleId IdType="pubmed">84898</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Feb 28;82(2-3):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16414245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2001 Sep;4(9):908-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11528422</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2002 Sep;43(4):651-61</Citation><ArticleIdList><ArticleId IdType="pubmed">12367610</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2000 Nov 1;20(21):7972-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11050117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Histochem Cytochem. 1998 Oct;46(10):1129-39</Citation><ArticleIdList><ArticleId IdType="pubmed">9742069</ArticleId></ArticleIdList></Reference><Reference><Citation>Seikagaku. 2003 May;75(5):378-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12822435</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Nov 1;58(1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12363385</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Dec;13(12):1102-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17938637</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotox Res. 2008 Oct;14(2-3):97-104</Citation><ArticleIdList><ArticleId IdType="pubmed">19073417</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2002 Mar 1;21(5):1004-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11867528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">26309020</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-837X</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>11</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Journal of medical economics</Title><ISOAbbreviation>J Med Econ</ISOAbbreviation></Journal><ArticleTitle>The need for cost-effective choices to treat patients with bipolar 1 disorders including asenapine.</ArticleTitle><Pagination><MedlinePgn>871-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3111/13696998.2015.1073736</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar 1 disorders (BPD) are a chronic disorder with prevalence rates of up to 2.6% of the adult population or higher and appreciable direct and indirect costs. As a result, these are a concern to health authorities especially given the low age of onset. Consequently, there is a need to treat BPD patients well and improve their quality-of-life. Pharmacotherapy includes mood stabilizers and atypical antipsychotics (AAPs). AAPs have different mechanisms of action and side-effects, so treatment needs to be tailored. Asenapine in clinical trials is as effective as olanzapine, with less metabolic side-effects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Chitnis and colleagues assessed the cost-effectiveness of asenapine among patients in healthcare databases.</AbstractText><AbstractText Label="RESULTS AND CONCLUSION" NlmCategory="CONCLUSIONS">They showed in routine care that asenapine also reduces hospital and emergency room admissions, making it cost neutral in BPD, which is of interest to health authorities and clinicians.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Godman</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>a a Department of Laboratory Medicine, Division of Clinical Pharmacology , Karolinska Institutet, Karolinska University Hospital Huddinge , Stockholm , Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b b Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde , Glasgow , UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Med Econ</MedlineTA><NlmUniqueID>9892255</NlmUniqueID><ISSNLinking>1369-6998</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Med Econ. 2015;18(11):863-70</RefSource><PMID Version="1">26121161</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006296" MajorTopicYN="N">Health Services</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asenapine</Keyword><Keyword MajorTopicYN="N">Atypical antipsychotics</Keyword><Keyword MajorTopicYN="N">Bipolar 1 disorder</Keyword><Keyword MajorTopicYN="N">Quality-of-life</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26309020</ArticleId><ArticleId IdType="doi">10.3111/13696998.2015.1073736</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25556671</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>174</Volume><PubDate><Year>2015</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Prevalence and predictors of bipolar disorders in patients with a major depressive episode: the Japanese epidemiological trial with latest measure of bipolar disorder (JET-LMBP).</ArticleTitle><Pagination><MedlinePgn>535-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2014.12.023</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(14)00809-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">For patients with a major depressive episode, early differential diagnosis of bipolar disorder and subsequent appropriate treatment are critical. This study, conducted in clinical settings in Japan, examined patients with a major depressive episode to investigate the prevalence and predictors of bipolar disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 448 patients with a major depressive episode were interviewed using the Mini-International Neuropsychiatric Interview to determine the presence of mood episodes and psychiatric comorbidities. The diagnosis of bipolar disorder was based on the collected information according to the DSM-IV-TR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 448 patients with a major depressive episode, 114 patients (25.4%) were diagnosed with bipolar disorder. Multivariate logistic regression identified five predictors that were significantly correlated with bipolar disorder: antidepressant-related switch to mania/hypomania, mixed depression, two or more previous mood episodes within the past year, early age at the onset of a major depressive episode (&lt;25 years), and a history of suicide attempts. The area under the curve of receiver operating characteristic analysis based on the multivariate logistic regression of the five predictors was 0.849.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The diagnosis of bipolar disorder in patients was already conclusively confirmed by long illness observations but was not confirmed by a prospective study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with a major depressive episode, the differential diagnosis of bipolar disorder and major depressive disorder, which exhibit similar depressive symptoms, is essential. Several predictors identified in the present study may be useful in supporting a differential diagnosis of these disorders in routine clinical practice.</AbstractText><CopyrightInformation>Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hokkaido University Graduate School of Medicine, Japan. Electronic address: tinoue@med.hokudai.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Yoshifumi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroscience Department, Medical Affairs Division, GlaxoSmithKline K.K., Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimura</LastName><ForeName>Toshifumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neuroscience Department, Medical Affairs Division, GlaxoSmithKline K.K., Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirakawa</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kinki University, Faculty of Medicine, Japan. Electronic address: sirakawa@med.kindai.ac.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">DSM-IV-TR</Keyword><Keyword MajorTopicYN="N">Differential diagnosis</Keyword><Keyword MajorTopicYN="N">Major depressive disorder</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25556671</ArticleId><ArticleId IdType="pii">S0165-0327(14)00809-X</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2014.12.023</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17097740</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>1-3</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Trait impulsivity in patients with mood disorders.</ArticleTitle><Pagination><MedlinePgn>227-31</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Impulsivity is a key component of the manic behavior of bipolar disorder and is reported to occur in bipolar patients as a stable characteristic, i.e. a trait. Nevertheless, impulsivity has not been widely studied in depressed bipolar patients. We assessed impulsivity in depressed and euthymic bipolar and unipolar patients and healthy controls. We hypothesized that bipolar subjects would have higher levels of trait impulsivity than the comparison groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Twenty-four depressed bipolar, 24 depressed unipolar, 12 euthymic bipolar, and 10 euthymic unipolar patients, as well as 51 healthy subjects were evaluated with the Barratt Impulsiveness Scale (BIS). Analysis of covariance with age and sex as covariates was used to compare mean group differences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Depressed bipolar, euthymic bipolar, and depressed unipolar patients did not differ, and showed greater impulsivity than healthy controls on all of the BIS scales. Euthymic unipolar patients scored higher than healthy controls only on motor impulsivity.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Higher number of past substance abusers in the bipolar groups, and no control for anxiety and personality disorders, as well as small sample sizes, limit the reach of this study.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study replicates prior findings of stable trait impulsivity in bipolar disorder patients, and extends them, confirming that this trait can be demonstrated in depressed patients, as well as manic and euthymic ones. Trait impulsivity may be the result of repeated mood episodes or be present prior to their onset, either way it would influence the clinical presentation of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peluso</LastName><ForeName>M A M</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Texas Health Science Center at San Antonio, USA. mampeluso@hotmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatch</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Glahn</LastName><ForeName>D C</ForeName><Initials>DC</Initials></Author><Author ValidYN="Y"><LastName>Monkul</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Sanches</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Najt</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Barratt</LastName><ForeName>E S</ForeName><Initials>ES</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>M01-RR-01346</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH01736</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH068662</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>11</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>04</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>09</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>11</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17097740</ArticleId><ArticleId IdType="pii">S0165-0327(06)00438-1</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2006.09.037</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11082479</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine).</ArticleTitle><Pagination><MedlinePgn>1028-31</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We have previously proposed that the therapeutic effect of transdermal nicotine in Tourette's syndrome may involve nicotinic receptor inactivation resulting from a prolonged continuous exposure to nicotine. In vitro studies with nicotine and preliminary positive experience with mecamylamine (Inversine), a nicotinic receptor antagonist, in the clinical treatment of Tourette's syndrome patients, further supports the receptor inactivation hypothesis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively documented an unexpected therapeutic response to mecamylamine (2.5-7.5 mg/day) in two Tourette's syndrome patients who were subsequently found to have comorbid bipolar disorder as defined by DSM-IV criteria.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In patient 1, the mood-stabilizing effect of mecamylamine was noticed by the patient during the course of mecamylamine treatment and brought to our attention, whereas for patient 2, manic symptoms were only apparent clinically following cessation of mecamylamine treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The clinical observations presented here suggest that nicotinic antagonists might be potential therapeutic agents for the treatment of bipolar disorder. Double-blind, placebo-controlled studies are now necessary to investigate these observations under more rigorous conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shytle</LastName><ForeName>R D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa, Florida 33613, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silver</LastName><ForeName>A A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Sanberg</LastName><ForeName>P R</ForeName><Initials>PR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018733">Nicotinic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>6EE945D3OK</RegistryNumber><NameOfSubstance UI="D008464">Mecamylamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008464" MajorTopicYN="N">Mecamylamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018733" MajorTopicYN="N">Nicotinic Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005879" MajorTopicYN="N">Tourette Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11082479</ArticleId><ArticleId IdType="pii">S0006-3223(00)00945-8</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(00)00945-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2912232</PMID><DateCompleted><Year>1989</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>146</Volume><Issue>1</Issue><PubDate><Year>1989</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Mania associated with high percentage of inhibition of monoamine oxidase.</ArticleTitle><Pagination><MedlinePgn>121</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bowden</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Seleshi</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Javors</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.4.3.4</RegistryNumber><NameOfSubstance UI="D008995">Monoamine Oxidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>O408N561GF</RegistryNumber><NameOfSubstance UI="D010624">Phenelzine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008995" MajorTopicYN="N">Monoamine Oxidase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010624" MajorTopicYN="N">Phenelzine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2912232</ArticleId><ArticleId IdType="doi">10.1176/ajp.146.1.121b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3400785</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9564</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>2</Issue><PubDate><Year>1988</Year><Month>Apr</Month></PubDate></JournalIssue><Title>American journal of psychotherapy</Title><ISOAbbreviation>Am J Psychother</ISOAbbreviation></Journal><ArticleTitle>Group therapy in manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>263-71</MedlinePgn></Pagination><Abstract><AbstractText>Noting the recent growth of self-help groups for manic-depressive illness and considering the scarcity of empirical studies on the effectiveness of group therapy in the treatment of this illness, this review examines the three available reports on groups and adds a fourth report on the authors' experience with a group over four-and-a-half years. The evidence argues in favor of combined lithium and group therapy. Some research questions and strategies for investigation follow.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wulsin</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bachop</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychother</MedlineTA><NlmUniqueID>0110672</NlmUniqueID><ISSNLinking>0002-9564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="N">Professional-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3400785</ArticleId><ArticleId IdType="doi">10.1176/appi.psychotherapy.1988.42.2.263</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25844756</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>76</Volume><Issue>4</Issue><PubDate><Year>2015</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.</ArticleTitle><Pagination><MedlinePgn>398-405</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.14m09410</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Mixed (subsyndromal hypomanic) features are prevalent in patients with bipolar depression and are associated with more severe and complex illness, including increased risk for suicide attempts, higher switch to mania during antidepressant therapy, and a higher rate of recurrence. The aim of this post hoc analysis was to evaluate the efficacy and safety of lurasidone in the treatment of patients with bipolar depression presenting with mixed features.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with a DSM-IV-TR diagnosis of major depressive episode associated with bipolar I disorder, with or without rapid cycling, and with a Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 20 and a Young Mania Rating Scale (YMRS) score ≤ 12 were randomly assigned to 6 weeks of double-blind, once-daily treatment with lurasidone 20-60 mg, lurasidone 80-120 mg, or placebo. The presence of mixed features was defined as a YMRS score ≥ 4 at study baseline. Efficacy analyses included change in MADRS total score from baseline to week 6 (the primary outcome in the original study, conducted between April 2009 and February 2012).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At baseline, mixed features were present in 56% of patients (lurasidone, n = 182/323; placebo, n = 90/162). Treatment with lurasidone (vs placebo) was associated with significantly greater reductions in MADRS scores in the mixed features group (-15.7 vs -10.9; P = .001; week 6; mixed model for repeated measures [MMRM]; effect size, 0.48) and in the group without mixed features (-15.2 vs -10.8; P = .002; week 6; MMRM; effect size, 0.48). Rates of protocol-defined treatment-emergent hypomania or mania were similar for patients with mixed features (lurasidone, 2.2%; placebo, 3.2%) and without mixed features (lurasidone, 3.4%; placebo, 0.0%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Lurasidone was found in this post hoc analysis to be efficacious in the treatment of patients with bipolar depression who present with mixed features (assessed cross-sectionally at study baseline). No increased risk of treatment-emergent mania was observed in either group.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov identifier: NCT00868699.</AbstractText><CopyrightInformation>© Copyright 2015 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>University of Toronto, Departments of Psychiatry and Pharmacology, Mood Disorders Psychopharmacology Unit, 399 Bathurst St, MP 9-325, Toronto, ON, Canada M5T 2S8 roger.mcintyre@uhn.on.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cucchiaro</LastName><ForeName>Josephine</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pikalov</LastName><ForeName>Andrei</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kroger</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Loebel</LastName><ForeName>Antony</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00868699</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054833">Isoindoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>O0P4I5851I</RegistryNumber><NameOfSubstance UI="D000069056">Lurasidone Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054833" MajorTopicYN="N">Isoindoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069056" MajorTopicYN="N">Lurasidone Hydrochloride</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25844756</ArticleId><ArticleId IdType="doi">10.4088/JCP.14m09410</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4024796</PMID><DateCompleted><Year>1985</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0044-4588</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>5</Issue><PubDate><Year>1985</Year></PubDate></JournalIssue><Title>Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952)</Title><ISOAbbreviation>Zh Nevropatol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Population patterns in the dynamics of episodes and remission in patients with endogenous psychoses].</ArticleTitle><Pagination><MedlinePgn>730-6</MedlinePgn></Pagination><Abstract><AbstractText>Analyzing the data on 1770 patients with paroxysmal schizophrenia with a disease standing of 15 years and over, the authors established a statistically significant correlation between the clinical picture of remissions and attacks in the preceeding and the subsequent cycle of the disease. This correlation was expressed in the fact and from the second cycle to the third, the probability of the appearance of the same psychopathological disturbances was at least two times as that of the development of any other concrete disorders. The first three cycles of the disease were analyzed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shmaonova</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Liberman</LastName><ForeName>Iu I</ForeName><Initials>IuI</Initials></Author><Author ValidYN="Y"><LastName>Khokhlov</LastName><ForeName>E N</ForeName><Initials>EN</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Populiatsionnye zakonomernosti dinamiki pristupov i remissiĭ u bol'nykh éndogennymi psikhozami.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevropatol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>8710066</NlmUniqueID><ISSNLinking>0044-4588</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4024796</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10404709</PMID><DateCompleted><Year>1999</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>3</Issue><PubDate><Year>1999</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The effect of the first manic episode in affective disorder: a case register study of hospitalised episodes.</ArticleTitle><Pagination><MedlinePgn>233-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It is poorly understood how the course of illness in depressive patients is affected by a manic episode.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The course of hospitalised episodes was compared for patients with depressive episodes only, patients who presented with a manic or circular first episode and patients who presented with a depressive first episode and later developed mania. The Danish psychiatric central register was used as a study base, including all hospital admissions with primary affective disorder in Denmark during 1971-1993.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 17,447 patients presented with a depressive first episode and 2903 patients with a manic or circular first episode. Among the 17,447 depressive patients, 762 patients presented with mania at later episodes (4.4%). Younger age at onset was associated with increased risk of developing mania. Patients who had a late first manic episode had the same rate of subsequent recurrence as patients with mania at first episode and this rate was higher than the rate of recurrence for patients who remained having depressive episodes only. Time since first manic episode was without importance in relation to the risk of subsequent recurrence.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients who present with depression and later develop mania have from onset the same risk of recurrence as initially bipolar patients.</AbstractText><AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">The data relate to admissions rather than episodes.</AbstractText><AbstractText Label="CLINICAL RELEVANCE" NlmCategory="CONCLUSIONS">Younger patients who present with depression have increased risk of developing bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Copenhagen, Rigshospitalet, Denmark. lars.kessing@dadlnet.dk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10404709</ArticleId><ArticleId IdType="pii">S0165032798001268</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(98)00126-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6962437</PMID><DateCompleted><Year>1983</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>3</Issue><PubDate><Year>1982</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Daytime sleep patterns of primary depressives: a morning nap study.</ArticleTitle><Pagination><MedlinePgn>287-98</MedlinePgn></Pagination><Abstract><AbstractText>The electroencephalographic sleep patterns of 10 primary depressives were recorded during baseline nights and two morning nap sessions using a fixed time schedule. Averaged sleep measures for baseline nights replicated previous findings of altered rapid eye movement (REM) sleep patterns and sleep continuity. REM sleep during morning naps occurred only in patients with elevated REM indexes on baseline and prenap nights; it failed to appear in morning sleep of patients who exhibited contrasting REM characteristics. An analysis of hourly REM sleep distribution and averaged deviations from group means revealed significant differences between the two groups which could account for the uneven daytime REM propensity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pugnetti</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cazzullo</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Leccardi</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sicuro</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Scarone</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012894" MajorTopicYN="Y">Sleep Stages</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012895" MajorTopicYN="N">Sleep, REM</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6962437</ArticleId><ArticleId IdType="pii">0165-1781(82)90065-8</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(82)90065-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2278981</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>3</Issue><PubDate><MedlineDate>1990 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Gender differences in affective, schizoaffective, and schizophrenic disorders. A review.</ArticleTitle><Pagination><MedlinePgn>159-72</MedlinePgn></Pagination><Abstract><AbstractText>The authors review the literature on sex differences in four DSM-III diagnoses: schizophrenia, schizoaffective psychoses, unipolar and bipolar affective disorders. The findings indicate that (1) gender differences occur most frequently in schizophrenic patients: schizophrenic women exhibit a less deteriorated course of illness; (2) sex differences in affective disordered patients support the unipolar-bipolar subtype distinction; and (3) sex differences are less compelling but also less studied in schizoaffective disorder. Theories attempting to explain sex differences in schizophrenia are reviewed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bardenstein</LastName><ForeName>K K</ForeName><Initials>KK</Initials><AffiliationInfo><Affiliation>Chestnut Lodge Research Institute, Rockville, MD 20850.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGlashan</LastName><ForeName>T H</ForeName><Initials>TH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 35174-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>115</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2278981</ArticleId><ArticleId IdType="pii">0920-9964(90)90034-5</ArticleId><ArticleId IdType="doi">10.1016/0920-9964(90)90034-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16566616</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>215-21</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Data characterizing bipolar disorder in older people are scarce, particularly on functional status. We evaluated health-related quality of life and functioning (HRQoLF) among older outpatients with bipolar disorder as well as the relationship of HRQoLF to bipolar illness characteristics.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We compared community-dwelling middle-aged and older adults (age range, 45 to 85 years) with bipolar disorder (N=54; mean age=57.6 years), schizophrenia (N=55; mean age=58.5 years), or no psychiatric illnesses (N=38; mean age=64.7 years) on indicators of objective functioning (e.g., education, occupational attainment, medical comorbidity) and health status (e.g., Quality of Well-Being scale [QWB] and the Medical Outcomes Study-Short Form Health Survey [SF-36]). Within the group with bipolar disorder, we examined the relationship between HRQoLF and clinical variables (e.g., phase and duration of illness, psychotic symptoms, cognitive functioning).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with bipolar disorder were similar in educational and occupational attainment to the normal comparison group, but they obtained lower scores on the QWB and SF-36 (with large effect sizes). Compared with schizophrenia, bipolar disorder was associated with better educational and work histories but similar QWB and SF-36 scores and more medical comorbidity. Patients in remission from bipolar disorder had QWB scores that were worse than those of normal comparison subjects. Greater severity of psychotic and depressive symptoms and cognitive impairment were associated with lower HRQoLF.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar disorder was associated with substantial disability in this sample of older adults, similar in severity to schizophrenia. Remission of bipolar disorder was associated with significant but incomplete improvement in functioning, whereas psychotic and depressive symptoms and cognitive impairment seemed to contribute to lower HRQoLF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Depp</LastName><ForeName>Colin A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, CA 92161, and the VA Health Services Research and Development Center for Mental Healthcare and Outcomes Research, Central Arkansas Veterans Healthcare System, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>C Ervin</ForeName><Initials>CE</Initials></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Dinesh</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Jeste</LastName><ForeName>Dilip V</ForeName><Initials>DV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH59101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH66248</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16566616</ArticleId><ArticleId IdType="doi">10.4088/jcp.v67n0207</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15554762</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>65</Volume><Issue>11</Issue><PubDate><Year>2004</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample.</ArticleTitle><Pagination><MedlinePgn>1499-504</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In the present study, we assessed the functional impact of depressive versus manic symptoms in bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A survey comprising the Sheehan Disability Scale (SDS), the Social Adjustment Scale Self-Report (SAS-SR), the Mood Disorder Questionnaire (MDQ), and other questions was mailed to a representative subset of 4810 individuals (with or without bipolar disorder) from a U.S. population-based epidemiologic study conducted in 2001.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 3191 evaluable surveys returned, 593 respondents screened positive for bipolar disorder on the MDQ and/or reported a physician diagnosis of bipolar disorder. In the 4 weeks prior to the survey, subjects reported a mean of 12.4 days of depressive symptoms and 7.0 days of manic symptoms (p &lt; .0001). The majority of days with depressive (79.8%) and manic (77.1%) symptoms were disruptive. Both total and mean scores on each domain of the SDS (work, social life, family life) reflect significantly greater impairment because of depressive versus manic symptoms during the 4 weeks prior to the survey (p &lt; .0001). Among the 118 employed subjects who missed at least 1 day of work in the past month, more workdays were missed because of depressive versus manic symptoms (0.78 vs. 0.15, p &lt; .004). For each domain of the SAS-SR, functional impairment was attributed significantly more often to depressive symptoms than manic symptoms (p &lt; .0001). Similar results were observed for the 12 months preceding the survey.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Self-reported depressive symptoms are more frequent than manic symptoms and cause greater disruption of occupational, family, and social functioning. These findings underscore the need to improve the recognition and management of bipolar depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>University Hospitals of Cleveland/Case Western Reserve School of Medicine, Cleveland, Ohio, USA. joseph.calabrese@uhhs.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschfeld</LastName><ForeName>Robert M A</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Reed</LastName><ForeName>Michael L</ForeName><Initials>ML</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH079261</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018434" MajorTopicYN="N">Sickness Impact Profile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15554762</ArticleId><ArticleId IdType="doi">10.4088/jcp.v65n1109</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24308489</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1601-183X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Genes, brain, and behavior</Title><ISOAbbreviation>Genes Brain Behav</ISOAbbreviation></Journal><ArticleTitle>An ASMT variant associated with bipolar disorder influences sleep and circadian rhythms: a pilot study.</ArticleTitle><Pagination><MedlinePgn>299-304</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/gbb.12103</ELocationID><Abstract><AbstractText>Patients with bipolar disorder (BD) experience persistent circadian rhythm and sleep abnormalities during periods of remission, and biological studies have shown that these patients have abnormal melatonin secretion profiles or reactivity to light. We previously reported the association with BD of a common polymorphism (rs4446909) of the promoter of the acetylserotonin O-methyltransferase (ASMT) gene, encoding one of the two enzymes involved in melatonin biosynthesis. This variant was associated with weaker transcription and lower levels of ASMT activity in lymphoblastoid cell lines. Actigraphy, based on the use of a mobile portable device for the analysis of sleep/wake cycles in natural conditions, may be useful for studies of carriers of the at-risk allele. We studied the association between the ASMT rs4446909 variant and sleep/activity, as assessed with the Pittsburgh Sleep Quality Index (PSQI) and by actigraphy, in 53 subjects (25 patients with BD in remission and 28 healthy controls). The two groups were similar for age, sex ratio, current mood symptoms, body mass index and risk of sleep apnea syndrome. In the total sample, the GG at-risk genotype was associated with longer sleep duration (P = 0.03), greater activity in active periods of sleep (P = 0.015) and greater interday stability (P = 0.003). These associations remained significant when disease status was included in the model. Only the association with interday stability remained significant after correction for multiple testing. This pilot study thus shows that a BD-associated functional variant involved in the melatonin synthesis pathway influences sleep and circadian rhythms in bipolar patients in remission and controls. </AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons Ltd and International Behavioural and Neural Genetics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geoffroy</LastName><ForeName>P A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>INSERM, U955, Psychiatrie Génétique; Pôle de Psychiatrie, AP-HP, Hôpital H. Mondor - A. Chenevier, Créteil; Pôle de Psychiatrie, Université Lille Nord de France, CHRU de Lille, Lille; Fondation FondaMental.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudebesse</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Henrion</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jamain</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Genes Brain Behav</MedlineTA><NlmUniqueID>101129617</NlmUniqueID><ISSNLinking>1601-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.1.1.4</RegistryNumber><NameOfSubstance UI="C523771">ASMT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.4</RegistryNumber><NameOfSubstance UI="D000121">Acetylserotonin O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000121" MajorTopicYN="N">Acetylserotonin O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="Y">Circadian Rhythm</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ASMT gene</Keyword><Keyword MajorTopicYN="N">Actigraphy</Keyword><Keyword MajorTopicYN="N">Pittsburgh Sleep Quality Index</Keyword><Keyword MajorTopicYN="N">activity</Keyword><Keyword MajorTopicYN="N">biomarkers</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">chronobiology</Keyword><Keyword MajorTopicYN="N">circadian rhythms</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>09</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24308489</ArticleId><ArticleId IdType="doi">10.1111/gbb.12103</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8464954</PMID><DateCompleted><Year>1993</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>1993</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Frequency of seasonal affective disorder among individuals seeking treatment at a northern Canadian mental health center.</ArticleTitle><Pagination><MedlinePgn>41-5</MedlinePgn></Pagination><Abstract><AbstractText>The frequency of seasonal affective disorder (SAD) was examined in clients receiving treatment for recurrent mood disturbances in a northern Canadian site. Approximately one-fifth of these individuals were identified as having SAD when file histories and a statistical criterion were used as the basis for assessment. The failure to find a higher prevalence rate at this latitude may be due to other studies' reliance on client self-report, a tendency for individuals with SAD to relocate south, or a greater tendency for clients with SAD to be seen by general practitioners and alcohol treatment centers in the north.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Health, Province of Manitoba, Thompson, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>G G</ForeName><Initials>GG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003155" MajorTopicYN="N">Community Mental Health Centers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008350" MajorTopicYN="N">Manitoba</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016574" MajorTopicYN="N">Seasonal Affective Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012931" MajorTopicYN="N">Social Environment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8464954</ArticleId><ArticleId IdType="pii">0165-1781(93)90006-3</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(93)90006-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10624556</PMID><DateCompleted><Year>2000</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>12</Issue><PubDate><Year>1999</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1711-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hamer</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Biol Psychiatry. 1999 Apr 15;45(8):953-8</RefSource><PMID Version="1">10386176</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>5</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>1</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10624556</ArticleId><ArticleId IdType="pii">S0006-3223(99)00198-5</ArticleId><ArticleId IdType="doi">10.1016/s0006-3223(99)00198-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4003613</PMID><DateCompleted><Year>1985</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>142</Volume><Issue>6</Issue><PubDate><Year>1985</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A haloperidol-carbamazepine interaction in a patient with rapid-cycling bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>785-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yerevanian</LastName><ForeName>B I</ForeName><Initials>BI</Initials></Author><Author ValidYN="Y"><LastName>Hodgman</LastName><ForeName>C H</ForeName><Initials>CH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4003613</ArticleId><ArticleId IdType="doi">10.1176/ajp.142.6.785b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6657807</PMID><DateCompleted><Year>1984</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2739</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>10</Issue><PubDate><Year>1983</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Psychiatrie, Neurologie, und medizinische Psychologie</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol (Leipz)</ISOAbbreviation></Journal><ArticleTitle>[Initial experiences with regulative music therapy in psychiatric patients].</ArticleTitle><Pagination><MedlinePgn>604-10</MedlinePgn></Pagination><Abstract><AbstractText>This is an initial report on experiences gained with the inclusion of regulative music therapy for patients with depressive reactions stemming from a variety of causes. The experience gained so far suggest that regulative music therapy can be beneficial during the readaptation phase in the course of rehabilitation of such patients. Orientation on conscious perception seems to be a characteristic of RMT among depressive patients during the first phase of training. This conscious perception leads the patient to a more rational form of confrontation with himself and his surroundings. This opens the way to a constructive approach to overcoming the conflicts experienced in the past.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reinhardt</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ficker</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Erste Erfahrungen mit Regulativer Musiktherapie bei psychiatrischen Patienten.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol (Leipz)</MedlineTA><NlmUniqueID>0376467</NlmUniqueID><ISSNLinking>0033-2739</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000275" MajorTopicYN="N">Adjustment Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009147" MajorTopicYN="N">Music Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6657807</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16137268</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1073-6077</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>3</Issue><PubDate><MedlineDate>2005 Jul-Sep</MedlineDate></PubDate></JournalIssue><Title>Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc</Title><ISOAbbreviation>J Child Adolesc Psychiatr Nurs</ISOAbbreviation></Journal><ArticleTitle>Milieu management of a child with bipolar illness.</ArticleTitle><Pagination><MedlinePgn>113-5</MedlinePgn></Pagination><Abstract><AbstractText>During inpatient psychiatric treatment, children with bipolar disorder may present particular management issues. They may experience intense periods of affect regulation that can spiral into frenetic, aggressive behaviors that are difficult to interrupt with de-escalation techniques. This case study presents such a child and the behavior patterns that resulted in seclusion and PRN medication. Also presented is the plan that staff derived which eventually helped this young boy regulate his behavior.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beal</LastName><ForeName>Davena</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children 's Inpatient Unit,Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delaney</LastName><ForeName>Kathleen R</ForeName><Initials>KR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Child Adolesc Psychiatr Nurs</MedlineTA><NlmUniqueID>9431738</NlmUniqueID><ISSNLinking>1073-6077</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000786" MajorTopicYN="N">Anger</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003463" MajorTopicYN="N">Cues</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008884" MajorTopicYN="N">Milieu Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009723" MajorTopicYN="N">Nurse-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010356" MajorTopicYN="N">Patient Isolation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011568" MajorTopicYN="N">Psychiatric Nursing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002666" MajorTopicYN="N">Psychology, Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020377" MajorTopicYN="N">Self Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016728" MajorTopicYN="N">Self-Injurious Behavior</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>9</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16137268</ArticleId><ArticleId IdType="pii">JCAP020</ArticleId><ArticleId IdType="doi">10.1111/j.1744-6171.2005.00020.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17164645</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2011</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1077-4114</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>12</Issue><PubDate><Year>2006</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of pediatric hematology/oncology</Title><ISOAbbreviation>J Pediatr Hematol Oncol</ISOAbbreviation></Journal><ArticleTitle>Prevalence of psychiatric disorders, depression, and suicidal behavior in child and adolescent with thalassemia major.</ArticleTitle><Pagination><MedlinePgn>781-4</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To study the rate of psychiatric disorder and suicidal behavior in children with thalassemia major.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">One hundred ten subjects with thalassemia major were interviewed according to the K-SADS Farsi version by face-to-face interview.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">The most common psychiatric disorders were major depressive disorder and separation anxiety disorder. The rate of oppositional defiant disorder, attention-deficit hyperactivity disorder, and bipolar mood disorder were 3.6%, 1.8%, and 0.9%, respectively. About 49% suffered from depressed mood and 62.7% suffered from irritability and anger. More than 43% of them had recurrent thought of death and 27.3% considered suicide in the last year.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The rate of psychiatric disorders was very low than that in the prior studies and the most common was major depressive disorder. However, the rate of psychiatric symptoms was very common. The rate of suicidal behavior was not more than that in the general population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghanizadeh</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Hafez Hospital, Shiraz, Iran. ghanizad@sums.ac.ir</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khajavian</LastName><ForeName>Sirin</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ashkani</LastName><ForeName>Hamid</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Pediatr Hematol Oncol</MedlineTA><NlmUniqueID>9505928</NlmUniqueID><ISSNLinking>1077-4114</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="Y">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017086" MajorTopicYN="N">beta-Thalassemia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17164645</ArticleId><ArticleId IdType="doi">10.1097/01.mph.0000243665.79303.9e</ArticleId><ArticleId IdType="pii">00043426-200612000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21481244</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><PubDate><Year>2011</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Clinical management and burden of bipolar disorder: a multinational longitudinal study (WAVE-bd study).</ArticleTitle><Pagination><MedlinePgn>58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-244X-11-58</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies in bipolar disorder (BD) to date are limited in their ability to provide a whole-disease perspective--their scope has generally been confined to a single disease phase and/or a specific treatment. Moreover, most clinical trials have focused on the manic phase of disease, and not on depression, which is associated with the greatest disease burden. There are few longitudinal studies covering both types of patients with BD (I and II) and the whole course of the disease, regardless of patients' symptomatology. Therefore, the Wide AmbispectiVE study of the clinical management and burden of Bipolar Disorder (WAVE-bd) (NCT01062607) aims to provide reliable information on the management of patients with BD in daily clinical practice. It also seeks to determine factors influencing clinical outcomes and resource use in relation to the management of BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">WAVE-bd is a multinational, multicentre, non-interventional, longitudinal study. Approximately 3000 patients diagnosed with BD type I or II with at least one mood event in the preceding 12 months were recruited at centres in Austria, Belgium, Brazil, France, Germany, Portugal, Romania, Turkey, Ukraine and Venezuela. Site selection methodology aimed to provide a balanced cross-section of patients cared for by different types of providers of medical aid (e.g. academic hospitals, private practices) in each country. Target recruitment percentages were derived either from scientific publications or from expert panels in each participating country. The minimum follow-up period will be 12 months, with a maximum of 27 months, taking into account the retrospective and the prospective parts of the study. Data on demographics, diagnosis, medical history, clinical management, clinical and functional outcomes (CGI-BP and FAST scales), adherence to treatment (DAI-10 scale and Medication Possession Ratio), quality of life (EQ-5D scale), healthcare resources, and caregiver burden (BAS scale) will be collected. Descriptive analysis with common statistics will be performed.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This study will provide detailed descriptions of the management of BD in different countries, particularly in terms of clinical outcomes and resources used. Thus, it should provide psychiatrists with reliable and up-to-date information about those factors associated with different management patterns of BD.</AbstractText><AbstractText Label="TRIAL REGISTRATION NO" NlmCategory="BACKGROUND">ClinicalTrials.gov: NCT01062607.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Programme, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Villarroel 170, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco-Colmenares</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Figueira</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Langosch</LastName><ForeName>Jens M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Moreno-Manzanaro</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Medina</LastName><ForeName>Esteban</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><CollectiveName>WAVE-bd Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01062607</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019090" MajorTopicYN="Y">Case Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="N">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>04</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21481244</ArticleId><ArticleId IdType="pii">1471-244X-11-58</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-11-58</ArticleId><ArticleId IdType="pmc">PMC3087674</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatr Serv. 2004 Sep;55(9):1029-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15345763</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):45-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17391349</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 Nov;30(6):1391-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11097079</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 2001 Jun;41:s169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11450179</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2009;78(5):285-97</Citation><ArticleIdList><ArticleId IdType="pubmed">19602917</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2005 Aug;15(4):425-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15935623</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1028-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12788248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Aug;101(1-3):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17254637</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995 Jan;56(1):5-13</Citation><ArticleIdList><ArticleId IdType="pubmed">7836345</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 1991 Oct-Dec;4(4):204-10</Citation><ArticleIdList><ArticleId IdType="pubmed">1789908</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1997 Dec 5;73(3):159-71</Citation><ArticleIdList><ArticleId IdType="pubmed">9481807</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2007 Jun 07;3:5</Citation><ArticleIdList><ArticleId IdType="pubmed">17555558</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):103-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17391354</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Feb;4(1):50-60</Citation><ArticleIdList><ArticleId IdType="pubmed">12047495</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1983 Feb;13(1):177-83</Citation><ArticleIdList><ArticleId IdType="pubmed">6133297</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Ther. 1991 Jul-Aug;13(4):489-95</Citation><ArticleIdList><ArticleId IdType="pubmed">1934001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):183-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17391360</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Feb;121(1-2):156-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19505727</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Nov;71(11):1465-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20816029</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1999 Jul;175:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10621769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Apr;7(2):126-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15762853</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Policy. 1990 Dec;16(3):199-208</Citation><ArticleIdList><ArticleId IdType="pubmed">10109801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Aug;94(1-3):157-63</Citation><ArticleIdList><ArticleId IdType="pubmed">16737741</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2010 Sep 15;172(6):637-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20660123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19933711</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Catatonia in the DSM--shall we move or not?</ArticleTitle><Pagination><MedlinePgn>205-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbp136</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heckers</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Rajiv</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bustillo</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D054711">Introductory Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002389" MajorTopicYN="N">Catatonia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="Y">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009459" MajorTopicYN="N">Neuroleptic Malignant Syndrome</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012560" MajorTopicYN="N">Schizophrenia, Catatonic</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19933711</ArticleId><ArticleId IdType="pii">sbp136</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbp136</ArticleId><ArticleId IdType="pmc">PMC2833126</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry (Edgmont). 2008 Dec;5(12):42-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19724775</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 May;110(1-3):1-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19328655</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2005 Jan-Feb;38(1):3-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15714008</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2002 May-Jun;43(3):167-74</Citation><ArticleIdList><ArticleId IdType="pubmed">11994832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2008 Apr-Jun;20(2):97-107</Citation><ArticleIdList><ArticleId IdType="pubmed">18568581</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Mar;36(2):314-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19586994</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1996 Feb;93(2):129-36</Citation><ArticleIdList><ArticleId IdType="pubmed">8686483</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1999 Mar;142(4):393-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10229064</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Apr 30;49(3):269-85</Citation><ArticleIdList><ArticleId IdType="pubmed">11356588</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2001;251 Suppl 1:I14-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11776265</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Mar;36(2):359-69</Citation><ArticleIdList><ArticleId IdType="pubmed">18644851</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Mar;36(2):239-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19969591</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2001 Mar 1;47(2-3):117-26</Citation><ArticleIdList><ArticleId IdType="pubmed">11278128</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Mar;36(2):231-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19776208</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):27-38</Citation><ArticleIdList><ArticleId IdType="pubmed">15610942</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7705092</PMID><DateCompleted><Year>1995</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>36</Volume><Issue>1</Issue><PubDate><MedlineDate>1995 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Is puerperal psychosis bipolar mood disorder?: a phenomenological comparison.</ArticleTitle><Pagination><MedlinePgn>77-81</MedlinePgn></Pagination><Abstract><AbstractText>The most widely held current view on puerperal psychosis (PP) is that it is a mood disorder; some researchers have even suggested that it may be linked to bipolar mood disorder (BMD). To compare the phenomena of PP and BMD, 20 patients with PP were compared with 20 concurrent age-matched women with BMD, using the Structured Clinical Interview for DSM-III-R (SCID). To exclude patients with possible unipolar disorder, subjects with depression were not considered for inclusion in the study. A significantly greater proportion of the PP group experienced delusions of control, auditory hallucinations, blunted affect, and emotional turmoil. Seven (35%) of the PP patients fulfilled DSM-III-R criteria for BMD. These results do not support the hypothesis that PP and BMD are the same illness. Further research is necessary to explore the possibility of a link between these two conditions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oosthuizen</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tygerberg Hospital, Stellenbosch University, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russouw</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="N">Puerperal Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7705092</ArticleId><ArticleId IdType="pii">0010-440X(95)90102-2</ArticleId><ArticleId IdType="doi">10.1016/0010-440x(95)90102-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6726215</PMID><DateCompleted><Year>1984</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>172</Volume><Issue>7</Issue><PubDate><Year>1984</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Perceptual span in schizophrenia and affective disorders.</ArticleTitle><Pagination><MedlinePgn>431-5</MedlinePgn></Pagination><Abstract><AbstractText>Perceptual span was assessed in schizophrenic, bipolar affective disorder-manic, bipolar affective disorder-depressed, and nonpsychotic inpatients. Both schizophrenics and manics processed less information than depressives, and did not differ from each other. This suggests that reduced span may be a concomitant of psychoses characterized by distractibility and thought disorder, rather than a trait specific to schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Bohannon</LastName><ForeName>W E</ForeName><Initials>WE</Initials></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Pauker</LastName><ForeName>N E</ForeName><Initials>NE</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 30138</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>S07RR07041</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005556" MajorTopicYN="Y">Form Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="N">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010364" MajorTopicYN="Y">Pattern Recognition, Visual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6726215</ArticleId><ArticleId IdType="doi">10.1097/00005053-198407000-00010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21545446</PMID><DateCompleted><Year>2011</Year><Month>09</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0144-6657</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>2011</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The British journal of clinical psychology</Title><ISOAbbreviation>Br J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Investigation into activation of dysfunctional schemas in euthymic bipolar disorder following positive mood induction.</ArticleTitle><Pagination><MedlinePgn>115-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1348/014466510X497841</ELocationID><Abstract><AbstractText>OBJECTIVES. There are dysfunctional cognitions that may be characteristic of bipolar disorder (BD), and which may be mood-state dependent. However, it has been found that such cognitions may be resilient to minor positive mood increase. The aim of this study is to investigate whether positive mood-induction procedure has the effect of altering the availability of dysfunctional schemas in a group of individuals with BD. DESIGN. The sentence completion task was designed to assess the content of dysfunctional schemas: it was modified for use with positive mood-induction procedure in the current study so that more dysfunctional schematic models would lead to completion of sentence stems by negative constructs, whereas functional schematic models led to completion of sentence stems by positive constructs. METHODS. Using the modified sentence completion task, 30 participants with remitted bipolar I disorder were compared with 30 individuals with no history of affective disorder. Results. At baseline the bipolar group inserted significantly more dysfunctional completions than the control group. Following mood induction, the number of dysfunctional completions was reduced for both groups. The bipolar group still inserted significantly more dysfunctional completions relating to autonomy than the control group following mood induction. However, no significant group by time interactions were identified. CONCLUSIONS. As predicted, participants' reports of dysfunctional attitudes reduced following the mood-induction procedure, although no difference was identified between the groups in terms of the size of this reduction. The bipolar group continued to insert significantly more dysfunctional completions for the factor of autonomy, suggesting that this group has more access to autonomy schemas, regardless of change in mood. This finding may have implications in terms of focus of therapy and relapse prevention work.</AbstractText><CopyrightInformation>©2010 The British Psychological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lomax</LastName><ForeName>Claire L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, London, UK. c.lomax@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Dominic</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Psychol</MedlineTA><NlmUniqueID>8105533</NlmUniqueID><ISSNLinking>0144-6657</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000124" MajorTopicYN="N">Achievement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002755" MajorTopicYN="N">Choice Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="N">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003858" MajorTopicYN="N">Dependency, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006040" MajorTopicYN="N">Goals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026684" MajorTopicYN="N">Personal Autonomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21545446</ArticleId><ArticleId IdType="doi">10.1348/014466510X497841</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16050919</PMID><DateCompleted><Year>2005</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0004-8674</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>8</Issue><PubDate><Year>2005</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Maintenance therapies in bipolar disorder: focus on randomized controlled trials.</ArticleTitle><Pagination><MedlinePgn>652-61</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Lithium remains the cornerstone of maintenance therapy for bipolar disorder despite growing use of other agents, including divalproex, lamotrigine, carbamazepine and the atypical antipsychotics. Lithium has the largest body of data to support its continued use as a prophylactic agent; however, most of this data comes from early studies that did not use contemporary analytic methods. Alternatives to lithium are needed because of the relatively high rate of non-response to lithium monotherapy and the drug's frequent side-effects. This article reviews available data with an emphasis on double-blind, placebo-controlled studies that examine the efficacy of lithium and other putative mood stabilizers: carbamazepine, divalproex, lamotrigine and olanzapine.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The authors reviewed key literature using Medline searches using key words: bipolar disorder, controlled trials, mood stabilizer, lithium, lomotrigine, divalproex, olanzapine, carbamazepine.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lithium remains the gold standard for overall preventative efficacy in bipolar disorder, especially to decrease manic or hypomanic relapse. Of the mood stabilizers that have marked prophylactic antimanic properties, lithium appears to possess the greatest antidepressant effect. Divalproex may also prevent recurrent bipolar mood episodes but the relative lack of controlled maintenance studies makes this less certain. There now exists an extensive and well-designed research database supporting the use of lamotrigine in the acute and prophylactic management of bipolar I disorder. Lamotrigine offers a spectrum of clinical effectiveness that complements lithium, in that it appears to stabilize mood 'from below baseline' by preventing episodes of depression and has been shown to be effective in rapid-cycling bipolar II disorder. Carbamazepine may be a useful alternative to lithium, divalproex and lamotrigine, particularly for patients with a history of mood-incongruent delusions and other comorbidities, but controlled data is more equivocal and it may lose some of its prophylactic effect over time. Emerging data continue to support the growing use of atypical antipsychotics, particularly olanzapine.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Any monotherapy for use as a maintenance therapy of bipolar disorder appears to be inadequate for long-term use in the management of the majority of patients with bipolar disorder. Combination therapy has become the standard of care in the treatment of bipolar disorder and particularly in patients with treatment-refractory variants such as those with rapid-cycling. The emerging consensus is that patients on monotherapy, if followed for sufficiently long periods, will eventually require concomitant treatment to maintain a full remission. There exists a need for controlled trials that use random assignment to parallel arms including combination therapy followed by data analyses that include both relapse rate and survival techniques.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muzina</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Research Unit, Department of Psychiatry and Psychology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. muzinad@ccf.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>54</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>7</Month><Day>30</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16050919</ArticleId><ArticleId IdType="pii">ANP1649</ArticleId><ArticleId IdType="doi">10.1080/j.1440-1614.2005.01649.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15050861</PMID><DateCompleted><Year>2004</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2008</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>8</Issue><PubDate><Year>2004</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Association of neural cell adhesion molecule 1 gene polymorphisms with bipolar affective disorder in Japanese individuals.</ArticleTitle><Pagination><MedlinePgn>804-10</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although the pathogenesis of mood disorders remains unclear, heritable factors have been shown to be involved. Neural cell adhesion molecule 1 (NCAM1) is known to play important roles in cell migration, neurite growth, axonal guidance, and synaptic plasticity. Disturbance of these neurodevelopmental processes is proposed as one etiology for mood disorder. We therefore undertook genetic analysis of NCAM1 in mood disorders.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We determined the complete genomic organization of human NCAM1 gene by comparing complementary deoxyribonucleic acid and genomic sequences; mutation screening detected 11 polymorphisms. The genotypic, allelic, and haplotype distributions of these variants were analyzed in unrelated control individuals (n = 357) and patients with bipolar disorder (n = 151) and unipolar disorder (n = 78), all from central Japan.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three single nucleotide polymorphisms, IVS6+32T&gt;C, IVS7+11G&gt;C and IVS12+21C&gt;A, displayed significant associations with bipolar disorder (for allelic associations, nominal p =.04, p =.02, and p =.004, respectively, all p &gt;.05 after Bonferroni corrections). Furthermore, the haplotype located in a linkage disequilibrium block was strongly associated with bipolar disorder (the p value of the most significant three-marker haplotype is .005).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest that genetic variations in NCAM1 or nearby genes could confer risks associated with bipolar affective disorder in Japanese individuals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Schizophrenia Research, Tokyo Metropolitan Organization for Medical Research, Tokyo Institute of Psychiatry, 2-1-8 Kamikitazawa, Setagaya-ku, Tokyo 156-8585, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itokawa</LastName><ForeName>Masanari</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kazuo</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Toyota</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Arai</LastName><ForeName>Mayumi</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Haga</LastName><ForeName>Seiichi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ujike</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Sora</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Kazuhiko</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Yoshikawa</LastName><ForeName>Takeo</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019006">Neural Cell Adhesion Molecules</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004252" MajorTopicYN="N">DNA Mutational Analysis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="Y">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019006" MajorTopicYN="N">Neural Cell Adhesion Molecules</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2003</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>01</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15050861</ArticleId><ArticleId IdType="doi">10.1016/j.biopsych.2004.01.009</ArticleId><ArticleId IdType="pii">S0006322304000940</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21440307</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>01</Day></DateCompleted><DateRevised><Year>2011</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>132</Volume><Issue>1-2</Issue><PubDate><Year>2011</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Despite clinical differences, bipolar disorder patients from acute wards and outpatient clinics have similar educational and disability levels compared to the general population.</ArticleTitle><Pagination><MedlinePgn>209-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2011.02.025</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aims of this study were to compare clinical characteristics and educational and occupational functioning in two Bipolar Disorder (BD) samples recruited respectively from acutely admitted inpatients and public outpatient clinics and to investigate if the two BD samples differed in the same way in education and work ability from the general population.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">DSM-IV BD patients were consecutively recruited from acute wards throughout Norway (N=252; 69.8% BD I; 25.0% BD II; 5.2% BD NOS) and from outpatient clinics in the Oslo region (N=230; 60.4% BD I; 33.5% BD II; 6.1% BD NOS) and demographic and clinical characteristics were compared. A reference sample from the general population (N=100 869) was used to compare levels of education, marital status and disability benefits.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The acute ward sample was older, and had more men, more BD I disorder, more hospitalisations and suicide attempts, longer illness duration, an earlier age of onset and first treatment and used a higher number of antipsychotics, anticonvulsants and lithium than the outpatient sample. Both samples were educated to the same level as their respective reference populations, but received disability benefit and were single to a higher but similar degree.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Clinical differences between the BD samples had no consequence for educational achievement and receipt of disability benefit compared to the general population indicating that other factors than severity of illness play a role for education and work abilities in BD patients.</AbstractText><CopyrightInformation>Copyright © 2011 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schoeyen</LastName><ForeName>Helle K</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Moodnet Research Group, Psychiatric Division, Stavanger University Hospital, Stavanger, Norway. hsc@sus.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaaler</LastName><ForeName>Arne E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Auestad</LastName><ForeName>Bjoern H</ForeName><Initials>BH</Initials></Author><Author ValidYN="Y"><LastName>Malt</LastName><ForeName>Ulrik F</ForeName><Initials>UF</Initials></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials></Author><Author ValidYN="Y"><LastName>Morken</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>03</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000554" MajorTopicYN="N">Ambulatory Care Facilities</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="Y">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="Y">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006306" MajorTopicYN="N">Health Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009664" MajorTopicYN="N" Type="Geographic">Norway</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018582" MajorTopicYN="N">Sick Leave</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012943" MajorTopicYN="N">Social Security</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>02</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21440307</ArticleId><ArticleId IdType="pii">S0165-0327(11)00079-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2011.02.025</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3409160</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>1988</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A paradoxical outcome of a regional review board decision: a case report.</ArticleTitle><Pagination><MedlinePgn>426-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapp</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Tamakloe</LastName><ForeName>B E</ForeName><Initials>BE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003134" MajorTopicYN="N">Commitment of Mentally Ill</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010344" MajorTopicYN="N">Patient Advocacy</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3409160</ArticleId><ArticleId IdType="doi">10.1177/070674378803300532</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26070045</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>184</Volume><PubDate><Year>2015</Year><Month>Sep</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Cellular models to study bipolar disorder: A systematic review.</ArticleTitle><Pagination><MedlinePgn>36-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2015.05.037</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(15)00344-4</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is an emerging interest in the use of cellular models to study psychiatric disorders. We have systematically reviewed the application of cellular models to understand the biological basis of bipolar disorder (BD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Published scientific literature in MEDLINE, PsychINFO and SCOPUS databases were identified with the following search strategy: [(Lymphoblastoid OR Lymphoblast OR Fibroblast OR Pluripotent OR Olfactory epithelium OR Olfactory mucosa) AND (Bipolar disorder OR Lithium OR Valproate OR Mania)]. Studies were included if they had used cell cultures derived from BD patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 65 articles on lymphoblastoid cell lines, 14 articles on fibroblasts, 4 articles on olfactory neuronal epithelium (ONE) and 2 articles on neurons reprogrammed from induced pluripotent stem cell lines (IPSC). Several parameters have been studied, and the most replicated findings are abnormalities in calcium signaling, endoplasmic reticulum (ER) stress response, mitochondrial oxidative pathway, membrane ion channels, circadian system and apoptosis related genes. These, although present in basal state, seem to be accentuated in the presence of cellular stressors (e.g. oxidative stress--rotenone; ER stress--thapsigargin), and are often reversed with in-vitro lithium.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Cellular modeling has proven useful in BD, and potential pathways, especially in cellular resilience related mechanisms have been identified. These findings show consistency with other study designs (genome-wide association, brain-imaging, and post-mortem brain expression). ONE cells and IPSC reprogrammed neurons represent the next generation of cell models in BD. Future studies should focus on family-based study designs and combine cell models with deep sequencing and genetic manipulations.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viswanath</LastName><ForeName>Biju</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India; National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India; Centre for Brain Development and Repair, Institute of Stem Cell Biology and Regenerative Medicine, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jose</LastName><ForeName>Sam P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Elite Mission Hospital, Koorkanchery, Thrissur, Kerala, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Squassina</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacogenomics, Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thirthalli</LastName><ForeName>Jagadisha</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purushottam</LastName><ForeName>Meera</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mukherjee</LastName><ForeName>Odity</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vladimirov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patrinos</LastName><ForeName>George P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>University of Patras, School of Health Sciences, Department of Pharmacy, Patras, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Zompo</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Pharmacogenomics, Section of Neuroscience and Clinical Pharmacology, Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy; Unit of Clinical Pharmacology, Teaching Hospital, Cagliari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bangalore, India; National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India. Electronic address: sjain.nimhans@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007473">Ion Channels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007473" MajorTopicYN="N">Ion Channels</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cell model</Keyword><Keyword MajorTopicYN="N">Fibroblast</Keyword><Keyword MajorTopicYN="N">Lymphoblast</Keyword><Keyword MajorTopicYN="N">Olfactory</Keyword><Keyword MajorTopicYN="N">Pluripotent</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26070045</ArticleId><ArticleId IdType="pii">S0165-0327(15)00344-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2015.05.037</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">25272338</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antidepressants in bipolar I disorder: never as monotherapy.</ArticleTitle><Pagination><MedlinePgn>1023-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2014.14070826</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2014 Oct;171(10):1067-73</RefSource><PMID Version="1">24935197</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25272338</ArticleId><ArticleId IdType="pii">1911267</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2014.14070826</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2360802</PMID><DateCompleted><Year>1990</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0364-5134</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>1990</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Mania after brain injury: neuroradiological and metabolic findings.</ArticleTitle><Pagination><MedlinePgn>652-9</MedlinePgn></Pagination><Abstract><AbstractText>We present a consecutive series of 8 patients who developed a manic episode after a brain injury. Five patients had cortical lesions (4 with damage to the right basotemporal region, and 1 with bilateral damage to the orbitofrontal area). While the other 3 patients had subcortical lesions (white matter of the right frontal lobe, right anterior limb of the internal capsule, and right head of the caudate), a fluorodeoxyglucose positron emission tomography scan showed hypometabolism in the right lateral basotemporal region in all 3 patients. These findings suggest a major role for the basal region of the right temporal lobe in the modulation of mood.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Starkstein</LastName><ForeName>S E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayberg</LastName><ForeName>H S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Berthier</LastName><ForeName>M L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Fedoroff</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>T R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Dannals</LastName><ForeName>R F</ForeName><Initials>RF</Initials></Author><Author ValidYN="Y"><LastName>Wagner</LastName><ForeName>H N</ForeName><Initials>HN</Initials></Author><Author ValidYN="Y"><LastName>Leiguarda</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>MH-00163</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS-15080</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS-15178</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011877" MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2360802</ArticleId><ArticleId IdType="doi">10.1002/ana.410270612</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28072662</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4112</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>Successful Treatment With Electroconvulsive Therapy of a Patient With Bipolar Disorder and a 7-mm Cerebral Aneurysm.</ArticleTitle><Pagination><MedlinePgn>e8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCT.0000000000000389</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Toprak</LastName><ForeName>Mesut</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of PsychiatryYale School of MedicineNew Haven, CTSamuel.wilkinson@yale.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilkinson</LastName><ForeName>Samuel T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Ostroff</LastName><ForeName>Robert B</ForeName><Initials>RB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IK6 RX002458</GrantID><Acronym>RX</Acronym><Agency>RRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 MH111000</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH062994</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017542" MajorTopicYN="N">Aneurysm, Ruptured</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002532" MajorTopicYN="N">Intracranial Aneurysm</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28072662</ArticleId><ArticleId IdType="doi">10.1097/YCT.0000000000000389</ArticleId><ArticleId IdType="pmc">PMC5315600</ArticleId><ArticleId IdType="mid">NIHMS834532</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J ECT. 2004 Mar;20(1):13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15087991</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2013 May;44(5):1256-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23520239</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroke. 2014 Feb;45(2):579-86</Citation><ArticleIdList><ArticleId IdType="pubmed">24370755</ArticleId></ArticleIdList></Reference><Reference><Citation>J ECT. 2014 Dec;30(4):e47-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25010028</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18076531</PMID><DateCompleted><Year>2008</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>8</Issue><PubDate><Year>2007</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Outcome following a first manic episode: cross-national US and Taiwan comparison.</ArticleTitle><Pagination><MedlinePgn>820-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Bipolar disorder (BD) is recognized as a significant psychiatric condition worldwide, yet little is known about cross-national differences in the course of illness. This information might clarify features of the disorder that are illness versus culturally specific. Therefore, the aim of this study was to identify differential and shared outcome predictors in first-episode manic bipolar patients in Cincinnati, OH, USA and Taipei, Taiwan.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">DSM-IV bipolar patients were identified at the time of their first manic or mixed episode and were prospectively followed in a naturalistic, longitudinal study for one year. Patients were recruited from a first psychiatric hospitalization at university-affiliated, urban hospitals in Taipei and Cincinnati. The primary outcome measures were remission, recovery, recurrence and percent of follow-up spent with affective symptoms and syndromes. Treatment adherence was also assessed, as were a number of possible mediator variables.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The two patient groups showed a number of significant differences in index clinical presentation on characteristics previously associated with outcome in other studies (e.g., substance abuse). The patients in Taipei showed significantly better outcome on virtually all measures. Some of these findings reflected differences in index (mediator) variables, whereas others persisted after controlling for potential baseline confounds.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The early course of BD varies between Chinese and American patients. Some of this variance results from demographic and clinical cross-national differences in premorbid variables. Other sources of variance remain to be identified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Bipolar Disorders Research, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0559, USA. stephen.strakowski@uc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Shang-Ying</ForeName><Initials>SY</Initials></Author><Author ValidYN="Y"><LastName>Delbello</LastName><ForeName>Melissa P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chiao-Chicy</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Fleck</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Caleb M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Arndt</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Amicone</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH058170</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="Y">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013624" MajorTopicYN="N" Type="Geographic">Taiwan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>3</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18076531</ArticleId><ArticleId IdType="pii">BDI411</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00411.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20080982</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1535-7228</ISSN><JournalIssue CitedMedium="Internet"><Volume>167</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychiatric disorders in preschool offspring of parents with bipolar disorder: the Pittsburgh Bipolar Offspring Study (BIOS).</ArticleTitle><Pagination><MedlinePgn>321-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ajp.2009.09070977</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors evaluated lifetime prevalence and specificity of DSM-IV psychiatric disorders and severity of depressive and manic symptoms at intake in preschool offspring of parents with bipolar I and II disorders.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A total of 121 offspring ages 2-5 years from 83 parents with bipolar disorder and 102 offspring of 65 demographically matched comparison parents (29 with non-bipolar psychiatric disorders and 36 without any lifetime psychopathology) were recruited for the study. Parents with bipolar disorder were recruited through advertisements and adult outpatient clinics, and comparison parents were ascertained at random from the community. Participants were evaluated with standardized instruments. All staff were blind to parental diagnoses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjustment for within-family correlations and both biological parents' non-bipolar psychopathology, offspring of parents with bipolar disorder, particularly those older than age 4, showed an eightfold greater lifetime prevalence of attention deficit hyperactivity disorder (ADHD) and significantly higher rates of having two or more psychiatric disorders compared to the offspring of the comparison parents. While only three offspring of parents with bipolar disorder had mood disorders, offspring of parents with bipolar disorder, especially those with ADHD and oppositional defiant disorder, had significantly more severe current manic and depressive symptoms than comparison offspring.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Preschool offspring of parents with bipolar disorder have an elevated risk for ADHD and have greater levels of subthreshold manic and depressive symptoms than children of comparison parents. Longitudinal follow-up is warranted to evaluate whether these children are at high risk for developing mood and other psychiatric disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Birmaher</LastName><ForeName>Boris</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA. birmaherb@upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelson</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Monk</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kalas</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Obreja</LastName><ForeName>Mihaela</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hickey</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Iyengar</LastName><ForeName>Satish</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brent</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Shamseddeen</LastName><ForeName>Wael</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Diler</LastName><ForeName>Rasim</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH060952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH060952-09</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH60952</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 2010 Jun;167(6):716; author reply 716-7</RefSource><PMID Version="1">20516164</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019958" MajorTopicYN="N">Attention Deficit and Disruptive Behavior Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010414" MajorTopicYN="N" Type="Geographic">Pennsylvania</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20080982</ArticleId><ArticleId IdType="pii">appi.ajp.2009.09070977</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.2009.09070977</ArticleId><ArticleId IdType="pmc">PMC2868596</ArticleId><ArticleId IdType="mid">NIHMS196899</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):939-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17064424</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):177-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10743850</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Feb;141(2):236-40</Citation><ArticleIdList><ArticleId IdType="pubmed">6691484</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Oct;34(10):1229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">911222</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Aug;39(8):879-83</Citation><ArticleIdList><ArticleId IdType="pubmed">7103676</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Oct;36(10):1426-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9334556</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Oct;65(10):1125-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18838629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Dec;3(6):325-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11843782</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Oct;63(10):1139-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17015816</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 May 1;63(9):884-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17945198</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):620-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9136496</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):828-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18076532</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann N Y Acad Sci. 2006 Dec;1094:235-47</Citation><ArticleIdList><ArticleId IdType="pubmed">17347355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Oct;157(10):1679-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11007724</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2006 Jun;117(6):2101-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16740853</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2006 Aug;16(4):456-66</Citation><ArticleIdList><ArticleId IdType="pubmed">16958570</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Psychiatry Hum Dev. 1984 Winter;15(2):75-85</Citation><ArticleIdList><ArticleId IdType="pubmed">6534642</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Feb;121(1-2):127-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19541368</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Sep 15;62(6):565-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17306774</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2007 Dec;17(6):853-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18315456</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2006 Jun;74(3):401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16822098</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet C Semin Med Genet. 2003 Nov 15;123C(1):26-35</Citation><ArticleIdList><ArticleId IdType="pubmed">14601034</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Jul;166(7):795-804</Citation><ArticleIdList><ArticleId IdType="pubmed">19448190</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 May;39(5):592-602</Citation><ArticleIdList><ArticleId IdType="pubmed">10802977</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Aug;66(8):897-905</Citation><ArticleIdList><ArticleId IdType="pubmed">19652129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2000 Dec;68(6):1038-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11142538</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1984 Feb;141(2):219-22</Citation><ArticleIdList><ArticleId IdType="pubmed">6362442</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2007 Apr;17(2):237-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17489719</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Aug;164(8):1140-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17671272</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1037-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17064428</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2006 Mar-Apr;47(3-4):313-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16492262</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):463-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14977459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1992 Jan;31(1):68-77</Citation><ArticleIdList><ArticleId IdType="pubmed">1537784</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Aug;49(8):624-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1637252</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2007;3:137-58</Citation><ArticleIdList><ArticleId IdType="pubmed">17716051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Jan;78(1):67-71</Citation><ArticleIdList><ArticleId IdType="pubmed">14672799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Nov;44(11):1104-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16239857</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):193-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11869768</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2006 Mar 22;295(12):1389-98</Citation><ArticleIdList><ArticleId IdType="pubmed">16551710</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):971-88</Citation><ArticleIdList><ArticleId IdType="pubmed">17064425</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10761347</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Oct 1;58(7):554-61</Citation><ArticleIdList><ArticleId IdType="pubmed">16112654</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):593-602</Citation><ArticleIdList><ArticleId IdType="pubmed">15939837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Aug;7(4):344-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16026487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2007 Oct;48(10):1005-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17915001</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):846-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16113615</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Winter;13(4):489-94</Citation><ArticleIdList><ArticleId IdType="pubmed">14977461</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Jun;34(6):715-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7608044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct;82 Suppl 1:S35-43</Citation><ArticleIdList><ArticleId IdType="pubmed">15571788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2003 Jul;42(7):786-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12819438</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2008 Summer;20(3):881-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18606036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Jan;65(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">18180428</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Mar;66(3):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19255378</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):356-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14754786</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1486-93</Citation><ArticleIdList><ArticleId IdType="pubmed">14627884</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Dec 7;145(2-3):155-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17083985</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Jul;42(7):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">4015311</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Aug;60(8):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">12912767</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2005 Nov;46(11):1200-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16238667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Apr;43(7):680-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19000625</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2007 Oct;48(10):961-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17914996</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Child Adolesc Psychiatry. 2007 Dec;16(8):484-94</Citation><ArticleIdList><ArticleId IdType="pubmed">17896121</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):265-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16449480</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2008 Apr;64(4):402-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18324662</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1988 Apr;145(4):506-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3348454</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Apr;164(4):582-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17403971</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2006 Oct;15(4):899-917, viii-ix</Citation><ArticleIdList><ArticleId IdType="pubmed">16952767</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11256686</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>3 Pt 1</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Lifetime prevalence of substance or alcohol abuse and dependence among subjects with bipolar I and II disorders in a voluntary registry.</ArticleTitle><Pagination><MedlinePgn>191-5</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the prevalence of substance abuse dependence and/or alcohol abuse dependence among subjects with bipolar I versus bipolar II disorder in a voluntary registry.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">One hundred randomly selected registrants in a voluntary case registry for bipolar disorder were interviewed, using the Structured Clinical Interview for DSM-IV Axis I Disorders, to validate the diagnosis of this registry. Corroborative information was obtained from medical records, family members and the treating psychiatrist. Eighty-nine adults (18-65 years) met criteria for bipolar disorder (bipolar I = 71, bipolar II = 18) and were included in this analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-one (57.8%) subjects with bipolar I disorder abused, or were dependent on one or more substances or alcohol, 28.2% abused, or were dependent on, two substances or alcohol, and 11.3% abused or were dependent on three or more substances or alcohol. Nearly 39% of bipolar II subjects abused or were dependent on one or more substances, nearly 17% were dependent on two or more substances or alcohol, and 11% were dependent on three or more substances or alcohol. Alcohol was the most commonly abused drug among either bipolar I or II subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Consistent with other epidemiologic and hospital population studies, this voluntary bipolar disorder registry suggests a high prevalence of comorbidity with alcohol and/or substance abuse dependence. Bipolar I subjects appear to have higher rates of these comorbid conditions than bipolar II subjects; however, as the number of bipolar II subjects was rather small, this suggestion needs confirmation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chengappa</LastName><ForeName>K N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, School of Medicine, PA 15213-2593, USA. chengappakn@msx.upmc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levine</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gershon</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>D J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="Y">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>18</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11256686</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2000.020306.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">497639</PMID><DateCompleted><Year>1980</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>135</Volume><PubDate><Year>1979</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Artistic productivity and lithium prophylaxis in manic-depressive illness.</ArticleTitle><Pagination><MedlinePgn>97-103</MedlinePgn></Pagination><Abstract><AbstractText>Twenty-four manic-depressive artists, in whom prophylactic lithium treatment had attenuated or prevented recurrences to a significant degree, were questioned about their creative power during the treatment. Twelve artists reported increased artistic productivity, six unaltered productivity, and six lowered productivity. The effect of lithium treatment on artistic productivity may depend on the severity and type of the illness, on individual sensitivity, and on habits of utilizing manic episodes productively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schou</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003405" MajorTopicYN="Y">Creativity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004526" MajorTopicYN="N">Efficiency</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">497639</ArticleId><ArticleId IdType="pii">S0007125000060050</ArticleId><ArticleId IdType="doi">10.1192/bjp.135.2.97</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18452444</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2008</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Neuropsychological task performance in bipolar spectrum illness: genetics, alcohol abuse, medication and childhood trauma.</ArticleTitle><Pagination><MedlinePgn>479-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2008.00591.x</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Impaired executive and memory function is a putative genetic trait marker of bipolar I disorder (BPD I). Although executive/memory function has been posited to be an endophenotype of BPD I, it is unclear whether this extends to bipolar spectrum illness. It is also unclear to what extent non-genetic factors such as childhood abuse, alcoholism and medication influence neurocognitive function. We assessed the neuropsychological performance of a large cohort of bipolar disorder probands and their affectively ill and healthy family members, while controlling for self-reported childhood sexual and emotional abuse, emotional neglect, alcohol abuse and medication.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 230 largely euthymic participants from 47 families, comprising 49 subjects with BPD I, 19 with bipolar II disorder (BPD II), 44 with recurrent major depression (MDE-R), 33 with a single lifetime episode of depression (MDE-S), 20 with other DSM-IV diagnoses and 65 unaffected relatives, were assessed with a battery of neuropsychological tasks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sexual abuse, emotional abuse and emotional neglect scores were associated with poorer cognitive performance. After controlling for childhood trauma, the BPD I group performed worse than unaffected relatives on tests of visual recall memory as well as verbal recall and recognition memory. In contrast, individuals with BPD II and bipolar spectrum illness did not differ significantly from unaffected relatives. Treatment with lithium and antipsychotic medication was associated with reduced executive and verbal recognition memory function. After controlling for medication and other covariates, only verbal recall memory was significantly impaired in the BPD I cohort.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Verbal recall deficits may be one manifestation of a genetically driven dysfunction of frontal-striatal cortical networks in BPD I.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savitz</LastName><ForeName>Jonathan B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Human Genetics, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. savitzj@mail.nih.gov</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Merwe</LastName><ForeName>Lize</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Stein</LastName><ForeName>Dan J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Solms</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ramesar</LastName><ForeName>Rajkumar S</ForeName><Initials>RS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002649" MajorTopicYN="N">Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005192" MajorTopicYN="N">Family Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18452444</ArticleId><ArticleId IdType="pii">BDI591</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2008.00591.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25572482</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1778-3585</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>European psychiatry : the journal of the Association of European Psychiatrists</Title><ISOAbbreviation>Eur Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Augmentative repetitive Transcranial Magnetic Stimulation (rTMS) in the acute treatment of poor responder depressed patients: a comparison study between high and low frequency stimulation.</ArticleTitle><Pagination><MedlinePgn>271-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eurpsy.2014.12.001</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0924-9338(14)00655-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">While the efficacy of repetitive transcranial magnetic stimulation (rTMS) in Major Depressive Disorder (MDD) is well established, the debate is still open in relation to bipolar depression and to a possible different effectiveness of high vs. low stimulation. The present study was aimed to assess and compare the efficacy and tolerability of different protocols of augmentative rTMS in a sample of patients with current Major Depressive Episode (MDE), poor drug response/treatment resistance and a diagnosis of MDD or bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirty-three patients were recruited in a 4-week, blind-rater, rTMS trial and randomised to the following three groups of stimulation: (1) (n=10) right dorsolateral prefrontal cortex (DLPFC) 1 HZ, 110% of the motor threshold (MT), 420 stimuli/day; (2) (n=10) right DLPFC, 1Hz, 110% MT, 900 stimuli/day; (3) (n=13) left DLPFC, 10Hz, 80% MT, 750 stimuli/day.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twenty-nine patients completed the treatment, showing a significant reduction of primary outcome measures (HAM-D, MADRS and CGI-S total scores: t=8.1, P&lt;0.001; t=8.6, P&lt;0.001; t=4.6, P&lt;0.001 respectively). No significant differences in terms of efficacy and tolerability were found between high vs. low frequency and between unipolar and bipolar patients. Side effects were reported by 21% of the sample. One of the 4 dropouts was caused by a hypomanic switch.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Augmentative rTMS appeared to be effective and well tolerated for the acute treatment of unipolar and bipolar depression with features of poor drug response/treatment resistance, showing a comparable effectiveness profile between protocols of high and low frequency stimulation.</AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dell'Osso</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy; Bipolar Disorders Clinic, Stanford Medical School, Stanford University, CA, USA. Electronic address: bernardo.dellosso@unimi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldani</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camuri</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobrea</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cremaschi</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benatti</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arici</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grancini</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altamura</LastName><ForeName>A Carlo</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Milan, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur Psychiatry</MedlineTA><NlmUniqueID>9111820</NlmUniqueID><ISSNLinking>0924-9338</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="Y">Prefrontal Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Augmentation</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Major depressive disorder</Keyword><Keyword MajorTopicYN="N">Poor drug response</Keyword><Keyword MajorTopicYN="N">Repetitive transcranial magnetic stimulation (rTMS)</Keyword><Keyword MajorTopicYN="N">Treatment resistance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25572482</ArticleId><ArticleId IdType="pii">S0924-9338(14)00655-5</ArticleId><ArticleId IdType="doi">10.1016/j.eurpsy.2014.12.001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11246086</PMID><DateCompleted><Year>2001</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>1-3</Issue><PubDate><Year>2001</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Can personality traits predict increases in manic and depressive symptoms?</ArticleTitle><Pagination><MedlinePgn>103-11</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There has been limited research investigating personality traits as predictors of manic and depressive symptoms in bipolar individuals. The present study investigated the relation between personality traits and the course of bipolar disorder. The purpose of this study was to identify specific personality traits that predict the course of manic and depressive symptoms experienced by bipolar individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample consisted of 39 participants with bipolar I disorder assessed by the Structured Clinical Interview for DSM-IV. Personality was assessed using the NEO Five-Factor Inventory. The Modified Hamilton Rating Scale for Depression and the Bech-Rafaelsen Mania Rating Scale were used to assess symptom severity on a monthly basis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Consistent with previous research on unipolar depression, high Neuroticism predicted increases in depressive symptoms across time while controlling for baseline symptoms. Additionally, high Conscientiousness, particularly the Achievement Striving facet, predicted increases in manic symptoms across time.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">The current study was limited by the small number of participants, the reliance on a shortened version of a self-report personality measure, and the potential state-dependency of the personality measures.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Specific personality traits may assist in predicting bipolar symptoms across time. Further studies are needed to tease apart the state-dependency of personality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>B E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>University of Miami, P.O. Box 249229, Coral Gables, FL 33124-2010, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R29 MH055950-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11246086</ArticleId><ArticleId IdType="pii">S0165032700001919</ArticleId><ArticleId IdType="pmc">PMC3137132</ArticleId><ArticleId IdType="mid">NIHMS252577</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(00)00191-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Psychiatry Res. 1993 Jul;48(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8416014</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1985 Feb;14(2):131-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Aug;49(8):630-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1637253</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Nov;134(11):1227-33</Citation><ArticleIdList><ArticleId IdType="pubmed">910973</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1979 Apr;59(4):420-30</Citation><ArticleIdList><ArticleId IdType="pubmed">433633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopathol Behav Assess. 1999 Dec 1;21(4):275-292</Citation><ArticleIdList><ArticleId IdType="pubmed">21765591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1983 Jul;40(7):801-10</Citation><ArticleIdList><ArticleId IdType="pubmed">6344834</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Nov 4;41(1):25-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8938202</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Brain Sci. 1999 Jun;22(3):491-517; discussion 518-69</Citation><ArticleIdList><ArticleId IdType="pubmed">11301519</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 Nov;109(4):721-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11195996</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 1994 Sep;67(3):485-98</Citation><ArticleIdList><ArticleId IdType="pubmed">7965602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers. 1992 Jun;60(2):441-76</Citation><ArticleIdList><ArticleId IdType="pubmed">1635050</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1983 Jun;140(6):695-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6846626</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Sep 9;40(1-2):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8882913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1986 Jul-Aug;11(1):81-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2944932</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Feb;52(2):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Apr;58(1):79-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10760562</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):379-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7864263</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Jul;157:19-24</Citation><ArticleIdList><ArticleId IdType="pubmed">2397360</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 May;49(5):371-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1586272</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1995 May;117(3):434-49</Citation><ArticleIdList><ArticleId IdType="pubmed">7777648</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Bull. 1979 Mar;86(2):420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18839484</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Aug;55(8):702-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9707380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1995 Mar 14;33(3):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">7790668</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jul;47(7):665-71</Citation><ArticleIdList><ArticleId IdType="pubmed">2113802</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1994;243(6):340-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8043619</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1999 Nov;108(4):558-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10609420</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1998;31(1):15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9500682</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1989 Aug;146(8):983-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2750997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7911851</PMID><DateCompleted><Year>1994</Year><Month>07</Month><Day>20</Day></DateCompleted><DateRevised><Year>2011</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0047-1852</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>5</Issue><PubDate><Year>1994</Year><Month>May</Month></PubDate></JournalIssue><Title>Nihon rinsho. Japanese journal of clinical medicine</Title><ISOAbbreviation>Nihon Rinsho</ISOAbbreviation></Journal><ArticleTitle>[Manic-depressive psychosis and electroencephalogram].</ArticleTitle><Pagination><MedlinePgn>1165-9</MedlinePgn></Pagination><Abstract><AbstractText>The literature dealing with electroencephalogram (EEG) in manic-depressive psychosis is reviewed. It is concluded that although there are no specific EEG patterns in the psychosis, some reports suggest a predominance of the alpha activity and a heightened arousal response. From many studies on sleep and depression, it appears that the EEG sleep architecture in depression is characterized by reduced total sleep time, intermittent awakenings, decreased slow-wave sleep and shortened REM latency. In particular, shortened REM latency is important for diagnosis of primary depression. Furthermore, the meaning of abnormal EEGs reported in the psychosis is worth investigating. In order to make the pathophysiology of manic-depressive psychosis clearer, it is important to carry out a comprehensive research, including clinical, physiological, biochemical and molecular biological study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hori</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Tsukuba.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shiraishi</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Nihon Rinsho</MedlineTA><NlmUniqueID>0420546</NlmUniqueID><ISSNLinking>0047-1852</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012895" MajorTopicYN="N">Sleep, REM</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>25</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7911851</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17267047</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>1-3</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>A comparative study on dual patients with affective disorder.</ArticleTitle><Pagination><MedlinePgn>109-14</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The main purpose of the study was to investigate whether there are differences between dual patients with affective disorders regarding the different kinds of substances abused - a topic which has hardly been dealt with in the literature.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Clinical charts of 94 dual and 94 non-dual patients, matched for sex, age, and diagnosis, were scrutinized and the data of both groups compared with each other, with regard to the substance of abuse.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 17.4% of all patients with affective disorders were found to be dual patients and the proportion of dual patients was equal among patients with unipolar disorder, bipolar disorder, and dysthymia. Only a few significant differences were found between dual and non-dual patients; more differences were identified when the dual group was divided into patients abusing alcohol (59%), opioids/cocaine (22%), and sedatives/hypnotics (19%). In particular, the group of patients abusing illegal drugs was found to be younger and to show more behavioral pathology. All three groups of dual patients differed regarding the onset of their affective illness.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Retrospective study of clinical records.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There are differences between dual patients with affective disorders abusing different substances. The choice of a particular substance of abuse appears to be the function of the age of onset of the disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Modestin</LastName><ForeName>Jiri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Burghölzli Hospital, University of Zurich, Lenggstrasse 31, CH-8032 Zurich, Switzerland. modestin@bli.unizh.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayser-Rapold</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wehrli</LastName><ForeName>Marianne Vogt</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Neuenschwander</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Malti</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019263" MajorTopicYN="N">Dysthymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>12</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17267047</ArticleId><ArticleId IdType="pii">S0165-0327(06)00566-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2006.12.014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25617037</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1535-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>The importance of anxiety states in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11920-014-0540-2</ELocationID><Abstract><AbstractText>Anxiety symptoms and syndromes are common in bipolar disorders, occurring in over half of all subjects with bipolar disorder type I. Despite methodological and diagnostic inconsistencies, most studies have shown a robust association between the presence of a broadly defined comorbid anxiety disorder and important indices of clinical morbidity in bipolar disorder, including a greater number of depressive episodes, worse treatment outcomes, and elevated risk of attempting suicide. Anxiety symptoms and/or syndromes often precede the onset of bipolar disorder and may represent a clinical phenotype of increased risk in subjects with prodromal symptoms. Although the causal relationship between anxiety and bipolar disorders remains unresolved, the multifactorial nature of most psychiatric phenotypes suggests that even with progress towards more biologically valid phenotypes, the "phenomenon" of comorbidity is likely to remain a clinical reality. Treatment studies of bipolar patients with comorbid anxiety have begun to provide preliminary evidence for the role of specific pharmacological and psychotherapeutic treatments, but these need to be confirmed in more definitive trials. Hence, there is an immediate need for further research to help guide assessment and help identify appropriate treatments for comorbid conditions. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goes</LastName><ForeName>Fernando S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Meyer 4-119A, 600 North Wolfe Street, Baltimore, MD, 21287, USA, fgoes1@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25617037</ArticleId><ArticleId IdType="doi">10.1007/s11920-014-0540-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Psychiatry. 2009 Jun;194(6):483-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19478285</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):542-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23429906</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Alcohol Depend. 2003 Jul 20;71(1):7-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12821201</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jun;35(6):773-82</Citation><ArticleIdList><ArticleId IdType="pubmed">655775</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Sep;45(9):984-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23933821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006;67 Suppl 1:5-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16426110</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Aug;65(8):1106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15323597</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion J Clin Psychiatry. 2009;11(5):215-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19956459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):363-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23707033</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 Oct;75(10):1062-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25007003</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2013 May 14;11:126</Citation><ArticleIdList><ArticleId IdType="pubmed">23672542</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2013 Jul;14(7):483-95</Citation><ArticleIdList><ArticleId IdType="pubmed">23752797</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry. 1970-1971;9:62-79</Citation><ArticleIdList><ArticleId IdType="pubmed">4921639</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Oct;133(3):371-80</Citation><ArticleIdList><ArticleId IdType="pubmed">21093062</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2014 Mar;31(3):196-206</Citation><ArticleIdList><ArticleId IdType="pubmed">24610817</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Jun;66(6):693-704</Citation><ArticleIdList><ArticleId IdType="pubmed">15960561</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 2012 Feb;24(1):6-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22303519</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2007 Apr-Jun;41(3-4):255-64</Citation><ArticleIdList><ArticleId IdType="pubmed">17052730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chronic Dis. 1970 Dec;23(7):455-68</Citation><ArticleIdList><ArticleId IdType="pubmed">26309916</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Sep;166:243-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25012437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Sep;14(6):641-53</Citation><ArticleIdList><ArticleId IdType="pubmed">22938168</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 May 17;366(20):1853-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22591291</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2014 Sep;31(9):721-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24995387</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Jan;72(1):81-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21208580</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2009;26(8):752-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19544314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Sep;29(1):49-52</Citation><ArticleIdList><ArticleId IdType="pubmed">8254143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 2003 Apr;17(2):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12755326</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Nov;47(11):983-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24198297</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2013 Aug;43(8):1625-37</Citation><ArticleIdList><ArticleId IdType="pubmed">23075829</ArticleId></ArticleIdList></Reference><Reference><Citation>Dtsch Arztebl Int. 2014 Jul 7;111(27-28):473-80</Citation><ArticleIdList><ArticleId IdType="pubmed">25138725</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Nov;62(11):1249-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16275812</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Feb;171(2):178-86</Citation><ArticleIdList><ArticleId IdType="pubmed">24077657</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Oct;195(4):301-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19794197</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2014 Feb 19;6(224):224ed4</Citation><ArticleIdList><ArticleId IdType="pubmed">24553384</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Addict. 2010 Sep-Oct;19(5):440-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20716307</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Oct;66(10):1205-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16259532</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Dec;161(12):2222-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15569893</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2014 Jun 25;311(24):2479-80</Citation><ArticleIdList><ArticleId IdType="pubmed">24854141</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2012 Jun;29(6):471-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22553107</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2012 Mar;200(3):210-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21984801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 Jan;75(1):77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24345758</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Jan;170(1):31-42</Citation><ArticleIdList><ArticleId IdType="pubmed">23223893</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Jul;189:20-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16816301</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):137-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17512607</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Mar;186:182-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15738496</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Nov;166(11):1238-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19797434</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Apr;17(4):377-88</Citation><ArticleIdList><ArticleId IdType="pubmed">22230881</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Jul;42(7):1449-59</Citation><ArticleIdList><ArticleId IdType="pubmed">22099954</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Mar;66(3):287-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19255378</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Oct;68(10):1012-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21969459</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Dec;8(6):696-709</Citation><ArticleIdList><ArticleId IdType="pubmed">17156156</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jun;115(3):376-85</Citation><ArticleIdList><ArticleId IdType="pubmed">19042026</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12957720</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0924-977X</ISSN><JournalIssue CitedMedium="Print"><Volume>13 Suppl 2</Volume><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Latest maintenance data on lithium in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>S51-5</MedlinePgn></Pagination><Abstract><AbstractText>Although lithium is generally considered to be the gold standard for maintenance therapy in bipolar disorder, evidence of its efficacy has rested on only a small number of adequately designed studies. Results from the lamotrigine bipolar trials, which included lithium as an active comparator, will substantially increase confidence in long-term lithium treatment. In a meta-analysis of these data, lithium was significantly more effective than placebo in preventing relapse in patients with bipolar disorder (relative risk [RR] 0.65; 95% confidence interval [CI] 0.50, 0.84). Furthermore, lithium had significant efficacy against manic relapse (RR 0.61; 95% CI 0.39, 0.95), with a less substantial, not statistically significant, effect against depressive relapse (RR 0.72; 95% CI 0.49, 1.07). Factors such as disease subtype, likelihood of adherence to treatment regimen, tolerability, and dose uncertainty should be considered in the selection of lithium maintenance therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Guy M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford OX3 7JX, UK. guy.goodwin@psychiatry.oxford.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geddes</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>22</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>11</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>6</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12957720</ArticleId><ArticleId IdType="pii">S0924977X03000786</ArticleId><ArticleId IdType="doi">10.1016/s0924-977x(03)00078-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29549335</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>03</Month><Day>16</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Shared and differential cortical functional abnormalities associated with inhibitory control in patients with schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>4686</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-018-22929-y</ELocationID><Abstract><AbstractText>Schizophrenia (SZ) and bipolar I disorder (BD-I) share genetic risk factors and cognitive impairments, but these conditions may exhibit differences in cortical functioning associated with inhibitory control. We measured hemodynamic responses during a stop-signal task using near-infrared spectroscopy (NIRS) in 20 patients with SZ, 21 patients with BD-I and 18 healthy controls (HCs). We used stop-signal reaction time (SSRT) to estimate behavioural inhibition. Compared with HCs, patients with either SZ or BD-I exhibited significantly reduced activation in the bilateral inferior, middle and superior frontal gyri. Furthermore, patients with BD-I showed inactivation of the right superior temporal gyri compared with patients with SZ or HCs. Patients with SZ or BD-I demonstrated significant negative correlations between SSRT and hemodynamic responses of the right inferior frontal gyrus. Moreover, patients with SZ exhibited correlations in the middle and superior frontal gyri. Our findings suggest that right inferior frontal abnormalities mediate behavioural inhibition impairments in individuals with SZ or BD-I. Differential patterns of orbitofrontal or superior temporal functional abnormalities may reflect important differences in psychopathological features between these disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tsujii</LastName><ForeName>Noa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kindai University Faculty of Medicine, Osaka, Japan. tujiinoa@med.kindai.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikawa</LastName><ForeName>Wakako</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adachi</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirose</LastName><ForeName>Tomoyuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirakawa</LastName><ForeName>Osamu</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kindai University Faculty of Medicine, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006439" MajorTopicYN="N">Hemodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007266" MajorTopicYN="Y">Inhibition, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019265" MajorTopicYN="N">Spectroscopy, Near-Infrared</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>04</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29549335</ArticleId><ArticleId IdType="doi">10.1038/s41598-018-22929-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-018-22929-y</ArticleId><ArticleId IdType="pmc">PMC5856811</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biol Psychiatry. 2007 Jul 15;62(2):158-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17097071</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2012 Jun;169(6):633-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22581312</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 1988;222:183-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3129910</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2015 Oct;57:284-96</Citation><ArticleIdList><ArticleId IdType="pubmed">26321590</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2008 Nov;2(4):225-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19190727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2006 Jul;32(3):562-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16384876</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Feb;18(1):4-18</Citation><ArticleIdList><ArticleId IdType="pubmed">26851067</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2008 Feb 1;39(3):1064-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18037310</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2006 Jun;60(3):332-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16732750</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2012 Feb 3;335(6068):601-4</Citation><ArticleIdList><ArticleId IdType="pubmed">22301321</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Oct 1;27(4):842-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15979346</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2015 Aug;69(8):440-7</Citation><ArticleIdList><ArticleId IdType="pubmed">25601291</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Jan;35(1):115-35</Citation><ArticleIdList><ArticleId IdType="pubmed">19011235</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2008 Jan;131(Pt 1):180-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18056163</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2002 Mar;3(3):201-15</Citation><ArticleIdList><ArticleId IdType="pubmed">11994752</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2015 Jul 16;5:12107</Citation><ArticleIdList><ArticleId IdType="pubmed">26178613</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Aug;45(8):742-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3395203</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2003 Feb;6(2):115-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12536210</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14529-34</Citation><ArticleIdList><ArticleId IdType="pubmed">9826734</ArticleId></ArticleIdList></Reference><Reference><Citation>J Appl Physiol (1985). 2001 May;90(5):1657-62</Citation><ArticleIdList><ArticleId IdType="pubmed">11299252</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Sep;37(5):913-20</Citation><ArticleIdList><ArticleId IdType="pubmed">21860037</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2005 Aug 15;27(2):323-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16019232</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2005 Oct;59(5):517-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16194252</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Cogn Sci. 2008 Nov;12(11):418-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18799345</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Dec 15;70(12):1151-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21903198</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2014 Jan 15;85 Pt 1:518-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23624170</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1990;28(11):1123-42</Citation><ArticleIdList><ArticleId IdType="pubmed">2290489</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1275-84</Citation><ArticleIdList><ArticleId IdType="pubmed">23771174</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1971 Mar;9(1):97-113</Citation><ArticleIdList><ArticleId IdType="pubmed">5146491</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2001 Nov;2(11):820-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11715058</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Mar;160(3):572-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12611842</ArticleId></ArticleIdList></Reference><Reference><Citation>Addict Biol. 2016 Mar;21(2):489-503</Citation><ArticleIdList><ArticleId IdType="pubmed">25619621</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Jan 1;29(1):172-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16125979</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Dec;47(12):1955-66</Citation><ArticleIdList><ArticleId IdType="pubmed">24070910</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Feb;99(1-3):250-62</Citation><ArticleIdList><ArticleId IdType="pubmed">18063344</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Jul 30;233(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25978934</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2006 Nov 1;33(2):542-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16959498</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Jul 1;68(1):41-50</Citation><ArticleIdList><ArticleId IdType="pubmed">20609836</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2014 Jan;59(1):18-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24444320</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2008 Aug 30;163(3):223-35</Citation><ArticleIdList><ArticleId IdType="pubmed">18635342</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Aug;66(8):811-22</Citation><ArticleIdList><ArticleId IdType="pubmed">19652121</ArticleId></ArticleIdList></Reference><Reference><Citation>J Int Neuropsychol Soc. 2010 Nov;16(6):1064-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20719043</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2008 May;40(2):479-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18522058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1654-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23663951</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Apr 15;50(3):1313-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20056157</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):6106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20220100</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2011 Jan 25;1370:194-203</Citation><ArticleIdList><ArticleId IdType="pubmed">21059348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Mar 1;26(9):2424-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16510720</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Feb 15;34(4):1506-18</Citation><ArticleIdList><ArticleId IdType="pubmed">17207638</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):114-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17391355</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Jul;195(1):67-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19567899</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 2003;41(14):1959-66</Citation><ArticleIdList><ArticleId IdType="pubmed">14572528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2014 Nov;159(2-3):491-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25261042</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2013 Jan 15;73(2):177-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23036958</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Rev. 2014 Jan;121(1):66-95</Citation><ArticleIdList><ArticleId IdType="pubmed">24490789</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychol. 2012 Jan;89(1):220-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22027085</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33360586</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>296</Volume><PubDate><Year>2021</Year><Month>02</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Impact of duration of untreated illness in bipolar I disorder (manic episodes) on clinical outcome, socioecnomic burden in Egyptian population.</ArticleTitle><Pagination><MedlinePgn>113659</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(20)33320-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2020.113659</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Bipolar disorder (BD) is a serious and chronic mental illness that may result in disability. We evaluated effect of the duration of untreated of bipolar (DUB) (manic episodes) on clinical outcomes, including episode severity, residual symptoms, duration of hospitalization, and suicide attempts, and on socioeconomic status of patients.</AbstractText><AbstractText Label="METHODS">A total of 216 participants who had bipolar I disorder (manic state) recruited from November 2017-December 2019 from an inpatient psychiatric unit. Patients divided into 2 groups based on DUB: Group A, with DUB &lt; 4 months; and Group B, with DUB ≥4 months. All participants had evaluation for demographic and clinical features, Socioeconomic scale, Young mania rating scale (YMRS) at admission and discharge.</AbstractText><AbstractText Label="RESULTS">Group A participants were more often male, urban residents, married, literate and educated, professionally employed. Group A had a younger age of onset, less duration of illness, less frequency of episode, less suicide attempts, less duration in hospital, high mean of socioeconomic, lower mean of YMRS at admission and discharge in compared to Group B.</AbstractText><AbstractText Label="CONCLUSION">A longer DUB (manic episodes)was associated with negative clinical outcomes (more frequent episode, more symptoms severity, longer hospital admission, more suicide severity, more residual symptoms) and low socioeconomic state of patients with BDI (manic episodes).</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Gellan K</ForeName><Initials>GK</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt; Department of Child &amp; Adolescent Psychiatry, Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London, London SE5 8AF, UK. Electronic address: gillankaram@aun.edu.eg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbeh</LastName><ForeName>Khalid</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalifa</LastName><ForeName>Hossam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Samaan</LastName><ForeName>Maggi Raoof</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Child &amp; Adolescent Psychiatry, Assiut mental health hospital, Assiut, Egypt.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004534" MajorTopicYN="N" Type="Geographic">Egypt</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087122" MajorTopicYN="N">Mania</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061665" MajorTopicYN="Y">Time-to-Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Duration of untreated</Keyword><Keyword MajorTopicYN="Y">Egypt</Keyword><Keyword MajorTopicYN="Y">Socioeconomic</Keyword><Keyword MajorTopicYN="Y">Young mania rating scale</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>28</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33360586</ArticleId><ArticleId IdType="pii">S0165-1781(20)33320-5</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2020.113659</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10576323</PMID><DateCompleted><Year>2000</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9762</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>9</Issue><PubDate><Year>1999</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of clinical psychology</Title><ISOAbbreviation>J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>Cognitive deficits in schizophrenia on the WAIS-R NI Sentence Arrangement Subtest. Wechsler Adult Intelligence Scale-Revised Neuropsychological Inventory.</ArticleTitle><Pagination><MedlinePgn>1085-94</MedlinePgn></Pagination><Abstract><AbstractText>Performance of participants diagnosed with schizophrenia on the Sentence Arrangement subtest of the WAIS-R NI and several tests sensitive to frontal lobe dysfunction was significantly poorer than that of manic depressive or control participants. Several measures of performance of patients diagnosed with schizophrenia on the WAIS-R NI Sentence Arrangement subtest appeared to support recent interpretations of the cognitive deficit seen in schizophrenia. These data represent the first demonstration of deficit performance by patients with schizophrenia on the Sentence Arrangement subtest. This is also supportive of the prediction that one of the areas whose activity may influence scores on this subtest is the prefrontal cortex. In addition, neither positive nor negative symptoms systematically correlated with the cognitive deficits reported despite specific predictions from the current literature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gard</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of North Texas, Denton 76203, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrell</LastName><ForeName>E H</ForeName><Initials>EH</Initials></Author><Author ValidYN="Y"><LastName>Poreh</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychol</MedlineTA><NlmUniqueID>0217132</NlmUniqueID><ISSNLinking>0021-9762</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014888" MajorTopicYN="N">Wechsler Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>11</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10576323</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1097-4679(199909)55:9&lt;1085::AID-JCLP6&gt;3.0.CO;2-G</ArticleId><ArticleId IdType="doi">10.1002/(sici)1097-4679(199909)55:9&lt;1085::aid-jclp6&gt;3.0.co;2-g</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28180904</PMID><DateCompleted><Year>2018</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>10</Month><Day>21</Day></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Clinical, Cognitive, and Neuroimaging Evidence of a Neurodevelopmental Continuum in Offspring of Probands With Schizophrenia and Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>1208-1219</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbx002</ELocationID><Abstract><AbstractText Label="Background">Studies in child and adolescent offspring of patients with schizophrenia or bipolar disorders may help understand the influence of neurodevelopmental factors on the premorbid phenotype of these disorders.</AbstractText><AbstractText Label="Aims">To assess whether a combination of neurodevelopmental factors discriminates between young offspring of patients with schizophrenia (SzO) or bipolar disorder (BpO) and community controls (CcO). To assess the association between these factors and rates of psychiatric diagnoses in high risk (HR) youth.</AbstractText><AbstractText Label="Methods">One hundred thirty-three HR offspring (47 SzO and 86 BpO) and 84 CcO, aged 6-17, underwent cross-sectional clinical, neurocognitive, and structural neuroimaging assessment. Information on perinatal events and early childhood development was also obtained. General linear mixed models were performed to assess group discrimination and association with lifetime axis I psychiatric disorders.</AbstractText><AbstractText Label="Results">Multivariate analyses revealed that greater neurological soft signs (NSS), less total grey matter volume (GMV) and a higher frequency of obstetric complications discriminated HR offspring from CcO. When comparing each group individually, greater NSS and a higher frequency of obstetric complications discriminated SzO from CcO, and BpO from CcO, while lower intelligence also discriminated SzO from CcO and from BpO. Within HR offspring, lower intelligence and less total GMV were associated with lifetime incidence of psychiatric disorders.</AbstractText><AbstractText Label="Conclusions">Both SzO and BpO showed evidence of neurodevelopmental insult, although this may have a greater impact in SzO. Lower intelligence and less total GMV hold potential as biomarkers of risk for psychiatric disorders in HR youth.</AbstractText><CopyrightInformation>© The Author 2017. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugranyes</LastName><ForeName>Gisela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychology, 2014SGR489, Institut Clinic de Neurociències, Hospital Clínic i Provincial, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Serna</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borras</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Gistau</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Early Intervention Team, Pere Mata Institute of Reus, Health Research Institute Pere Virgili (IISPV), Reus, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pariente</LastName><ForeName>Jose C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero</LastName><ForeName>Soledad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baeza</LastName><ForeName>Inmaculada</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychology, 2014SGR489, Institut Clinic de Neurociències, Hospital Clínic i Provincial, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz-Caneja</LastName><ForeName>Covadonga M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez-Toscano</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernardo</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychology, 2014SGR489, Institut Clinic de Neurociències, Hospital Clínic i Provincial, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychology, 2014SGR489, Institut Clinic de Neurociències, Hospital Clínic i Provincial, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychology, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-Fornieles</LastName><ForeName>Josefina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry and Psychology, 2014SGR489, Institut Clinic de Neurociències, Hospital Clínic i Provincial, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="Y">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007360" MajorTopicYN="N">Intelligence</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007744" MajorTopicYN="Y">Obstetric Labor Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">neurodevelopmental disorders</Keyword><Keyword MajorTopicYN="Y">neuroimaging</Keyword><Keyword MajorTopicYN="Y">relatives</Keyword><Keyword MajorTopicYN="Y">schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28180904</ArticleId><ArticleId IdType="pii">2979289</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbx002</ArticleId><ArticleId IdType="pmc">PMC5737486</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Radiology. 2000 Sep;216(3):672-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10966694</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2002 Jan;15(1):273-89</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 May;59(5):449-56</Citation><ArticleIdList><ArticleId IdType="pubmed">11982449</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2002 May;24(3):280-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11992210</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2002 Nov;181:387-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12411263</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jul;60(7):709-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12860775</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12960712</ArticleId></ArticleIdList></Reference><Reference><Citation>Epidemiol Rev. 2004;26:53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15234947</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2004 Spring;16(2):461-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15487606</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Apr;188:366-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16582064</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Sep;86(1-3):110-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16765029</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Nov 1;60(9):957-65</Citation><ArticleIdList><ArticleId IdType="pubmed">16934765</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 May;92(1-3):132-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17344025</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2007 Oct 15;38(1):95-113</Citation><ArticleIdList><ArticleId IdType="pubmed">17761438</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2007 Sep;191:258-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17766768</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2007 Oct;97(10):1756-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17895405</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):828-38</Citation><ArticleIdList><ArticleId IdType="pubmed">18076532</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2008 May;47(5):532-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18356765</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2008 May;47(5):526-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18356766</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2008 Aug;103(1-3):114-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18442896</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2008 Jul;34(4):734-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18515820</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 Oct 1;32(7):1617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">18538910</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Apr;39(4):625-34</Citation><ArticleIdList><ArticleId IdType="pubmed">18606046</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Mar;35(2):415-24</Citation><ArticleIdList><ArticleId IdType="pubmed">18791074</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Oct;39(10):1649-55</Citation><ArticleIdList><ArticleId IdType="pubmed">19265566</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2009 Aug;259(5):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19390766</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Child Adolesc Psychiatry. 2010 Feb;19(2):151-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19711026</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1991 Jan 1;29(1):1-2</Citation><ArticleIdList><ArticleId IdType="pubmed">2001443</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2011 Jan;54 Suppl 1:S272-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20441795</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 May 15;69(10):953-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21168123</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1349-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21549798</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2012 Mar;38(2):209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">21857009</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2011 Dec 30;194(3):319-325</Citation><ArticleIdList><ArticleId IdType="pubmed">22041532</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2012 Dec;17(12):1228-38</Citation><ArticleIdList><ArticleId IdType="pubmed">22488257</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2013 Jan;43(1):119-31</Citation><ArticleIdList><ArticleId IdType="pubmed">22575089</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2012 Nov;69(11):1099-1103</Citation><ArticleIdList><ArticleId IdType="pubmed">22752149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Sep;39(5):1067-76</Citation><ArticleIdList><ArticleId IdType="pubmed">22941745</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Neuropsychiatry. 2013;18(1-2):44-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22998599</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2013 Sep;39(5):1056-66</Citation><ArticleIdList><ArticleId IdType="pubmed">23002182</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Nov 30;204(2-3):68-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23146250</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Jan;70(1):22-30</Citation><ArticleIdList><ArticleId IdType="pubmed">23147713</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:72-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23266480</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Apr;145(1-3):56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23375940</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2013 Dec;48(3):404-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23440732</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2013 Nov;136(Pt 11):3215-26</Citation><ArticleIdList><ArticleId IdType="pubmed">23698280</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Jul;70(7):677-85</Citation><ArticleIdList><ArticleId IdType="pubmed">23699867</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2013 Aug 15;208(3):225-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23790979</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Jul;19(7):848-52</Citation><ArticleIdList><ArticleId IdType="pubmed">23917947</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Jan;40(1):28-38</Citation><ArticleIdList><ArticleId IdType="pubmed">23960245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2014 Sep;19(9):1017-1024</Citation><ArticleIdList><ArticleId IdType="pubmed">24280982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Sep;16(6):624-32</Citation><ArticleIdList><ArticleId IdType="pubmed">24499422</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2014 Mar;20(2):147-53</Citation><ArticleIdList><ArticleId IdType="pubmed">24638050</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2014 Jul;31(7):583-90</Citation><ArticleIdList><ArticleId IdType="pubmed">24643978</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2014 Dec 15;23(24):6677-83</Citation><ArticleIdList><ArticleId IdType="pubmed">25055870</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Jan;45(2):381-94</Citation><ArticleIdList><ArticleId IdType="pubmed">25065268</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Clin Pediatr. 2012 Dec 08;1(4):20-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25254163</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 May;41(3):708-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25378438</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:336-41</Citation><ArticleIdList><ArticleId IdType="pubmed">25545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2016 May;21(5):693-700</Citation><ArticleIdList><ArticleId IdType="pubmed">26055426</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2016 Jun;171(4):495-505</Citation><ArticleIdList><ArticleId IdType="pubmed">26183902</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2015 Aug;54(8):677-84.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">26210337</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2016 Jan;42(1):77-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26231719</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2015 Aug 25;15:205</Citation><ArticleIdList><ArticleId IdType="pubmed">26302744</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 Oct;168(1-2):197-203</Citation><ArticleIdList><ArticleId IdType="pubmed">26363969</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2016 Apr 9;387(10027):1561-72</Citation><ArticleIdList><ArticleId IdType="pubmed">26388529</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2016 Apr;57(4):446-56</Citation><ArticleIdList><ArticleId IdType="pubmed">26577292</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2016 May;42(3):633-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26615187</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2016 Feb 28;236:173-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26775167</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Epidemiol. 2016 Apr;45(2):543-53</Citation><ArticleIdList><ArticleId IdType="pubmed">26874928</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Feb 17;11(2):e0148045</Citation><ArticleIdList><ArticleId IdType="pubmed">26885824</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 2016 Mar-Apr;24(2):104-17</Citation><ArticleIdList><ArticleId IdType="pubmed">26954595</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2016 May 1;73(5):497-505</Citation><ArticleIdList><ArticleId IdType="pubmed">27007234</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1989 Mar;27(3):335-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2710870</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2017 Jan;112(Pt B):297-306</Citation><ArticleIdList><ArticleId IdType="pubmed">27245499</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 Aug;46(11):2351-61</Citation><ArticleIdList><ArticleId IdType="pubmed">27282778</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian J Psychiatr. 2016 Aug;22:53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">27520894</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2017 Jan;56(1):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">27993232</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J (Clin Res Ed). 1987 Sep 19;295(6600):681-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3117295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Jul;44(7):660-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3606332</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1979 Jun;36(6):665-74</Citation><ArticleIdList><ArticleId IdType="pubmed">444019</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 1983 Nov;28(7):527-31</Citation><ArticleIdList><ArticleId IdType="pubmed">6652602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1982-1983;17(4):319-34</Citation><ArticleIdList><ArticleId IdType="pubmed">7187776</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1996 Dec;49(12):1373-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8970487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9204677</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Dis Child. 1976 Mar;51(3):170-9</Citation><ArticleIdList><ArticleId IdType="pubmed">952550</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16282872</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1076-2752</ISSN><JournalIssue CitedMedium="Print"><Volume>47</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of occupational and environmental medicine</Title><ISOAbbreviation>J Occup Environ Med</ISOAbbreviation></Journal><ArticleTitle>Lost time, absence costs, and reduced productivity output for employees with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1117-24</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">We sought to evaluate the incremental health-related lost work time and at-work productivity loss for employees with bipolar disorder (BPD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Health-related absence and real productivity output of employees with BPD were compared with that of non-BPD and other employee cohorts from a large employer database using multivariate regression to control for cohort differences.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjusting for confounding factors, employees with BPD had significantly higher absence costs (1,219 dollars) and 11.5 additional lost days (P&lt;0.05) per year than those without BPD. Adjusted annual productivity output was 20% lower for the BPD group (P&lt;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Employees with BPD are less likely to be present for work. When present, their productivity level is similar to that of other employees, but over the course of a year, their absence rates result in significant productivity losses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Nathan L</ForeName><Initials>NL</Initials><AffiliationInfo><Affiliation>HCMS Group, Cheyenne, Wyoming 82001, USA. nathan_kleinman@hcmsgroup.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brook</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Krithika</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gardner</LastName><ForeName>Harold H</ForeName><Initials>HH</Initials></Author><Author ValidYN="Y"><LastName>Brizee</LastName><ForeName>Truman J</ForeName><Initials>TJ</Initials></Author><Author ValidYN="Y"><LastName>Smeeding</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Occup Environ Med</MedlineTA><NlmUniqueID>9504688</NlmUniqueID><ISSNLinking>1076-2752</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003365" MajorTopicYN="N">Costs and Cost Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019992" MajorTopicYN="N">Databases as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017598" MajorTopicYN="N">Efficiency, Organizational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004650" MajorTopicYN="Y">Employee Performance Appraisal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018582" MajorTopicYN="Y">Sick Leave</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014959" MajorTopicYN="N" Type="Geographic">Wyoming</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16282872</ArticleId><ArticleId IdType="pii">00043764-200511000-00004</ArticleId><ArticleId IdType="doi">10.1097/01.jom.0000177048.34506.fc</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24825960</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-8584</ISSN><JournalIssue CitedMedium="Internet"><Volume>2014</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Behavioural neurology</Title><ISOAbbreviation>Behav Neurol</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and multiple sclerosis: a case series.</ArticleTitle><Pagination><MedlinePgn>536503</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/536503</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The prevalence of psychiatric disturbance for patients with multiple sclerosis (MS) is higher than that observed in other chronic health conditions. We report three cases of MS and bipolar disorder and we discuss the possible etiological hypothesis and treatment options.</AbstractText><AbstractText Label="OBSERVATIONS" NlmCategory="METHODS">All patients fulfilled the McDonald criteria for MS. Two patients were followed up in psychiatry for manic or depressive symptoms before developing MS. A third patient was diagnosed with MS and developed deferred psychotic symptoms. Some clinical and radiological features are highlighted in our patients: one manic episode induced by high dose corticosteroids and one case of a new orbitofrontal MRI lesion concomitant with the emergence of psychiatric symptoms. All patients needed antipsychotic treatment with almost good tolerance for high dose corticosteroids and interferon beta treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">MRI lesions suggest the possible implication of local MS-related brain damage in development of pure "psychiatric fits" in MS. Genetic susceptibility is another hypothesis for this association. We have noticed that interferon beta treatments were well tolerated while high dose corticosteroids may induce manic fits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sidhom</LastName><ForeName>Youssef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben Djebara</LastName><ForeName>Mouna</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hizem</LastName><ForeName>Yosr</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdelkefi</LastName><ForeName>Istabrak</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kacem</LastName><ForeName>Imen</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gargouri</LastName><ForeName>Amina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouider</LastName><ForeName>Riadh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Razi Hospital, Manouba, 2010 Tunis, Tunisia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Behav Neurol</MedlineTA><NlmUniqueID>8914585</NlmUniqueID><ISSNLinking>0953-4180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>07</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24825960</ArticleId><ArticleId IdType="doi">10.1155/2014/536503</ArticleId><ArticleId IdType="pmc">PMC4006599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neurologist. 2007 Nov;13(6):343-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18090712</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2011 Jul;24(4):336-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21546839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo Clin Proc. 2006 Oct;81(10):1361-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17036562</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurol (Paris). 2010 Jan;166(1):39-48</Citation><ArticleIdList><ArticleId IdType="pubmed">19735928</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2010 Dec;32(4):454-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21308269</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1996 Winter;8(1):54-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8845702</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2003 Aug;27(5):835-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12921917</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Allergy Asthma Immunol. 2004 May;92(5):500-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15191017</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Psychiatry. 2007 May;20(3):278-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17415083</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurol (Paris). 2009 Mar;165 Suppl 4:S156-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19361681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Neurol (Paris). 2006 Jun;162(6-7):729-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16840981</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):226-31</Citation><ArticleIdList><ArticleId IdType="pubmed">14754769</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1987 Apr;44(4):376-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3827692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Sci. 2006 Jun 15;245(1-2):59-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16631798</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1988 Aug;18(3):733-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3186872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2006 Dec;12(6):802-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17263010</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2010;22(1):14-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20233111</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1996 Spring;8(2):206-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9081558</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1986 Jan;143(1):94-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3942295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arq Neuropsiquiatr. 2007 Dec;65(4B):1177-80</Citation><ArticleIdList><ArticleId IdType="pubmed">18345425</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1988 Oct;38(10):1631-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2843795</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Scand. 1993 Dec;88(6):388-93</Citation><ArticleIdList><ArticleId IdType="pubmed">8116337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurovirol. 2000 May;6 Suppl 2:S160-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10871806</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neurol Belg. 1996 Mar;96(1):62-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8669231</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12921902</PMID><DateCompleted><Year>2003</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0278-5846</ISSN><JournalIssue CitedMedium="Print"><Volume>27</Volume><Issue>5</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Progress in neuro-psychopharmacology &amp; biological psychiatry</Title><ISOAbbreviation>Prog Neuropsychopharmacol Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Possible role of 3'(2')-phosphoadenosine-5'-phosphate phosphatase in the etiology and therapy of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>723-7</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar affective disorder (BPD) is a multifactorial, severe, chronic and disabling illness with 50% heritability that affects 1-2% of the population. Lithium ions (Li) are the drug of choice for BPD. Yet, 20-40% of patients fail to respond to Li. Although numerous biochemical and cellular effects have been attributed to Li, its therapeutic mechanism of action has not been elucidated. This review presents the possible involvement of 3'(2')-phosphoadenosine-5'-phosphate (PAP) phosphatase in the etiology of bipolar disorder and the mechanism of action of Li. Of the enzymes inhibited by Li, PAP phosphatase is inhibited with the lowest Ki (0.3 mM). At therapeutic concentrations of Li (0.5-1.5 mM), inhibition is greater than 80%. Therefore, PAP phosphatase is a strong candidate for Li's therapeutic mechanism of action. In yeast, a PAP phosphatase knockout mutation leads to the accumulation of PAP, which affects ribosomal-, transfer- and small nucleolar-RNA processing. PAP accumulation in the mammalian brain following Li inhibition of PAP phosphatase may very well account for the observed effects of Li on gene expression and behavior. Furthermore, we have reported significant changes in PAP phosphatase levels in postmortem frontal cortex of bipolar patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Agam</LastName><ForeName>Galila</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Stanley Research Center and Zlotowski Center for Neuroscience, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beersheva, Israel. agamg@netvision.net.il</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaltiel</LastName><ForeName>Galit</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Prog Neuropsychopharmacol Biol Psychiatry</MedlineTA><NlmUniqueID>8211617</NlmUniqueID><ISSNLinking>0278-5846</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000227">Adenine Nucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.2</RegistryNumber><NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000227" MajorTopicYN="N">Adenine Nucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010744" MajorTopicYN="N">Phosphoric Monoester Hydrolases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>35</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>10</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12921902</ArticleId><ArticleId IdType="pii">S0278-5846(03)00125-8</ArticleId><ArticleId IdType="doi">10.1016/S0278-5846(03)00125-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27992891</PMID><DateCompleted><Year>2017</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2391-5854</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>Oct</Month><Day>31</Day></PubDate></JournalIssue><Title>Psychiatria polska</Title><ISOAbbreviation>Psychiatr Pol</ISOAbbreviation></Journal><ArticleTitle>Negative experiences in childhood and the development and course of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>989-1000</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">61159</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.12740/PP/61159</ELocationID><Abstract><AbstractText>The aim of this paper is to review the effects of negative childhood experiences on the development and course of bipolar disorder (BD) and to discuss the involved mechanisms. The negative childhood experiences that may play a role in BD are critical or traumatic events including all kinds of abuse, loss of a parent or parents resulting from death, suicide, separation, divorce or prolonged separation. Previous studies indicate that in BD patients negative childhood events are more frequent than in control group. In BD patients these events are associated with an earlier onset and more severe course of the illness, including more frequent relapses, suicidal behavior, substance abuse and somatic diseases. This paper presents the possibility of the specific impact of individual events on the clinical outcome of BD. Mechanisms explaining the impact of negative childhood events on the development and course of BD include the interaction between biological predisposition and stress factors, the concept of kindling and activation of negative cognitive schemas. Early negative experiences cause a modification of the expression of the mediators of stress and neurotransmitters in certain areas of the brain. The interaction of these mediators with the development of neural networks may lead to long-lasting structural and functional changes. Molecular genetic studies indicate the possibility of interactions between environmental factors (stress) and the polymorphisms of serotonin transporter, brain-derived neurotrophic factor (BDNF) and toll-like receptor (TLR2). It has also been hypothesized that childhood experiences affect DNA methylation, acting as a form of molecular memory and modifying brain activity over the next decade.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jaworska-Andryszewska</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Klinika Psychiatrii Dorosłych UM w Poznaniu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Klinika Psychiatrii Dorosłych UM w Poznaniu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>pol</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Negatywne doświadczenia dziecięce a powstawanie i przebieg choroby afektywnej dwubiegunowej.</VernacularTitle></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Psychiatr Pol</MedlineTA><NlmUniqueID>0103314</NlmUniqueID><ISSNLinking>0033-2674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054523" MajorTopicYN="N">Adult Survivors of Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002649" MajorTopicYN="N">Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004198" MajorTopicYN="Y">Disease Susceptibility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059647" MajorTopicYN="N">Gene-Environment Interaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">negative childhood experiences</Keyword><Keyword MajorTopicYN="Y">violence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27992891</ArticleId><ArticleId IdType="pii">61159</ArticleId><ArticleId IdType="doi">10.12740/PP/61159</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29108106</PMID><DateCompleted><Year>2019</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>06</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature.</ArticleTitle><Pagination><MedlinePgn>359-369</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12566</ELocationID><Abstract><AbstractText Label="OBJECTIVES">More than 50% of people with bipolar disorder will be age 60 years or older by 2030. There is a need for more data to guide assessment and treatment in older age bipolar disorder (OABD); however, interpretation of findings from small, single-site studies may not be generalizable and there are few large trials. As a step in the direction of coordinated large-scale OABD data collection, it is critical to identify which measurements are currently used and identify potential gaps in domains typically assessed.</AbstractText><AbstractText Label="METHODS">An international group of OABD experts performed a systematic literature review to identify studies examining OABD in the past 6 years. Relevant articles were assessed to categorize the types of clinical, cognitive, biomarker, and neuroimaging OABD tools routinely used in OABD studies.</AbstractText><AbstractText Label="RESULTS">A total of 53 papers were identified, with a broad range of assessments. Most studies evaluated demographic and clinical domains, with fewer studies assessing cognition. There are relatively few biomarker and neuroimaging data, and data collection methods were less comprehensively covered.</AbstractText><AbstractText Label="CONCLUSION">Assessment tools used in the recent OABD literature may help to identify both a minimum and a comprehensive dataset that should be evaluated in OABD. Our review also highlights gaps where key clinical outcomes have not been routinely assessed. Biomarker and neuroimaging assessment could be further developed and standardized. Clinical data could be combined with neuroimaging, genetic, and other biomarkers in large-scale coordinated data collection to further improve our understanding of OABD phenomenology and biology, thereby contributing to research that advances care.</AbstractText><CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rej</LastName><ForeName>Soham</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3908-9124</Identifier><AffiliationInfo><Affiliation>GeriPARTy Group, Division of Geriatric Psychiatry, Jewish General Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quayle</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forester</LastName><ForeName>Brent P</ForeName><Initials>BP</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dols</LastName><ForeName>Annemiek</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1964-0318</Identifier><AffiliationInfo><Affiliation>Department of Old Age Psychiatry, GGZ inGeest, EMGO Institute of Care and Health Research, VU University Medical Centre, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gatchel</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, McLean Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Peijun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry&amp; Neurology, Case Western Reserve University School of Medicine, University Hospitals Case Medical Centre, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Psychiatry Service, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gough</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>GeriPARTy Group, Division of Geriatric Psychiatry, Jewish General Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sajatovic</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry&amp; Neurology, Case Western Reserve University School of Medicine, University Hospitals Case Medical Centre, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eyler</LastName><ForeName>Lisa T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California San Diego, San Diego, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Desert-Pacific Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015577" MajorTopicYN="N">Geriatric Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020380" MajorTopicYN="N">Needs Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011580" MajorTopicYN="Y">Psychological Techniques</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">assessment</Keyword><Keyword MajorTopicYN="Y">bipolar disorders</Keyword><Keyword MajorTopicYN="Y">measurement tools</Keyword><Keyword MajorTopicYN="Y">older age</Keyword><Keyword MajorTopicYN="Y">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>09</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29108106</ArticleId><ArticleId IdType="doi">10.1111/bdi.12566</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2948989</PMID><DateCompleted><Year>1987</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>2</Issue><PubDate><MedlineDate>1986 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Mania in prepubertal children: has it been underdiagnosed?</ArticleTitle><Pagination><MedlinePgn>151-4</MedlinePgn></Pagination><Abstract><AbstractText>Prior to the introduction of lithium, mania was underdiagnosed in the U.S.A. Almost 50% of adults who met DSM-III criteria for mania had previously been diagnosed to have schizophrenia. To determine if mania had similarly been underdiagnosed in prepubertal children, 157 cases of 'severely disturbed' children described in the literature were reviewed. Approximately one-half (16/33) of the children diagnosed in this study as manic according to DSM-III had originally received another diagnosis. These results indicate that mania should be considered in the differential diagnosis of psychotic children, particularly those with affective symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>R A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Weller</LastName><ForeName>E B</ForeName><Initials>EB</Initials></Author><Author ValidYN="Y"><LastName>Tucker</LastName><ForeName>S G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Fristad</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012561" MajorTopicYN="N">Schizophrenia, Childhood</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2948989</ArticleId><ArticleId IdType="pii">0165-0327(86)90022-4</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(86)90022-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4027309</PMID><DateCompleted><Year>1985</Year><Month>10</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>9</Issue><PubDate><Year>1985</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Phenelzine-induced hypomania: effect of verapamil.</ArticleTitle><Pagination><MedlinePgn>1009-14</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubovsky</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Franks</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Schrier</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RR0051</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>CJ0O37KU29</RegistryNumber><NameOfSubstance UI="D014700">Verapamil</NameOfSubstance></Chemical><Chemical><RegistryNumber>O408N561GF</RegistryNumber><NameOfSubstance UI="D010624">Phenelzine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010624" MajorTopicYN="N">Phenelzine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014700" MajorTopicYN="N">Verapamil</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4027309</ArticleId><ArticleId IdType="pii">0006-3223(85)90199-4</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(85)90199-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20382908</PMID><DateCompleted><Year>2010</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1758-1095</ISSN><JournalIssue CitedMedium="Internet"><Volume>103</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Journal of the Royal Society of Medicine</Title><ISOAbbreviation>J R Soc Med</ISOAbbreviation></Journal><ArticleTitle>James Crichton Browne and controlled evaluation of drug treatment for mental illness.</ArticleTitle><Pagination><MedlinePgn>160-1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1258/jrsm.2009.09k073</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Clive E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Cochrane Schizophrenia Group, Sir Colin Campbell Building, University of Nottingham Innovation Park, Triumph Road, Nottingham NG7 2TU, UK. clive.adams@nottingham.ac.uk</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J R Soc Med</MedlineTA><NlmUniqueID>7802879</NlmUniqueID><ISSNLinking>0141-0768</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028321">Plant Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029982" MajorTopicYN="Y">Conium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028321" MajorTopicYN="N">Plant Preparations</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Browne</LastName><ForeName>James Crichton</ForeName><Initials>JC</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20382908</ArticleId><ArticleId IdType="pii">103/4/160</ArticleId><ArticleId IdType="doi">10.1258/jrsm.2009.09k073</ArticleId><ArticleId IdType="pmc">PMC2853404</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J R Soc Med. 2005 Sep;98(9):428-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16140860</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2007 Jan 6;334 Suppl 1:s7</Citation><ArticleIdList><ArticleId IdType="pubmed">17204765</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Hist. 1995 Oct;39(4):399-432</Citation><ArticleIdList><ArticleId IdType="pubmed">8558991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24448212</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><PubDate><Year>2014</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application.</ArticleTitle><Pagination><MedlinePgn>e350</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/tp.2013.119</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a debilitating mental illness characterized by severe fluctuations in mood, sleep, energy and executive functioning. Pharmacological studies of selective serotonin reuptake inhibitors and the monoamine system have helped us to clinically understand bipolar depression. Mood stabilizers such as lithium and valproic acid, the first-line treatments for bipolar mania and depression, inhibit glycogen synthase kinase-3 beta (GSK-3β) and regulate the Wnt pathway. Recent investigations suggest that microglia, the resident immune cells of the brain, provide a physiological link between the serotonin system and the GSK-3β/Wnt pathway through neuroinflammation. We review the pharmacological, translational and brain imaging studies that support a role for microglia in regulating neurotransmitter synthesis and immune cell activation. These investigations provide a model for microglia involvement in the pathophysiology and phenotype of BD that may translate into improved therapies. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>C C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, John Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawa</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, John Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pomper</LastName><ForeName>M G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry and Behavioral Sciences, John Hopkins University School of Medicine, Baltimore, MD, USA [2] Division of Neuroradiology, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 HD073315</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH094268</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH015330</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2T32MH015330-32</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057054" MajorTopicYN="Y">Molecular Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009480" MajorTopicYN="Y">Neuropharmacology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24448212</ArticleId><ArticleId IdType="pii">tp2013119</ArticleId><ArticleId IdType="doi">10.1038/tp.2013.119</ArticleId><ArticleId IdType="pmc">PMC3905229</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1379-84</Citation><ArticleIdList><ArticleId IdType="pubmed">17728423</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 May;60(5):497-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2008 Apr 16;(2):CD005169</Citation><ArticleIdList><ArticleId IdType="pubmed">18425912</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2000 Spring;8(2):160-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10804077</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2012 Jul 30;203(1):67-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22892349</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscientist. 2002 Oct;8(5):497-511</Citation><ArticleIdList><ArticleId IdType="pubmed">12374432</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Geriatr Psychiatry. 2011 Dec;19(12):1016-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21841458</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychosom Res. 2007 Aug;63(2):131-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17662748</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Feb;64(2):201-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17283287</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Jan 10;144(1-2):16-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22749156</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1355-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18316149</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Apr 1;57(7):696-701</Citation><ArticleIdList><ArticleId IdType="pubmed">15820225</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2013 Aug 29;246:199-229</Citation><ArticleIdList><ArticleId IdType="pubmed">23644052</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 Jul;73(1):34-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12802786</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005 Dec;66(12):1586-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16401162</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Jan 29;105(4):1333-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18212115</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurovirol. 2005 Aug;11(4):346-55</Citation><ArticleIdList><ArticleId IdType="pubmed">16162478</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2006;2:267-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17716071</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2004 Jul 28;24(30):6791-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15282284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 May;33(5):699-771</Citation><ArticleIdList><ArticleId IdType="pubmed">19428491</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 2007 Jul;206(1):33-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17481608</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Gen Sect. 1994;95(2):157-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7865169</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1996 Dec;1(6):453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9154246</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2013 Jul;31:161-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23064081</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Diab Rep. 2009 Feb;9(1):51-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19192425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Signal. 2013 Apr;25(4):822-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23266471</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2007 Apr;48(4):573-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17401094</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):606-13, 557</Citation><ArticleIdList><ArticleId IdType="pubmed">18268503</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Aug;13(8):800-12</Citation><ArticleIdList><ArticleId IdType="pubmed">18504423</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2006 Aug;27(8):402-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16822554</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurocytol. 1997 Feb;26(2):77-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9181482</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Feb 1;49(3):2588-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19853044</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Aug;70(8):1078-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19497250</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Sep;102(1-3):65-72</Citation><ArticleIdList><ArticleId IdType="pubmed">17270276</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8710892</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2008 Jul;8(7):1101-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18590480</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2007 Oct 12;149(1):203-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17850978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurotherapeutics. 2007 Jul;4(3):443-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17599710</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2012 Feb;53(2):330-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22241913</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 2013 Jul;136(Pt 7):2228-38</Citation><ArticleIdList><ArticleId IdType="pubmed">23775979</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2010 Jun 04;10:39</Citation><ArticleIdList><ArticleId IdType="pubmed">20525372</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):751-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18178625</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2007 Jan;48(1):158-67</Citation><ArticleIdList><ArticleId IdType="pubmed">17204713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2006 Aug 30;26(35):9022-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16943560</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 May 1;59(9):821-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16213473</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 Aug 1;50(3):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">11513821</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14817-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20679216</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2001;19(5 Pt 1):483-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11465308</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 May 1;65(9):732-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19150053</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Jul;50(7):1047-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19525468</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 1;59(11):1006-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16487491</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Radiopharm. 2012 Jan;5(1):19-28</Citation><ArticleIdList><ArticleId IdType="pubmed">22074478</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jul 18;301(5631):386-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12869766</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jun;13(6):558-69</Citation><ArticleIdList><ArticleId IdType="pubmed">18317468</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuroinflammation. 2011 Aug 10;8:94</Citation><ArticleIdList><ArticleId IdType="pubmed">21831269</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Nov 15;58(10):825-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16026765</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Struct Funct. 2008 Sep;213(1-2):93-118</Citation><ArticleIdList><ArticleId IdType="pubmed">18704495</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Feb;98(1-2):143-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16952400</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Oct 15;48(8):766-77</Citation><ArticleIdList><ArticleId IdType="pubmed">11063973</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Mar 15;61(6):806-12</Citation><ArticleIdList><ArticleId IdType="pubmed">17210135</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Apr;65(4):395-407</Citation><ArticleIdList><ArticleId IdType="pubmed">18391128</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 1996 Jan;137(1):354-66</Citation><ArticleIdList><ArticleId IdType="pubmed">8536636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2003 Sep;23(9):1096-112</Citation><ArticleIdList><ArticleId IdType="pubmed">12973026</ArticleId></ArticleIdList></Reference><Reference><Citation>J Physiol Paris. 2002 Apr-Jun;96(3-4):289-99</Citation><ArticleIdList><ArticleId IdType="pubmed">12445908</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13290-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9789081</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Jul;65(7):785-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18606951</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunol Allergy Clin North Am. 2009 May;29(2):321-37</Citation><ArticleIdList><ArticleId IdType="pubmed">19389585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 1991 Mar;11(2):314-22</Citation><ArticleIdList><ArticleId IdType="pubmed">1997503</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Jul 1;56(1):18-23</Citation><ArticleIdList><ArticleId IdType="pubmed">15219468</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 Jan;33(1):110-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17912251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2002 Nov 1;58(1):63-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12363391</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2007 Mar;32(2):86-102</Citation><ArticleIdList><ArticleId IdType="pubmed">17353938</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2007 Sep;12(9):815-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17440432</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 May 1;280(5364):747-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9563953</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):870-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17678634</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2013 Jan;33(1):53-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22968319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2006 Dec;11(12):1116-25</Citation><ArticleIdList><ArticleId IdType="pubmed">16969367</ArticleId></ArticleIdList></Reference><Reference><Citation>J Leukoc Biol. 2012 Nov;92(5):959-75</Citation><ArticleIdList><ArticleId IdType="pubmed">22875882</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2013 Jan;61(1):10-23</Citation><ArticleIdList><ArticleId IdType="pubmed">22615180</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 1996 Jul 8;7(10):1675-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8904780</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Dec;61(12):1271-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15583118</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2013 Mar;29:136-146</Citation><ArticleIdList><ArticleId IdType="pubmed">23305936</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 May 1;51(9):715-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11983185</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2010 Jan;10(1):59-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20021321</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2011 Jan;52(1):24-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21149489</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroimage. 2010 Feb 15;49(4):2924-32</Citation><ArticleIdList><ArticleId IdType="pubmed">19948230</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Aug 1;58(3):190-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16084839</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2002;53:409-35</Citation><ArticleIdList><ArticleId IdType="pubmed">11818483</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr Rev. 2007 Dec;65(12 Pt 2):S253-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18240558</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Jun 1;63(11):1022-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18242584</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods. 2002 Jul;27(3):287-99</Citation><ArticleIdList><ArticleId IdType="pubmed">12183117</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2012 Jan;35(1):36-46</Citation><ArticleIdList><ArticleId IdType="pubmed">22217451</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Jul;61(7):705-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15237082</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2007 Mar;320(3):1087-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17167170</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2002 Sep 1;52(5):404-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12242056</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2013 Jan;61(1):62-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22740320</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2008 Apr;10(2):178-89</Citation><ArticleIdList><ArticleId IdType="pubmed">18474212</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2009 Aug;50(8):1276-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19617321</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 Feb 6;158(3):1021-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18662748</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2006 Oct;31(10):2121-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16452991</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2012 Mar;26(3):469-79</Citation><ArticleIdList><ArticleId IdType="pubmed">22251606</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1306-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20654672</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2012 Dec;37(12):1901-11</Citation><ArticleIdList><ArticleId IdType="pubmed">22541717</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):952-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17391822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2002;7(5):468-73</Citation><ArticleIdList><ArticleId IdType="pubmed">12082564</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2003;121(4):847-53</Citation><ArticleIdList><ArticleId IdType="pubmed">14580934</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurosci. 2008 Jan;9(1):46-56</Citation><ArticleIdList><ArticleId IdType="pubmed">18073775</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Int. 2008 May;52(6):1297-303</Citation><ArticleIdList><ArticleId IdType="pubmed">18328600</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2001 Nov;21(11):1342-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11702049</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2001 May 1;49(9):741-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11331082</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Physiol (Oxf). 2011 Nov;203(3):363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21557822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1654-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23663951</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Dec 1;56(11):819-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15576057</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1997 Sep;2(5):398-402</Citation><ArticleIdList><ArticleId IdType="pubmed">9322234</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):743-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17988365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Mar;14(2):175-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22420593</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain. 1992 Oct;115 ( Pt 5):1249-73</Citation><ArticleIdList><ArticleId IdType="pubmed">1422788</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2007 Dec;9(6):512-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18221633</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Mar 20;136(6):1017-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19303846</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Feb;6(1):43-52</Citation><ArticleIdList><ArticleId IdType="pubmed">14996140</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Neuropharmacol. 2012 Sep;10(3):239-53</Citation><ArticleIdList><ArticleId IdType="pubmed">23449817</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2006 Feb 16;1073-1074:25-37</Citation><ArticleIdList><ArticleId IdType="pubmed">16448631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2013 Jun;125(6):803-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23534675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 May;3(3):220-6, 190-1</Citation><ArticleIdList><ArticleId IdType="pubmed">9672897</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nucl Med. 2006 May;47(5):815-26</Citation><ArticleIdList><ArticleId IdType="pubmed">16644752</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2002 Aug;71(2):337-48</Citation><ArticleIdList><ArticleId IdType="pubmed">12098102</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2007 Jan;31(1):28-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17207098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct 15;82(2):309-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15488263</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000;61 Supp 13:42-57</Citation><ArticleIdList><ArticleId IdType="pubmed">11153812</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Aug;13(8):742-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18332878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nucl Med Biol. 2002 Jul;29(5):509-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12088720</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2000 Feb 28;857(1-2):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">10700573</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegener Dis. 2008;5(5):277-85</Citation><ArticleIdList><ArticleId IdType="pubmed">18520162</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2008 Mar;153 Suppl 1:S428-37</Citation><ArticleIdList><ArticleId IdType="pubmed">18311157</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2004 Jan;29(1):11-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14719046</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 Dec;14(12):1095-104</Citation><ArticleIdList><ArticleId IdType="pubmed">18458677</ArticleId></ArticleIdList></Reference><Reference><Citation>Innate Immun. 2012 Jun;18(3):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">21994254</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):217-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14754766</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17519979</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2004 Mar;38(3):135-40</Citation><ArticleIdList><ArticleId IdType="pubmed">14961931</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Sep;162(9):1697-705</Citation><ArticleIdList><ArticleId IdType="pubmed">16135630</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Neurol Disord Drug Targets. 2007 Jun;6(3):219-33</Citation><ArticleIdList><ArticleId IdType="pubmed">17511618</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2001 Jul 15;55(5):585-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11576755</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 May;62(5):529-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15867106</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27287789</PMID><DateCompleted><Year>2016</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0353-5053</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>2016</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatria Danubina</Title><ISOAbbreviation>Psychiatr Danub</ISOAbbreviation></Journal><ArticleTitle>Long term use of lithium and factors associated with treatment response among patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>146-53</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lithium has been the gold standard in treating bipolar disorder. In recent years, the use of lithium seems to be diminished although it is well tolerated among the bipolar disorder patients.</AbstractText><AbstractText Label="SUBJECTS AND METHODS" NlmCategory="METHODS">This study aimed to evaluate the efficacy and tolerability of lithium as well as to determine factors associated with lithium response among patient with bipolar disorder. A retrospective study was done in a tertiary care hospital in Malaysia which included 47 bipolar disorder patients that were prescribed with lithium maintenance therapy in the time frame of January 2009 until December 2013.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of all the baseline characteristics tested, only psychotic feature differentiated lithium monotherapy group and combination therapy group significantly (χ(2)=4.732, p=0.03). When compared to period before lithium maintenance, all outcome measures (i.e. annual relapse rate, proportion time spent ill and duration of mood episode) showed significant improvement after lithium maintenance in both treatment groups. Lithium discontinuation only occurred in five cases of adverse effects. Predominant depressive mood episode before lithium maintenance (OR=0.159, p=0.033) and first euthymic interval after lithium maintenance (OR=1.109, p=0.047) significantly predicted lithium response.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Lithium significantly reduced the frequency and time spent in relapse in patients with bipolar disorder. Predominant depressive mood polarity before lithium maintenance and longer first euthymic interval after lithium maintenance had been identified to predict lithium response significantly.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Gan Wei</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Faculty of Pharmacy, University Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia, marhanis.salihah@gmail.com, marhanis@ukm.edu.my.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makmor-Bakry</LastName><ForeName>Mohd</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Omar</LastName><ForeName>Marhanis Salihah</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Croatia</Country><MedlineTA>Psychiatr Danub</MedlineTA><NlmUniqueID>9424753</NlmUniqueID><ISSNLinking>0353-5053</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27287789</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6806254</PMID><DateCompleted><Year>1982</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>7</Issue><PubDate><Year>1982</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Does subclinical hypothyroidism predispose to tricyclic-induced rapid mood cycles?</ArticleTitle><Pagination><MedlinePgn>290-1</MedlinePgn></Pagination><Abstract><AbstractText>A 24-year-old woman with a unipolar depression had an augmented thyroid-stimulating hormone response to thyrotropin-releasing hormone (TRH), suggesting subclinical hypothyroidism. Desipramine produced rapid cycling between depression and hypomania. After discontinuation of the desipramine she was successfully treated with lithium and thyroid hormone replacement. We discuss the possible role of hypothyroidism in the etiology of tricyclic-induced rapid mood cycling, and suggest that the TRH test may help identify depressed patients predisposed to rapid mood cycling on tricyclics. The possibility that such patients respond to lithium and/or thyroid hormone replacement needs to be further investigated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Extein</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Pottash</LastName><ForeName>A L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>M S</ForeName><Initials>MS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Y5F15120W</RegistryNumber><NameOfSubstance UI="D013973">Thyrotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q51BO43MG4</RegistryNumber><NameOfSubstance UI="D013974">Thyroxine</NameOfSubstance></Chemical><Chemical><RegistryNumber>TG537D343B</RegistryNumber><NameOfSubstance UI="D003891">Desipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003891" MajorTopicYN="N">Desipramine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013973" MajorTopicYN="N">Thyrotropin-Releasing Hormone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013974" MajorTopicYN="N">Thyroxine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6806254</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12411210</PMID><DateCompleted><Year>2002</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>159</Volume><Issue>11</Issue><PubDate><Year>2002</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Brain imaging in affective disorders: more questions about causes versus effects.</ArticleTitle><Pagination><MedlinePgn>1807-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schatzberg</LastName><ForeName>Alan F</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010104">Oxygen Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2002 Jul;159(7):1119-26</RefSource><PMID Version="1">12091189</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2002 Nov;159(11):1830-40</RefSource><PMID Version="1">12411216</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Am J Psychiatry. 2002 Nov;159(11):1841-7</RefSource><PMID Version="1">12411217</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010104" MajorTopicYN="N">Oxygen Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012039" MajorTopicYN="N">Regional Blood Flow</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>2</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>12</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>2</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12411210</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.159.11.1807</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19352219</PMID><DateCompleted><Year>2009</Year><Month>06</Month><Day>26</Day></DateCompleted><DateRevised><Year>2009</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-5873</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatric genetics</Title><ISOAbbreviation>Psychiatr Genet</ISOAbbreviation></Journal><ArticleTitle>Support for tryptophan hydroxylase-2 as a susceptibility gene for bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>142-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YPG.0b013e32832a4f95</ELocationID><Abstract><AbstractText>Bipolar affective disorder (BPAD) is a highly inherited genetic disorder and may be caused in part by deficits in serotonergic neurotransmission. We investigated whether variants within the tryptophan hydroxylase-2 (TPH2) gene, which is required for the synthesis of serotonin (5-HT), are associated with susceptibility to developing BPAD. Thirteen single nucleotide polymorphisms (SNPs) within TPH2 were genotyped in a collection of 151 Irish BPAD type I trios and were tested for association using the transmission disequilibrium test. SNPs rs1386482 and rs1386486, which are in very strong linkage disequilibrium, were associated with BPAD (P=0.006). The association retained significance after a correction for multiple testing. The associated SNPs are in perfect linkage disequilibrium with SNPs previously associated with BPAD (rs4290270) and impulsivity (rs1386483), a core trait of BPAD. These results strongly support a role for TPH2 in the aetiology of BPAD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Roche</LastName><ForeName>Siobhan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Smurfit Institute of Genetics, Trinity College, Dublin, Ireland. siobhan.roche@tcd.ie</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKeon</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychiatr Genet</MedlineTA><NlmUniqueID>9106748</NlmUniqueID><ISSNLinking>0955-8829</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="C494784">TPH2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.4</RegistryNumber><NameOfSubstance UI="D014365">Tryptophan Hydroxylase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014365" MajorTopicYN="N">Tryptophan Hydroxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>4</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19352219</ArticleId><ArticleId IdType="doi">10.1097/YPG.0b013e32832a4f95</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8929049</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4487</ISSN><JournalIssue CitedMedium="Print"><Volume>154</Volume><Issue>4</Issue><PubDate><Year>1996</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Annales medico-psychologiques</Title><ISOAbbreviation>Ann Med Psychol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Mania in an elderly subject: I. -- manic-depressive disorders of late onset].</ArticleTitle><Pagination><MedlinePgn>217-25</MedlinePgn></Pagination><Abstract><AbstractText>Late mania may inaugurate a late-onset bipolar illness. Atypical features and organic brain abnormalities are frequently associated. Late-onset bipolar illness is apparently characterized by a strong instability of mood and a super or subsensitivity to neuroleptics and antidepressant drugs. However, there is a strong efficacy of lithium salts and lithium may be used as a curative and preventive treatment or as a therapeutic test, especially in atypical cases. The occurrence of mania in elderly people involves a specifical etiologic, therapeutic and diagnostic approach.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahé</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Service de Psychiatrie, Hôpital Richaud, Versailles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Féline</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>La manie du sujet âgé: I--Les maladies maniaco-dépressives à début tardif.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Med Psychol (Paris)</MedlineTA><NlmUniqueID>2984692R</NlmUniqueID><ISSNLinking>0003-4487</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>25</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8929049</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31394485</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><PubDate><Year>2019</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Lithium prophylaxis in early-onset Bipolar disorder: a descriptive study.</ArticleTitle><Pagination><MedlinePgn>172-174</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(19)30272-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2019.07.053</ELocationID><Abstract><AbstractText>Subjects fulfilling DSM 5 criteria of Bipolar I disorder with onset before 18 years on Lithium prophylaxis were included. A total of 575 subjects with Bipolar Disorder were screened, 141 had early-onset Bipolar disorder, 72 patients were on Lithium and 52 provided informed consent and entered the study. Thirty-four were in the prospective group, and 18 were in the retrospective arm. Mean age at onset was 16.13 (1.40) years. About 31% (n = 16) were initiated on Lithium following first episode. Mean age at initiating lithium was 19.73 (3.82) years. Clinical profile and treatment response of early-onset bipolar disorder in the Indian context needs further study.</AbstractText><CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Selvarajan</LastName><ForeName>Sandhiya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>JIPMER, Department of Clinical Pharmacology, Dhanvantri Nagar, Puducherry, 605006, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manohar</LastName><ForeName>Harshini</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>JIPMER, Department of Psychiatry, Dhanvantri Nagar, Puducherry, 605006, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Saibal</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>JIPMER, Department of Clinical Pharmacology, Dhanvantri Nagar, Puducherry, 605006, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakkarabani</LastName><ForeName>Priyanka</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>JIPMER, Department of Psychiatry, Dhanvantri Nagar, Puducherry, 605006, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandasamy</LastName><ForeName>Preeti</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>JIPMER, Department of Psychiatry, Dhanvantri Nagar, Puducherry, 605006, India. Electronic address: preeti.k@jipmer.edu.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adolescent</Keyword><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">Early-onset</Keyword><Keyword MajorTopicYN="N">Lithium</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31394485</ArticleId><ArticleId IdType="pii">S1876-2018(19)30272-2</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2019.07.053</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6505774</PMID><DateCompleted><Year>1985</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0038-4348</ISSN><JournalIssue CitedMedium="Print"><Volume>77</Volume><Issue>12</Issue><PubDate><Year>1984</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Southern medical journal</Title><ISOAbbreviation>South Med J</ISOAbbreviation></Journal><ArticleTitle>Propranolol-induced mania.</ArticleTitle><Pagination><MedlinePgn>1603</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>South Med J</MedlineTA><NlmUniqueID>0404522</NlmUniqueID><ISSNLinking>0038-4348</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9Y8NXQ24VQ</RegistryNumber><NameOfSubstance UI="D011433">Propranolol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011433" MajorTopicYN="N">Propranolol</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6505774</ArticleId><ArticleId IdType="doi">10.1097/00007611-198412000-00036</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6731648</PMID><DateCompleted><Year>1984</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>7</Issue><PubDate><Year>1984</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Cerebral ventricular enlargement and suicide in schizophrenia and mania.</ArticleTitle><Pagination><MedlinePgn>919</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nasrallah</LastName><ForeName>H A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>McCalley-Whitters</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006849" MajorTopicYN="N">Hydrocephalus</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6731648</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.7.919b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32882577</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>130</Volume><PubDate><Year>2020</Year><Month>11</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Comorbidity and patterns of familial aggregation in attention-deficit/hyperactivity disorder and bipolar disorder in a family study of affective and anxiety spectrum disorders.</ArticleTitle><Pagination><MedlinePgn>355-361</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(20)30928-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2020.08.017</ELocationID><Abstract><AbstractText>The aim of this study is to examine the familial aggregation of Attention-deficit/hyperactivity disorder (ADHD) and its cross-transmission with bipolar disorder (BD) in a community-based family study of mood spectrum disorders. A clinically-enriched community sample of 562 probands recruited from the greater Washington, DC metropolitan area and their 698 directly interviewed relatives were included in analyses. Inclusion criteria were English speaking and consent to contact at least two first-degree relatives. Standard family study methodology was used and DSM-IV classified mental disorders were ascertained through a best-estimate procedure based on direct semi-structured interviews and multiple family history reports. There was specificity of familial aggregation of both bipolar I disorder (BD I) and bipolar II disorder (BD II) (i.e., BD I OR = 6.08 [1.66, 22.3]; BD II OR = 2.98 [1.11, 7.96]) and ADHD (ADHD OR = 2.13 [1.16, 3.95]). However, there was no evidence for cross-transmission of BD and ADHD in first degree relatives (i.e., did not observe increased rates of BD in relatives of those with ADHD and vice versa; all ps &gt; 0.05). The specificity of familial aggregation of ADHD and BD alongside the absence of shared familial risk are consistent with the notion that the comorbidity between ADHD and BD may be attributable to diagnostic artifact, could represent a distinct BD suptype characterized by childhood-onset symptoms, or the possibility that attention problems serve as a precursor or consequence of BD.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Rachel F L</ForeName><Initials>RFL</Initials><AffiliationInfo><Affiliation>Genetic Epidemiology Research Branch, National Institute of Mental Health, Intramural Research Program, Building 35A, Room 2E410, MSC 3720, Bethesda, MD, 20892, USA. Electronic address: rachel_walsh@temple.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheppard</LastName><ForeName>Brooke</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Genetic Epidemiology Research Branch, National Institute of Mental Health, Intramural Research Program, Building 35A, Room 2E410, MSC 3720, Bethesda, MD, 20892, USA; Department of Epidemiology, Johns Hopkins' Bloomberg School of Public Health, 615 North Wolfe Street, W6508, Baltimore, MD, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Lihong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Genetic Epidemiology Research Branch, National Institute of Mental Health, Intramural Research Program, Building 35A, Room 2E410, MSC 3720, Bethesda, MD, 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Cortlyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Genetic Epidemiology Research Branch, National Institute of Mental Health, Intramural Research Program, Building 35A, Room 2E410, MSC 3720, Bethesda, MD, 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Meter</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Genetic Epidemiology Research Branch, National Institute of Mental Health, Intramural Research Program, Building 35A, Room 2E410, MSC 3720, Bethesda, MD, 20892, USA; The Feinstein Institutes for Medical Research, The Zucker Hillside Hospital, Division of Psychiatry Research, 350 Community Dr, Manhasset, NY, 11030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merikangas</LastName><ForeName>Kathleen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Genetic Epidemiology Research Branch, National Institute of Mental Health, Intramural Research Program, Building 35A, Room 2E410, MSC 3720, Bethesda, MD, 20892, USA. Electronic address: merikank@mail.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA MH002804</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="Y">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Attention-deficit/hyperactivity disorder</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Comorbidity</Keyword><Keyword MajorTopicYN="Y">Epidemiology</Keyword><Keyword MajorTopicYN="Y">Family study</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>08</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32882577</ArticleId><ArticleId IdType="pii">S0022-3956(20)30928-6</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2020.08.017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">737263</PMID><DateCompleted><Year>1979</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>1978</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>High-dose lithium therapy.</ArticleTitle><Pagination><MedlinePgn>759-62</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kocsis</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>K W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Reding</LastName><ForeName>G R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Stokes</LastName><ForeName>P E</ForeName><Initials>PE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">737263</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1101044</PMID><DateCompleted><Year>1975</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0077-0094</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><PubDate><Year>1975</Year></PubDate></JournalIssue><Title>Modern problems of pharmacopsychiatry</Title><ISOAbbreviation>Mod Probl Pharmacopsychiatry</ISOAbbreviation></Journal><ArticleTitle>Relationship of genetic factors to course and drug response in schizophrenia, mania and depression.</ArticleTitle><Pagination><MedlinePgn>1-11</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winokur</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Mod Probl Pharmacopsychiatry</MedlineTA><NlmUniqueID>0425142</NlmUniqueID><ISSNLinking>0077-0094</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="Y">Pharmacogenetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>26</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1975</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1101044</ArticleId><ArticleId IdType="doi">10.1159/000397913</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>